Section |
Name |
Details |
A5.02.08 |
|
Consider first line dressings appropriate to wound bed type and exudate level |
A5.05.02 |
|
Consider standard interactive dressings first |
A5.06.01 |
|
Consider standard interactive dressings first. Dressings advised by TVN
|
A5.10 |
|
Consider standard dressings first |
02.02.01 |
Bendroflumethiazide |
2.5mg dose (higher doses are not indicated in hypertension) |
02.05.01 |
Minoxidil tablets Loniten® |
|
13.14.06 |
Salicylic acid 5% w/w in emulsifying ointment |
|
10.02.01 |
3,4,diaminopyridine |
Hospital only |
A5.15 |
3M Cavilon Durable Barrier Cream |
Skin protectant Type of wound product is suitable for Intact skin As a barrier against bodily fluids, prevention of skin damage associated with incontinence Can be used alongside containment products Can be used to prevent friction to vulnerable areas of skin Frequency of use Reapply sparingly twice daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use on infected skin Not be used as an emollient Not to be used around the peri wound Can increase adherence of some dressing products and therefore care should be taken when adhesive products are being used in conjunction with the cream on people with fragile skin Rationale for inclusion in formulary The only barrier cream that can be used in conjunction with containment products without blocking the absorption of the pad Cost effective, does not require reapplication at every episode of hygiene
|
A5.15 |
3M Cavilon No Sting Barrier Film Pump Spray and applicators |
Protective transparent barrier film Type of wound product is suitable for Superficial broken skin and abrasions As a barrier against bodily fluids, prevention of skin damage associated with incontinence Can be used alongside containment products Can be used to prevent friction to vulnerable areas of skin Can be used on superficial abrasions caused by incontinence Can be used to protect peri wound from exudate Can be used to protect against aggressive adhesive products Can be used to protect the skin surrounding stoma sites Frequency of use Every 72 hours Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use on infected skin Allow product to dry before applying the containment products, dressings or clothing (30 seconds) Too many layers can make the area of skin feel stiff Can affect electrode readings in the treated area Rationale for inclusion in formulary Available in a foam applicator and spray to aid application Non sticky after use Can be used on broken areas of skin Cost effective, does not require reapplication at every episode of hygiene
|
05.03.01 |
Abacavir Ziagen® |
|
05.03.01 |
Abacavir and Lamivudine Kivexa® |
|
10.01.03 |
Abatacept Orencia® |
Hospital only
Available via Home Care |
08.01.05 |
Abemaciclib Verzenios® |
In line with NICE |
08.03.04.02 |
Abiraterone Zytiga® |
|
04.10.01 |
Acamprosate Campral EC® |
|
02.08.02 |
Acenocoumarol Sinthrome® |
|
02.02.07 |
Acetazolamide |
Itracranial hypertension |
11.06 |
Acetazolamide |
- Specialist Ophthalmologist Recommendation
|
11.06 |
Acetazolamide |
Hospital Only |
11.06 |
Acetazolamide M/R |
- Specialist Ophthalmologist Recommendation
|
12.01.01 |
Acetic Acid 2% Earcalm ® |
|
20 |
Acetic Acid Solution 3% |
- Restricted for use by endoscopy only
|
03.07 |
Acetylcysteine |
Hospital Only
- Tablets
- Sachets- available as 200mg powder for oral solution- licensed product.
- Effervescent tablets
|
11.08.01 |
Acetylcysteine 10% eye drops |
|
11.08.01 |
Acetylcysteine 5% with Hypromellose 0.35% Ilube® |
|
05.03.02.01 |
Aciclovir oral |
Tablets
Dispersible tablets £
Suspension ££ |
05.03.02.01 |
Aciclovir injection |
|
11.03.03 |
Aciclovir 3% eye ointment |
|
13.10.03 |
Aciclovir 5% cream |
|
13.05.02 |
Acitretin |
|
03.01.02 |
Aclidinium Eklira Genuair® |
|
03.01.04 |
Aclidinium / formoterol inhaler Duaklir Genuair® |
|
A5.08.07 |
Actico® |
Cohesive inelastic high compression bandage. Short stretch bandage
Type of wound product is suitable for
Venous leg ulceration
Lymphoedema
Management of chronic oedema
Duration dressing remains on wound before changing
Daily to 7 days
Frequency of dressing change
Dependant on exudate levels if wound present or oedema management.
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Not recommended on those patients with an ABPI lower than 0.8. Caution in diabetic patients
Caution when cardiac overload or renal failure present or suspected.
Rationale for inclusion in formulary
Only cohesive short stretch bandage. Nurses competent in its usage.
|
A5.02.01 |
ActiForm Cool |
Hydrogel Sheet Type of wound product is suitable for Necrotic or sloughy wounds that require hydration and cooling pain relief Can be used on dry wounds with the backing left in place Cut to shape of the wound Requires a secondary dressing Duration dressing remains on wound before changing 1-3 days if dressings become discoloured or opaque or at first signs of exudate strike through Frequency of dressing change If dressing becomes discoloured or opaque or at first signs of exudate strike through. Do not allow to dry out Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Should not be used as a covering for deep narrow cavities or sinuses. Do not use on infected wounds. Not suitable for heavily exuding wounds Known product or component sensitivity Not for application on ischaemic wounds Rationale for inclusion in formulary Dry necrotic, sloughy or painful wounds For ease of application - sheet gel rather than liquid Primary dressing Can be used prior to larval therapy to maintain moisture levels
|
A5.03.01 |
Actilite (Honey Dressing) |
Non-adherent viscose net dressing 99% Manuka honey and 1% Manuka oil. Type of wound product is suitable for A primary dressing for low to moderate shallow exuding wound with light slough. Granulating or epithelialising wounds with clinical signs of infection. Requires a secondary dressing. Max Duration dressing remains on wound before changing 3-7 Days Frequency of dressing change 3 to 7 days depending on exudate Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known allergy to Bee Venom and Honey products Blood sugars should be monitored in patients with diabetes Stinging sensation may be experienced. If unacceptable for patient then discontinue. Rationale for inclusion in formulary For antimicrobial and de-sloughing properties Ease of application Can be cut to size Easy removal in one piece Availability of different sizes Not found to be harmful to peri-wound skin Malodour Cost effective |
A5.02.05 |
ActivHeal Foam |
Two layer dressing consisting of a polyurethane bacterial barrier membrane with a centrally located hydrophilic pad +/- acrylic adhesive border. Type of wound product is suitable for Moderately exuding wounds with signs of granulation, epithelialisation or slough. Can be used as primary or secondary Duration dressing remains on wound before changing 1-7 days Frequency of dressing change Up to 7 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Full thickness burns Surgical implantations Rationale for inclusion in formulary Cost effective Simple to use on the foot and digits Can be cut to shape |
A5.02.05 |
ActivHeal Foam (Tracheostomy) |
Tracheostomy foam dressing Type of wound product is suitable for ActivHeal Foam Tracheostomy dressing has a fenestration, which allows the dressing to fit neatly around a tracheostomy tube. The dressing can also be used around intubation and cannula insertion procedures, external bone fixators and appropriately-sized wound drainage tubes. Duration dressing remains on wound before changing Dependant on clinical need and soiling Frequency of dressing change Up to 7 days, dependant on clinical need and soiling Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use if reaction to any of its components Rationale for inclusion in formulary Specific dressing shaped and able to cut for tracheostomies. Cost effective |
A5.03.01 |
Activon ®Tube |
100% medical grade Manuka Honey. Type of wound product is suitable for Use as topical treatment for infected sloughy shallow or cavity wounds. Primary or addition to other Activon products. Requires secondary dressing. Max Duration dressing remains on wound before changing Up to 4 days Frequency of dressing change Daily in acute infection Up to 4 days in chronic infection dependant on exudate Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Wounds with active blood loss Known allergies to bee Venom and Honey products Blood sugars should be monitored in diabetic patients Stinging sensation may be experienced – discontinue if not tolerant. Rationale for inclusion in formulary Anti-microbial and de-sloughing properties Control of odours Benefit of adding to other action products and increasing honey Suitable for use in cavities Cost effective |
A5.03.01 |
Activon Tulle (Honey Dressing) |
Knitted viscose mesh impregnated with 100% Manuka Honey. Type of wound product is suitable for Creates a moist healing environment effectively eliminates odour. Provides anti-microbial action. Debrides and de-sloughs shallow wounds where the exudate level has started to decrease. Requires secondary dressing Max Duration dressing remains on wound before changing Up to 4 days Frequency of dressing change Daily in acute infection Up to 4 days for chronic infection depending on exudate Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Wounds with active blood loss Known allergies to bee Venom and Honey products Blood sugars should be monitored in diabetic patients Stinging sensation may be experienced – discontinue if not tolerant. Rationale for inclusion in formulary Anti-microbial and de-sloughing properties for wounds with reduced levels of exudate. Control of odours Ease of application and removal in one piece Can be cut to size Available to various size Cost effective |
01.05.03 |
Adalimumab Humira® |
Injection
For specialist use only in line with NICE guidance below
|
10.01.03 |
Adalimumab |
- Hospital only
- Biosimilar brands available:
- Amgevita®
- Hulio®
- Imraldi®
- Hyrimoz®
|
11.99.99.99 |
Adalimumab Humira® |
In line with NICE |
13.05.03 |
Adalimumab |
|
13.06.01 |
Adapalene |
Avoid in pregnancy |
13.06.01 |
Adapalene with benzoyl peroxide Epiduo® |
May be used in preference to antimicrobial-containing agents. |
05.03.03 |
Adefovir Dipivoxil Hepsera® |
|
02.03.02 |
Adenosine injection |
|
08.02.02 |
AdoPORT® Tacrolimus |
|
03.04.03 |
Adrenaline / Epinephrine Jext® |
Injection technique is device specific. To ensure patients receive the auto-injector device that they have been trained to use, prescribers should prescribe by brand. |
03.04.03 |
Adrenaline / epinephrine EpiPen® |
There are currently supply issues with adrenaline autoinjectors (October 2018-on) - See anaphylaxis UK advice
Injection technique is device specific. To ensure patients receive the auto-injector device that they have been trained to use, prescribers should prescribe by brand. |
03.04.03 |
Adrenaline/Epinephrine (Emerade ®) |
Injection technique is device specific. To ensure patients receive the auto-injector device that they have been trained to use, prescribers should prescribe by brand. |
08.01.05 |
Afatinib Giotrif® |
In line with NICE |
11.08.02 |
Aflibercept Eylea® |
Use in line with NICE |
04.03.04 |
Agomelatine Valdoxan® |
|
05.05.08 |
Albendazole |
UNLICENSED |
08.01.05 |
Alectinib |
In line with NICE |
08.02.03 |
Alemtuzumab Lemtrada® |
In line with NICE |
06.06.02 |
Alendronic Acid Binosto® |
- £££
- Third line option in individuals who have not tolerated first line alendronate tablets and second line risedronate tablets and in whom a bone-sparing agent is still considered clinically necessary.
- The need for continued bisphosphonate treatment should be re-evaluated periodically particularly after 5 or more years of use
|
06.06.02 |
Alendronic Acid tablets |
- The need for continued bisphosphonate treatment should be re-evaluated periodically particularly after 5 or more years of use
|
09.06.04 |
Alfacalcidol injection |
Hospital only |
09.06.04 |
Alfacalcidol oral preparations |
|
21 |
Alfentanil |
Injection |
07.04.01 |
Alfuzosin Hydrochloride |
tablets
M/R tablets |
A5.03.01 |
Algivon (Honey Dressing) |
Alginate dressing impregnated with 100% Manuka Honey. Type of wound product is suitable for Primary dressing for infected, shallow cavity wounds, particularly if necrotic or malodorous with moderate exudate. Requires secondary dressing. Max Duration dressing remains on wound before changing Up to 4 days for chronic infection Frequency of dressing change Daily for acute infection Up to 4 days for chronic infection/depending upon exudate Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Wounds with active blood loss Known allergy to be venom and honey products Blood sugars should be monitored in diabetic patients Stinging sensation may be experienced – discontinue if not tolerated Rationale for inclusion in formulary Antimicrobial and de sloughing properties Absorbent Malodour Ease of application and removal in one piece Can be cut to size Available in various sizes Can be shaped to wound size and depth Cost effective |
03.04.01 |
Alimemazine |
Second line- in children as per guidance |
02.12 |
Alirocumab Praluent® |
To be used in line with NICE TA393 |
02.05.05.03 |
Aliskiren Rasilez® |
For existing patients only |
13.05.01 |
Alitretinoin Toctino® |
Dermatologists only in line with NICE TA 177 |
A5.03.03 |
Allevyn Ag® |
A non adherent foam dressing impregnated with silver sulphadiazine that can be cut to suit the patient Type of wound product is suitable for For use around infected pin sites Duration dressing remains on wound before changing Daily or as directed Frequency of dressing change Daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Patients who have a known sensitivity to Silver Sulphadiazine or Sulphonamides Females who are at or near full term pregnancy or lactating Not for use on neonates or new born infants during the first month of life Rationale for inclusion in formulary Used around infected pin sites in patients with external metalwork to help reduce bacterial load HOSPITAL USE ONLY |
A5.02.05 |
Allevyn Cavity |
Type of wound product is suitable for Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds surgical wounds, malignant wounds donor sites and fungating ulcers Can be used as a primary or secondary dressing Duration dressing remains on wound before changing Can stay in place up to 3-7 days Frequency of dressing change Dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) In common with all adhesive products, some cases of irritation and/or maceration of the skin may occur. It should be noted that inappropriate use or too frequent dressing changes, particularly in patients with fragile skin, can result in skin stripping. If this occurs change to the Allevyn gentle border range. If redness or sensitisation occur, discontinue use Caution under compression when exudate levels are moderate to high. Rationale for inclusion in formulary Can be used for low to moderate exudate levels Different sizes and shapes available Cost effective |
A5.02.03 |
Allevyn Life |
Hydrocellular foam dressing Type of wound product is suitable for Shallow granulating wounds, acute and chronic exuding wounds, full and partial thickness wounds such as leg ulcer, malignant wound, surgical wound. Primary dressing Silicone adhesive Duration dressing remains on wound before changing Up to 7 days dependent on dressing indicators Frequency of dressing change Up to 3 times a week maximum Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use with oxidising agents such as hypochlorite solutions or hydrogen peroxide Discontinue if reddening or sensitivity occurs. Do not cut Caution under compression where exudate levels are moderate to high Rationale for inclusion in formulary Fragile skin with absorbency and conformability, problematic healing wounds. Odour control. |
A5.02.05 |
Allevyn Non-Adhesive |
Type of wound product is suitable for
Wound management by secondary intention on acute, chronic, full thickness or partial
thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds surgical wounds, malignant wounds donor sites and fungating ulcers
Can be used as a primary or secondary dressing
Duration dressing remains on wound before changing
Can stay in place up to 3-7 days
Frequency of dressing change
Dependent on exudate levels
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
In common with all adhesive products, some cases of irritation and/or maceration of the skin may occur.
It should be noted that inappropriate use or too frequent dressing changes, particularly in patients with fragile skin, can result in skin stripping. If this occurs change to the Allevyn gentle border range.
If redness or sensitisation occur, discontinue use
Caution under compression when exudate levels are moderate to high.
Rationale for inclusion in formulary
Can be used for low to moderate exudate levels
Different sizes and shapes available
Cost effective
|
A5.02.05 |
Allevyn range |
Available in adhesive, non adhesive and gentle Type of wound product is suitable for Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds surgical wounds, malignant wounds donor sites and fungating ulcers Can be used as a primary or secondary dressing Duration dressing remains on wound before changing Can stay in place up to 3-7 days Frequency of dressing change Dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) In common with all adhesive products, some cases of irritation and/or maceration of the skin may occur. It should be noted that inappropriate use or too frequent dressing changes, particularly in patients with fragile skin, can result in skin stripping. If this occurs change to the Allevyn gentle border range. If redness or sensitisation occur, discontinue use Caution under compression when exudate levels are moderate to high. Rationale for inclusion in formulary Can be used for low to moderate exudate levels Different sizes and shapes available Cost effective
|
09.05.01.01 |
Alliance Calcium Syrup® |
- Replacement for Calcium Sandoz ® (discontinued)
|
10.01.04 |
Allopurinol |
|
06.01.02.03 |
Alogliptin Vipidia® |
|
07.01.01.01 |
Alprostadil Prostin VR® |
|
07.04.05 |
Alprostadil cream Vitaros® |
Specialist initiation
- For patients who would otherwise use alprostadil injection.
|
07.04.05 |
Alprostadil Intracavernosal injection |
|
02.10.02 |
Alteplase |
Hospital only drug |
09.04 |
Althera® |
|
09.04 |
Altraplen Compact® (formally known as Nutriplen®) |
- More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
- Alternative to second line supplement choice
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
- Not suitable for child under 3 years; use with caution in child 3–6 years.
|
13.12 |
Aluminimum Salts |
|
09.05.02.02 |
Aluminium Hydroxide |
- Specialist Recommendation
|
04.09.01 |
Amantadine Hydrochloride |
- Capsules
- Syrup- for patients with swallowing difficulties
|
05.01.04 |
Amikacin |
|
02.02.03 |
Amiloride Hydrochloride |
Tablets
Oral solution |
03.01.03 |
Aminophylline Phyllocontin Continus® |
|
03.01.03 |
Aminophylline IV |
|
02.03.02 |
Amiodarone injection |
|
02.03.02 |
Amiodarone tablets |
Supported by RICaD
|
04.02.01 |
Amisulpride (oral) |
- tablets
- solution
- Supported by ESCA, see link below.
|
04.03.01 |
Amitriptyline |
Tablets
Sugar Free solution £££ |
04.07.03 |
Amitriptyline |
1st line
low abuse potential, low cost
off label use
|
04.07.04.02 |
Amitriptyline |
|
02.06.02 |
Amlodipine |
|
13.10.02 |
Amorolfine 5% nail lacquer |
££ |
03.13 |
Amoxicillin |
Hospital only |
05.01.01.03 |
Amoxicillin injection |
|
05.01.01.03 |
Amoxicillin oral presentations |
|
03.13 |
Amphotericin Fungizone® |
Hospital only |
05.02 |
Amphotericin lipid complex infusion |
|
05.02 |
Amphotericin infusion |
|
11.03.02 |
Amphotericin (eye) |
|
09.01.04 |
Anagrelide Xagrid® |
|
10.01.03 |
Anakinra Kineret® |
Hospital only |
04.07.04.01 |
Analgesics Migraleve Pink ® |
|
08.03.04.01 |
Anastrozole |
|
06.04.01.01 |
Angeliq® |
|
05.02.04 |
Anidulafungin |
|
01.01.01 |
Antacid and Oxetacaine |
Suspension Specialist use only |
13.08.01 |
Anthelios XL® |
- Approved at December 2015 APC meeting following a drug application.
Non-formulary if not for ACBS approved indication
|
14.05.03 |
Anti-D (Rh0) Immunoglobulin |
|
01.07.02 |
Anusol-HC |
|
02.08.02 |
Apixaban |
Following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants.
BSSE APC Primary Care Clinical Pathway for Arial Fibrillation Detection and Management Use following Hip and Knee surgery- full course of treatment supplied on discharge.
For the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Apixaban in DVT/ PE |
04.09.01 |
Apomorphine Dacepton® |
- solution for injection in cartridge
- solution for infusion (accepted July 2020)
|
04.09.01 |
Apomorphine APO-go® |
|
A5.16 |
Appeel ® |
available in 4 different applications Type of wound product is suitable for Adhesive dressing or appliance removal where skin stripping, loss of skin integrity and pain is a concern Sachet– suitable for larger dressing removal Wipes – ideal for adhesive around tubes Foam applicator – ideal for infants or use of the face Spray, single patient, multiple use product for all dressings and/or urinary sheath removal Frequency of use Use at each dressing change Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Should not be used when there is a known sensitivity to any of the ingredients If in doubt, patch test a small area, prior to use The product is flammable and should be used in a well ventilated area Avoid use around, flames and sources of ignition Rationale for inclusion in formulary For pain free removal of dressings where fragile skin is a concern
|
11.08.02 |
Apraclonidine 1% SDU eye drops |
|
11.08.02 |
Apraclonidine 0.5% |
|
13.05.03 |
Apremilast |
In line with NICE Use in adults is commissioned by CCGs |
04.06 |
Aprepitant Emend® |
for use with chemotherapy only |
09.04 |
Aptamil Pepti® Junior |
|
A5.02.04 |
Aquacel range |
Type of wound product is suitable for
Moderate to heavy exudate, sloughy, necrotic or granulating wounds. Available in rope
for cavities
Duration dressing remains on wound before changing
Maximum 7 days
Frequency of dressing change
1-7 days depends on clinical need
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Not suitable for dry wounds. Non dissolvable. Known product or component sensitivity
Do not cut
Rationale for inclusion in formulary
Aids debridement of slough or necrotic tissue
Remains intact so easily removed in one piece
Absorbs exudate which aids most wound healing facilitating atraumatic dressing change,
Cost effective
|
A5.03.03 |
Aquacel® Ag + Extra range |
Hydrofibre with silver Type of wound product is suitable for Management of clinically infected, sloughy, necrotic or granulating wounds with moderate to heavy exudate. Moderate to highly exuding wounds. Aquacel Ag Plus Extra can be used to break down biofilms Requires a secondary dressing Duration dressing remains on wound before changing Dependent upon exudate 1 - 7 days Frequency of dressing change Dependent upon level of exudate and clinical presentation Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Should not be used on individuals who are sensitive to or have had an allergic reaction to the dressing or its components. Not suitable for dry wounds. No haemostatic properties. Rationale for inclusion in formulary Specialist antimicrobial product Moderate to high exudate levels Can be used to break down biofilms Remains intact on wound bed and easily removable in one piece (non dispersible) |
13.02.01 |
Aquadrate® |
Contains 10% urea
Over the counter preparation suitable for self-care/purchase if appropriate |
A5.02.01 |
AquaForm |
Hydrogel: Clear viscose sterile gel
Aids autolytic debridement and removal of devitalised tissue.
Type of wound product is suitable for
Low exuding, necrotic or sloughy wounds
Duration dressing remains on wound before changing
Up to 3 days
Frequency of dressing change
1-3 days
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not suitable for heavily exuding wounds. Caution known product or component sensitivity.
Full thickness burns or infected wounds
Not for application to ischaemic wounds
Rationale for inclusion in formulary
Required for wound beds that need donation of moisture to rehydrate the wound bed and debride. Cost effective
|
07.03.04 |
Arcing spring diaphragm |
Sizes 60-95mm (rising in 5mm) |
04.02.02 |
Aripiprazole Abilify Maintena® |
The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED. |
04.02.01 |
Aripiprazole tablets |
- Supported by ESCA, see link below.
- use in Tourette's syndrome approved
|
08.01.05 |
Arsenic Trioxide Trisenox® |
|
05.04.01 |
Artemether with lumefantrine Riamet® |
|
05.04.01 |
Artesunate |
Injection |
15.02 |
Articaine Hydrochloride with Adrenaline Septanest® |
Dental use |
09.06.03 |
Ascorbic Acid |
|
09.08.01 |
Asfotase alfa |
In line with NICE Highly Specialised Technology guidance |
02.09 |
Aspirin (antiplatelet) Dispersible |
|
04.07.01 |
Aspirin 300mg dispersible tablets |
topical analgesia- for gargling |
05.03.01 |
Atazanavir Reyataz® |
|
02.04 |
Atenolol |
|
08.02.03 |
Atezolizumab Tecentriq® |
In line with NICE |
04.04 |
Atomoxetine Strattera ® |
Please note that commissioning discussion is underway. However the present status is as follows:-
Birmingham and Solihull CCG Age 6 and over - Solihull practices. Supported with ESCA
Age 16 and over - Birmingham practices. Supported with ESCA
Age under 16 - Birmingham practices
Sandwell and West Birmingham CCG
Age 6 and over. Supported with ESCA. Click here for shared care document for patients seen by Black Country Partnership NHS FT
|
02.12 |
Atorvastatin tablets |
|
07.01.03 |
Atosiban Tractocile® |
|
05.04.08 |
Atovaquone |
|
09.04 |
Atraplen® Protein (formally known as Nutriplen® Protein) |
- Used in cases where increased protein is required
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula.
- Not suitable for child under 3 years; use with caution in child 3–6 years
|
A5.01.01 |
Atrauman |
Type of wound product is suitable for
For flat granulating and epithelising wound for non to heavy exudate where adherence may occur. To be used as a primary dressing with a secondary for absorption.
Duration dressing remains on wound before changing
Up to 7 days
Frequency of dressing change
1-7 days, depending on levels of exudate
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.
Known product or component sensitivity
Rationale for inclusion in formulary
Used to reduce adherence to wound bed. Most cost effective non adherent dressing.
Dressing impregnated with neutraltriglycerides to prevent penetration of granulation tissue.
Petroleum free.
|
A5.03.03 |
Atrauman Ag® |
Non adherent Primary Dressing containing metallic silver Type of wound product is suitable for For clinically infected shallow, granulating wounds with low exudate. To be used as a primary dressing with a secondary for absorption. Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change 1-7 days, depending on levels of exudate Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known product or component sensitivity Must be removed prior to x-ray, ultrasound, diathermy and MRI Rationale for inclusion in formulary Used to reduce adherence to wound bed with clinical signs of infection Most cost effective non adherent dressing containing silver. Dressing impregnated with neutral triglycerides to prevent penetration of granulation tissue. Petroleum free. Specialist Recommendation |
01.02 |
Atropine |
Injection |
21 |
Atropine 1% |
Eye drops
Oral use for drooling/secretions in neurological disease |
15.01.03 |
Atropine SF solution |
|
15.01.03 |
Atropine sulphate |
|
11.05 |
Atropine Sulphate 0.5% drops |
|
11.05 |
Atropine Sulphate 1% drops |
|
11.05 |
Atropine Sulphate single use Minims® |
- Specialist Ophthalmologist Recommendation -used by glaucoma surgeons for neovascular glaucoma.
|
15.01.03 |
Atropine tablets |
- For Myaesthenia Gravis only.
|
09.01.04 |
Avatrombopag Doptelet® |
|
13.02.01 |
Aveeno cream® |
£££- Paediatrics only
£££- Recommended by specialist for oncology use only.
|
08.02.03 |
Avelumab Bavencio® |
- Hospital only
- In line with NICE
|
10.01.03 |
Avelumab Bavencio ® |
In line with NICE
Hospital only |
07.04.05 |
Aviptadil 25mcg / Phentolamine 2mg Invicorp® |
- Approved on formulary December 2017
- Specialist initiation.
- 3rd line after oral PDE-5 inhibitors failed and patient not responding to or intolerant of alprostadil.
- To be reviewed within 12 months to assess alprostadil supply issues and patent expiry
|
08.02.04 |
Axicabtagene ciloleucel YESCARTA® |
|
09.04 |
Aymes® Complete |
- 1.5 kcal/mL and 5 g (or more) protein/100 mL
- Second line choice for 200ml ready-made. If powder is not tolerated or contraindicated
|
09.04 |
Aymes® Creme |
- More than 1.5 kcal/ml and 5g (or more) protein/100ml
- Low energy per serving as a semi-solid supplement where low volume is required only.
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, preoperative
preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula Not suitable for child under 3 years; use with caution in child 3–6 years.
|
09.04 |
Aymes® Shake/Savoury |
- In line with food first
- Not suitable for CKD 4-5, renal pts.
- Not suitable for lactose intolerance
- Not suitable for bile acid malabsorption or fat maldigestion associated with biliary diseases/conditions
- To be made up with whole milk.
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula . Use with caution in child 1–6 years.
|
08.01.03 |
Azacitidine Vidaza® |
|
01.05.03 |
Azathioprine |
Tablets 25mg, 50mg Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults– unlicensed but in line with national guidelines. For use in Inflammatory Bowel Disease (IBD) as per effective shared care agreement (ESCA). See link below. |
03.12 |
Azathioprine |
- in conjunction with prednisolone (plain tablets, not EC)
- Supported by ESCA , see link below.
|
04.13 |
Azathioprine |
Specialist use only for neurological conditions |
08.02.01 |
Azathioprine |
Oncology/haematology |
10.01.03 |
Azathioprine |
Supported by ESCA, see link below. |
13.05.03 |
Azathioprine (dermatology) |
- supported by ESCA, see link below
|
13.06.01 |
Azelaic Acid 15% gel Finacea® |
|
13.06.01 |
Azelaic Acid 20% cream Skinoren® |
|
11.04.02 |
Azelastine Optilast® |
|
12.02.01 |
Azelastine and fluticasone Dymista |
Third line option for adults and children over 12 years with moderate to severe allergic rhinitis who have failed to respond to a steroid nasal spray with the addition of an oral antihistamine.
Follow treatment algorithm
|
05.01.05 |
Azithromycin |
- Do not prescribe azithromycin as stand-alone medication for the indication of gonorrhoea. Refer to GUM clinic for IM ceftriaxone as per current UK guidelines.
|
05.01.05 |
Azithromycin |
Tablets/ suspension. When used in line with Primary care antimicrobial guidelines
Tablets only. For COPD or bronchiectasis patients who have ≥3 exacerbations per year. Off-label use. Supported by RICaD and Guidelines on Respiratory use of long term azithromycin in adults
- Do not prescribe azithromycin as stand-alone medication for the indication of gonorrhoea. Refer to GUM clinic for IM ceftriaxone as per current UK guidelines.
|
11.03.01 |
Azithromycin Azyter® |
- First line for ophthalmic chlamydia
|
05.01.02.03 |
Aztreonam |
|
10.02.02 |
Baclofen |
|
21 |
Baclofen |
Tablets, oral liquid
For hiccup
Off label use according to WM Cares guideline |
10.02.02 |
Baclofen intrathecal |
Hospital only |
13.02.01.01 |
Balneum Plus ®Bath Additive |
Over the counter preparation suitable for self-care/purchase if appropriate |
13.02.01 |
Balneum® Plus cream |
- urea 5%, lauromacrogols 3%
Over the counter preparation suitable for self-care/purchase if appropriate |
01.05.01 |
Balsalazide Sodium Colazide® |
|
03.01.01.01 |
Bambuterol tablets Bambec® |
Specialist initiation for severe brittle asthma/ cystic fibrosis |
10.01.03 |
Baricitinib ® Olumiant |
In line with NICE |
09.04 |
Basecal® |
- Fat and Carbohydrate
- Over one year of age. Metabolic disorder pts
- Also these are the only protein free (containing fat, carbohydrate, vitamins and minerals) powders aimed at children ≥1-year-old and adults with inborn errors of protein metabolism (particularly patients with urea cycle disorders and organic acidaemias). Basecal 100 and Basecal 200 are commonly added as an energy source in low protein module tube feeds. The dose will depend on energy requirements and tolerance to natural protein. It is commonly used in combination with a controlled amount of natural protein e.g. measured dose of standard enteral tube feed. It will help meet essential energy and nutrient requirements. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
|
14.04 |
BCG vaccine diagnostic agent |
|
14.04 |
BCG vaccine Intradermal |
|
03.02 |
Beclometasone and formoterol Fostair®NEXThaler® |
|
03.02 |
Beclometasone and formoterol Fostair® |
Alternative to Seretide Evohaler/ Seretide 250 Accuhaler
When reviewing/ stepping down, consider switch if appropriate |
03.02 |
Beclometasone Dipropionate |
- Soprobec® is a less expensive brand of beclometasone dipropionate than Clenil Modulite®
- Kelhale® is a less expensive brand for prescribing beclometasone dipropionate as extra fine particles in patients >18 years of age.
Kelhale® has extra-fine particles, is equivalent to Qvar® (non-formulary), is more potent than traditional beclometasone dipropionate CFC-containing inhalers and is approximately twice as potent as Soprobec® and Clenil Modulite®. Kelhale® should only be prescribed for existing Qvar® patients >18 years of age and not initiated for new patients.
May 2020 - see Clenil® Modulite® 100mcg (beclometasone): release of batch specific variation
|
12.02.01 |
Beclometasone Dipropionate nasal preparations |
|
03.02.03 |
Beclometasone/formoterol/glycopyrronium Trimbow® |
COPD Appendix 4 - Criteria for triple therapy and for triple inhaler use in COPD
|
03.04.02 |
Bee and Wasp Allergen Extracts Pharmalgen® |
|
08.01.01 |
Bendamustine |
|
A5.02.04 |
BeneHold TASA |
Approved April 2019
Hydrocolloid Range with film border
Type of wound product is suitable for Lightly to moderately exuding wounds
Duration dressing remains on wound before changing Up to 7 days
Frequency of dressing change Only when necessary - up to 7 days
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use on third-degree burns. Should not be used on individuals who are sensitive to or have had an allergic reaction to the dressing or its components.
Rationale for inclusion in formulary Reduced dressing changes. More cost effective. Reduce use of more expensive foam dressings. |
03.14 |
Benralizumab |
In line with NICE |
13.06.01 |
Benzoyl Peroxide |
|
13.06.01 |
Benzoyl Peroxide 3% with Clindamycin 1% Duac® Once Daily |
|
13.06.01 |
Benzoyl Peroxide 5% with Clindamycin 1% Duac® Once Daily |
|
12.03.01 |
Benzydamine 0.15% oral rinse |
|
12.03.01 |
Benzydamine 0.15% oral spray |
|
05.01.01.01 |
Benzylpenicillin |
|
05.01.01.01 |
Benzylpenicillin Benzathine |
Only GUM STD services |
04.06 |
Betahistine Dihydrochloride |
|
06.03.02 |
Betamethasone |
|
13.04 |
Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic Ointment® |
Potency: potent |
13.04 |
Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic Scalp Application® |
Potency: potent |
13.04 |
Betamethasone (as Valerate) 0.025% Betnovate-RD Ointment® |
Potency: Moderate |
13.04 |
Betamethasone (as Valerate) 0.025% Betnovate-RD Cream® |
Potency: Moderate |
13.04 |
Betamethasone (as Valerate) 0.1% Betnovate ® |
Potency: Potent
Cream
Ointment
Scalp application |
13.04 |
Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet cream® |
Potency: potent |
11.04.01 |
Betamethasone 0.1% eye drops |
|
11.04.01 |
Betamethasone 0.1% eye ointment |
|
12.01.01 |
Betamethasone 0.1% with Neomycin 0.5% ear drops |
|
11.04.01 |
Betamethasone 0.1% with Neomycin 0.5% eye drops |
|
13.04 |
Betamethasone Dipropionate 0.064% with Clotrimazole 1% Lotriderm® |
Potency: potent |
12.01.01 |
Betamethasone ear drops |
|
12.02.01 |
Betamethasone Sodium Phosphate nasal preparations |
|
13.04 |
Betamethasone valerate medicated plaster Betesil® |
Potency: Potent
Maximum treatment period 30 days |
09.04 |
Betaquick® |
- High-energy supplements: fat
- 21% MCT emulsion, used orally and in cooking as an energy source for children and adults on a ketogenic diet
|
11.06 |
Betaxolol 0.25% eye drops |
- Specialist Ophthalmologist Recommendation
|
11.06 |
Betaxolol 0.5% Unit Dose Eye Drops |
- Specialist Ophthalmologist Recommendation
|
11.06 |
Betaxolol 0.5% eye drops |
- Specialist Ophthalmologist Recommendation
|
07.04.01 |
Bethanechol Chloride Myotonine® |
|
08.01.05 |
Bevacizumab |
Funding available through Cancer Drugs Fund (CDF) for indications listed in CDF list.
Click here to access latest CDF list. |
11.08.02 |
Bevacizumab intravitreal injection Avastin® |
|
08.01.05 |
Bexarotene |
|
02.12 |
Bezafibrate |
immediate release formulation
modified release formulation |
A5.02.05 |
Biatain dressings |
Polyurethane foam dressing with bevelled edges Type of wound product is suitable for Moderately exuding wounds with signs of granulation, epithelialisation or slough. Can be used as primary or secondary Duration dressing remains on wound before changing 1-7 days Frequency of dressing change Up to 7 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use with oxidising solutions such as hydrogen peroxide Full thickness burns Surgical implantations Rationale for inclusion in formulary Simple to use on the foot and digits Can be cut to shape |
08.03.04.02 |
Bicalutamide |
|
11.06 |
Bimatoprost 0.01% eye drops |
- Specialist Ophthalmologist Recommendation.
- 2nd line
|
11.06 |
Bimatoprost with Timolol Ganfort® |
- Specialist Ophthalmologist Recommendation
|
12.03.05 |
Biotene Oralbalance® Saliva replacement gel |
Approved for
- Palliative Care
- Dental practitioners
|
06.01.01.02 |
Biphasic Insulin Aspart NovoMix® 30 |
|
06.01.01.02 |
Biphasic Insulin Lispro Humalog® Mix |
Humalog Mix25
Humalog Mix50 |
06.01.01.02 |
Biphasic Isophane Insulin Humulin® M3 |
|
06.01.01.02 |
Biphasic Isophane Insulin Insuman® Comb |
Insuman Comb 15
Insuman Comb 25
Insuman Comb 50 |
01.06.02 |
Bisacodyl |
Tablet E/C 5mg, Suppository 10mg
|
12.04 |
Bismuth Iodine Paraffin Paste BIPP ® |
|
12.04 |
Bismuth Subnitrate and Iodoform Paste for Gauze |
|
01.03.03 |
Bismuth subsalicylate Pepto Bismol® |
For use in H Pylori eradication in penicillin allergy and previous clarithromycin, as per Antimicrobial guidelines. |
02.04 |
Bisoprolol |
|
02.08.01 |
Bivalirudin Angiox® |
|
13.07 |
Bleomycin |
|
08.02.03 |
Blinatumomab Blincyto® |
In line with NICE |
06.01.06 |
Blood Glucose Meters |
|
05.03.03 |
Boceprevir Victrelis® |
|
12.03.01 |
Bonjela Junior Dental Gel Bonjela® Junior |
From 3 months of age |
08.01.05 |
Bortezomib Velcade® |
In line with NICE |
02.05.01 |
Bosentan Tracleer® |
NHS England commissioned |
08.01.05 |
Bosutinib Bosulif® |
In line with NICE
Hospital only- NHSE commissioned |
01.02 |
Botulinium Toxin A |
Achalasia
- Use for SWB only in endoscopy
- 100 units
|
04.12 |
Botulinum neurotoxin type A Xeomin® |
In line with NICE |
04.07.04.02 |
Botulinum Toxin Type A botox® |
In line with NICE |
13.12 |
Botulinum toxin type A |
hyperhidrosis (commissioning discussion to take place) |
14.04 |
Botulism antitoxin |
|
09.04.01 |
Bread |
Essential protein-free basic products. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 1 slice ordinary bread = 4g protein and is not allowed in low protein diets. |
08.01.05 |
Brentuximab vedotin Adcetris® |
|
08.01.05 |
Brigatinib Alunbrig® |
In line with NICE |
11.06 |
Brimonidine Tartrate |
- Specialist Ophthalmologist Recommendation
|
11.06 |
Brimonidine Tartrate 0.2% with Timolol 0.5% Combigan® |
- Specialist Ophthalmologist Recommendation
|
13.06.03 |
Brimonidine tartrate gel Mirvaso® |
For facial erythema in rosacea |
11.06 |
Brinzolamide 10mg/ml |
- Specialist Ophthalmologist Recommendation
|
11.06 |
Brinzolamide 10mg/ml with Brimonidine 2mg/ml Simbrinza® |
- Specialist Ophthalmologist Recommendation
- Third line option, after prostaglandin analogues (1st line) and beta-blocker/ prostaglandin analogue plus beta-blocker (2nd line)
- For patients in whom monotherapy provides insufficient IOP reduction.
|
11.06 |
Brinzolamide 10mg/ml with Timolol 5mg/ml |
- Specialist Ophthalmologist Recommendation
- 2nd/3rd line
|
04.08.01 |
Brivaracetam Briviact® |
- Initiation by Tertiary Epilepsy Specialist only.
- For adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with severe refractory epilepsy warranting tertiary specialist input for patients who have tried three or more AEDs. The patient has used levetiracetam and has documentation of intolerance and patient is using a third line agent (perampanel, zonisamide, lacosamide, eslicarbazepine) which would be replaced by brivaracetam.
- Supported by an ESCA
|
04.08.01 |
Brivaracetam Briviact ® |
|
10.01.03 |
Brodalumab Kyntheum ® |
In line with NICE
|
13.05.02 |
Brodalumab Kyntheum® |
- Hospital only
- In line with NICE
|
11.08.02 |
Brolucizumab Beovu®
| Use in line with NICE |
06.07.01 |
Bromocriptine |
|
01.05.02 |
Budesonide Budenofalk® |
2mg/dose foam enema
Approved July 2018 |
03.02 |
Budesonide |
Dry powder Inhaler
Nebulised solution |
01.05.02 |
Budesonide 1mg orodispersible tablets Jorveza® |
Specialist use only.
Formulary status to be reviewed on publication of NICE TA (expected October 2019) |
03.02 |
Budesonide and formoterol Symbicort Turbohaler® |
Should be prescribed by the intended brand to ensure patients receive the device they are used to.
For asthma only
Non-Formulary for COPD |
01.05.02 |
Budesonide capsules |
|
01.05.02 |
Budesonide MMX Cortiment® |
|
02.02.02 |
Bumetanide |
|
21 |
Buprenorphine |
Patches
Recommend 7-day patch |
04.07.02 |
Buprenorphine patches |
- for specialist initiation: specialist pain clinics, palliative care and for patients with swallowing difficulties
Patches should be prescribed by BRAND
|
04.10.03 |
Buprenorphine S/L tablets > |
|
04.07.02 |
Buprenorphine sublingual tablets |
For use in opioid dependence, see section 4.10.3 |
04.03.04 |
Bupropion |
off label use |
04.10.02 |
Bupropion Hydrochloride Zyban® |
|
06.07.02 |
Buserelin |
For assisted conception
|
08.03.04.02 |
Buserelin |
Listed in Chapter 6 for other indications |
06.07.02 |
Buserelin nasal spray |
For assisted conception
|
04.01.02 |
Buspirone Hydrochloride |
££ Second line |
08.01.01 |
Busulfan Tablets |
|
A5.02.02 |
C View |
Vapour-permeable adhesive film
Type of wound product is suitable for
Dry non infected wounds, retention of lines, fixation of secondary dressings, protection of intact skin, protection of skin against friction, protection of newly epithelialized wounds
Duration dressing remains on wound before changing
Up to 7 days
Frequency of dressing change
Up to 7 days
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Clinically infected wounds, bleeding or exuding wounds
Rationale for inclusion in formulary
Retention of lines, protection of intact skin, fixation of other dressings. Waterproof
|
03.04.03 |
C1 esterase inhibitor Cinryze® |
Hospital only- NHSE Commissioned |
03.04.03 |
C1 esterase Inhibitor Berinert® |
Hospital only- NHSE commissioned |
08.01.05 |
Cabazitaxel Jevtana® |
In line with NICE |
06.07.01 |
Cabergoline |
|
08.01.05 |
Cabozantinib Cabometyx® |
In line with NICE |
13.14.03 |
Cade oil 12% w/w and salicylic acid 6% w/w in emulsifying ointment |
|
03.05.01 |
Caffeine citrate |
unlicensed |
09.04.01 |
Cake, biscuits, and snacks |
Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. |
13.03 |
Calamine Aqueous Cream |
Over the counter preparation suitable for self-care/purchase if appropriate |
13.03 |
Calamine Lotion |
Over the counter preparation suitable for self-care/purchase if appropriate |
09.05.01.01 |
Calcichew® |
|
13.05.02 |
Calcipotriol 50mcg/g ointment |
|
13.05.02 |
Calcipotriol 50mcg/ml scalp application |
££££ |
13.05.02 |
Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet Gel® |
Scalp psoriasis: usual duration of treatment is 4 weeks
Mild to moderate plaque psoriasis, apply once daily to max. 30% of body surface (max. 15 g daily) for 8 weeks |
13.05.02 |
Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet ointment ® |
4 weeks therapy then assess
Maximum 15g per day or 100g per week.
Step down to calcipotrol oint as per NICE CG153 |
13.05.02 |
Calcipotriol 50micrograms/g with Betamethasone 0.05mg/g Enstilar® |
Cutaneous foam formulation
The recommended treatment period is 4 weeks
Maximum 15g per day
Excipients include liquid paraffin and butane- Extremely flammable aerosol
|
06.06.01 |
Calcitonin (salmon) / Salcatonin |
Injection
Nasal spray |
09.06.04 |
Calcitriol |
|
13.05.02 |
Calcitriol 3micrograms/g Silkis® |
- Specialist recommendation
- For delicate areas,face and flexures
|
09.06.04 |
Calcium and Vit D preparations |
Follow local guidance |
08.01 |
Calcium Folinate |
|
09.05.02.02 |
Calcium Salts |
- Specialist Recommendation
|
09.04 |
Calogen® |
- High-energy supplements: fat
- Used as a source of LCT, as an energy supplement and additive to feed to enhance energy density.
- Does not contain protein
- Also this is the only LCT fat source that can be used as a fat energy source in patients with organic acidaemias e.g. propionic acidaemia and methyl malonic acidaemia and urea cycle disorders. It may also be used as part of a modular feed or protein-free energy source. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat (or fat and carbohydrate) supplement. Liquid supplements
|
09.04 |
Calogen® Extra |
- Protein, fat, and carbohydrate
- Only to be used on dietetic advice for oral and tube feeds
- Used where energy, protein and micronutrients required.
- Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years; use with caution in child 3–6 years. May require dilution for child 3–5 years.
|
09.04 |
Calogen® Extra Shots |
- Protein, fat, and carbohydrate
- Used on dietetic advice only
- Used where hygiene concerns/infection control – single use sterile dose – where Calogen Extra bottle is not appropriate
- Used where energy, protein and micronutrients required in small volume
- Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement.
- Not suitable for child under 3 years; use with caution in child 3–6 years. May require dilution for child 3–5 years.
|
06.01.02.03 |
Canagliflozin Invokana® |
In line with NICE
See Type 2 diabetes DMMAG Guideline for the choice of oral and non-insulin antihyperglycaemic agents in adults
SLGT2 inhibitors are not to be used in primary care for type 1 diabetes until further local guidance becomes available |
02.05.05.02 |
Candesartan cilexetil tablets |
|
04.08.01 |
Cannabidiol Epidyolex® |
In line with NICE |
13.09 |
Capasal® |
Over the counter preparation suitable for self-care/purchase if appropriate |
08.01.03 |
Capecitabine Tablets |
|
12.03.01 |
Caphosol® |
Oncology and haematology use |
08.02.03 |
Caplacizumab Cablivi® |
Use in accordance with NICE guidance. |
05.01.09 |
Capreomycin |
|
04.07.03 |
Capsaicin |
|
10.03.02 |
Capsaicin cream |
Tier 2 , £££
|
10.03.02 |
Capsaicin cream |
see chapter 4.7.3 for neuropathic pain
|
02.05.05.01 |
Captopril tablets |
For existing patients only |
04.02.03 |
Carbamazepine |
|
04.07.03 |
Carbamazepine |
trigeminal neuralgia only |
04.08.01 |
Carbamazepine |
Tablets
M/R tablets
SF liquid
Suppositories
MHRA Advice
Patients being treated for epilepsy should be maintained on a specific manufacturer's product- APC preferred brand is TEGRETOL |
06.02.02 |
Carbimazole |
|
03.07 |
Carbocisteine |
|
A5.02.08 |
CarboFLEX |
Odour absorbent wound contact dressings containing activated charcoal Type of wound product is suitable for For the management of moderate to heavily exuding malodorous wounds including fungating Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change As exudate level determines Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known sensitivity to the dressing or its components As soon as CarboFLEX becomes contaminated with exudate, odour control diminishes The underlying cause of wound odour should be identified prior to commencement of product Rationale for inclusion in formulary CarboFLEX is a layered dressing to provide higher levels of fluid handling On shallow or cavity wounds with moderate to heavy levels of exudate |
11.08.01 |
Carbomers Clinitas Gel® |
Clinitas Gel does not have benzalkonium chloride (BAK) as a preservative. It is preserved with cetrimide. |
07.01.01 |
Carboprost |
|
09.04 |
Carbzero |
- High-energy supplements: fat
- 20% LCT emulsion, used as an energy source for children and adults on a ketogenic diet, may be used orally or in cooking
- For use in ketogenic diets. Long chain triglyceride liquid emulsion used as a milk replacement (when diluted) for some patients with PKU on very low protein diets who cannot tolerate other low protein milk replacements. It will help meet essential energy requirements. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
|
08.01.05 |
Carfilzomib Kyprolis® |
In line with NICE |
11.08.01 |
Carmellose 0.5% SDU Xailin Fresh ® |
|
11.08.01 |
Carmellose1% multi Moorfields |
|
08.01.01 |
Carmustine Gliadel® |
|
02.04 |
Carvedilol |
|
05.02.04 |
Caspofungin |
|
05.01.02.01 |
Cefalexin oral presentations |
Only when used in line with Antimicrobial guidelines When used outside Antimicrobial guidelines, on Specialist recommendation.
|
05.01.02.01 |
Cefotaxime injection |
Only when used in line with Antimicrobial guidelines When used outside Antimicrobial guidelines, on Specialist recommendation.
|
03.13 |
Ceftazidime |
Hospital only |
05.01.02.01 |
Ceftazidime |
|
05.01.02.01 |
Ceftriaxone |
|
03.13 |
Cefuroxime |
Hospital only |
05.01.02.01 |
Cefuroxime |
|
11.03.01 |
Cefuroxime |
Hospital only |
10.01.01 |
Celecoxib |
|
A5.08.07 |
Cellona® |
Sub compression wadding bandage to pad and shape a limb prior to compression therapy Type of wound product is suitable for Provides padding for larger limbs under compression. Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Daily up to weekly dependant on exudate and oedema management. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Advised not to apply directly to skin as can cause irritation. Rationale for inclusion in formulary Cost effective for use in larger quantities when used in lymphoedema management. |
08.01.05 |
Cemiplimab |
Use in line with NICE |
09.04.01 |
Cereals |
Essential protein-free basic products. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 2 regular Weetabix = 4.5g protein and this protein amount is more than the amount of protein that may be tolerated. |
08.01.05 |
Ceritinib Zykadia® |
In line with NICE |
10.01.03 |
Certolizumab Pegol Cimzia® |
In line with NICE
Hospital only
Available via Home Care |
12.01.03 |
Cerumol® |
|
03.04.01 |
Cetirizine |
OTC preparation suitable for self-care/purchase if appropriate |
13.02.01 |
Cetraben emollient cream® |
Over the counter preparation suitable for self-care/purchase if appropriate |
A5.13 |
Cetraben Pump cream |
Emollient containing white soft paraffin and light liquid paraffin Type of wound product is suitable for For inflamed, dry, chapped skin Frequency of use Daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy or hypersensitivity to any of the ingredients Rationale for inclusion in formulary Treatment of dry skin Dermatology approved |
06.07.02 |
Cetrorelix Cetrotide® |
|
08.01.05 |
Cetuximab Erbitux® |
|
04.01.01 |
Chloral Hydrate |
|
08.01.01 |
Chlorambucil Tablets |
|
05.01.07 |
Chloramphenicol injection |
|
11.03.01 |
Chloramphenicol |
0.5% eye drops First line
0.5% Minims (SDU)
1% eye ointment |
12.01.01 |
Chloramphenicol ear drops |
Only with positive culture/sensitivity data. |
04.01.02 |
Chlordiazepoxide |
Adjunct in acute alcohol withdrawal |
04.10.01 |
Chlordiazepoxide |
Adjunct in acute alcohol withdrawal |
13.11.02 |
Chlorhexidine acetate 0.015% with cetrimide 0.15% Travasept 100® |
|
12.03.04 |
Chlorhexidine gluconate 0.2% mouthwash |
|
12.03.04 |
Chlorhexidine gluconate 1% dental gel |
|
13.11.02 |
Chlorhexidine gluconate preparations |
|
12.02.03 |
Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin® |
Contains arachis (peanut) oil, not suitable for patients with allergy to peanuts.
Patients with soya allergy should also avoid Naseptin® |
03.04.01 |
Chlorphenamine |
OTC preparation suitable for self-care/purchase if appropriate |
04.02.01 |
Chlorpromazine (oral) |
- tablets
- syrup
- Supported by ESCA, see link below.
|
04.06 |
Chlorpromazine Hydrochloride |
nausea
hyperemesis in pregnancy (off label use) |
04.02.01 |
Chlorpromazine injection |
|
02.02.01 |
Chlortalidone Tablets |
|
14.04 |
Cholera vaccine Dukoral® |
- via travel vaccine service
|
12.03.01 |
Choline Salicylate dental gel |
For patients over 16 years |
06.05.01 |
Choriogonadotropin Alfa Ovitrelle® |
Hospital only |
A5.04.02 |
Cica-Care |
Silicone sheet for scar treatment Type of wound product is suitable for Not for use on open wounds- to be applied on healed scar only. This is not a dressing but a scar treatment Duration dressing remains on wound before changing 23 hours Frequency of dressing change Daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use on open or infected wounds. Do not use on skin affected by acne. Discontinue use if a rash or itching occur. Rationale for inclusion in formulary Scar therapy Silicone sheets have been shown to soften, flatten scarring aiding movement, nerve sensations and function. Self adherent, Re-usable |
03.02 |
Ciclesonide Alvesco® |
- Initiation by a respiratory specialist
- Supported by a RICaD
|
01.05.03 |
Ciclosporin |
Capsules 10mg, 25mg, 50mg, 100mg, IV infusion 50mg/ml
Treatment of ulcerative colitis- for specialist use only
MHRA specify that ciclosporin must be prescribed and dispensed by brand as bioavailability differences exist between brands
|
04.13 |
Ciclosporin |
Specialist use only for neurological conditions |
08.02.02 |
Ciclosporin Neoral® Sandimmun® |
Post transplant- if prescribing is NOT established with GP before 1st April 2013
Post transplant - if prescribing IS established with GP before 1st April 2013
|
10.01.03 |
Ciclosporin |
Supported by ESCA, see link below. |
13.05.03 |
Ciclosporin |
- supported by ESCA, see link below
|
11.99.99.99 |
Ciclosporin 2mg/g eye ointment Optimmune® |
|
11.99.99.99 |
Ciclosporin 1 mg/mL eye drops, emulsion Ikervis® |
- Specialist initiation.
- In line with NICE
|
11.99.99.99 |
Ciclosporin 1mg/ml eye drops, emulsion Verkazia® |
- Specialist Opthalmologist Initiation
- Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents
|
09.05.01.02 |
Cinacalcet Mimpara® |
NHSE commissioned for dialysis only.
All prescribing retained by secondary care. |
04.06 |
Cinnarizine tablets |
|
05.01.12 |
Ciprofloxacin infusion |
|
05.01.12 |
Ciprofloxacin oral presentations |
Only when used in line with Antimicrobial guidelines
When used outside Antimicrobial guidelines, on Specialist recommendation.
|
11.03.01 |
Ciprofloxacin 0.3% |
- Specialist Ophthalmologist recommendation(Corneal consultant)
|
12.01.01 |
Ciprofloxacin 0.3% drops |
- Off label use of eye drops
- Specialist Recommendation
|
12.01.01 |
Ciprofloxacin 2mg/ml ear drops Cetraxal® |
|
04.03.03 |
Citalopram oral drops |
- Not recommended routinely due to QT prolongation risk
|
04.03.03 |
Citalopram tablets |
- Not recommended routinely due to QT prolongation risk
|
08.02.04 |
Cladribine Mavenclad® |
In line with NICE Hospital only- NHSE commissioned |
05.01.05 |
Clarithromycin injection |
|
05.01.05 |
Clarithromycin oral presentations |
|
06.04.01.01 |
Climanor® |
|
05.01.06 |
Clindamycin Capsules |
Only when used in line with Antimicrobial guidelines
When used outside Antimicrobial guidelines, on Specialist recommendation.
|
07.02.02 |
Clindamycin Dalacin® |
2% cream |
13.06.02 |
Clindamycin |
- Specialist initiation
- 12 week course
|
13.06.01 |
Clindamycin 1% topical solution Dalacin T ® |
|
05.01.06 |
Clindamycin 300mg/2mL Injection |
|
A5.08.03 |
Clinifast |
££
Elasticated Sub bandage lining
Type of wound product is suitable for
To be used under retention and compression bandages when conformity is required
Can be used for wet/dry wrapping.
Duration dressing remains on wound before changing
As required
Frequency of dressing change
As required
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Ensure the correct size for a limb is selected
Rationale for inclusion in formulary
Cost effective choice when conformity to a limb is required
|
A5.07.03 |
Clinipore |
Permeable non woven, synthetic adhesive tape
For securing bandages
Frequency of dressing change
Determined by wound type and dressing change
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
None listed
Rationale for inclusion in formulary
Available on drug tariff, cost effective and evaluated as meeting the requirements of a tape including adherence.
|
A5.02.08 |
Clinisorb |
Odour absorbent charcoal dressing Type of wound product is suitable for Malodourous wounds such as fungating wounds Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change 1-7 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not indicated as a primary dressing in dry wounds Store at room temperature Exudate levels will reduce the effectiveness of the charcoal Rationale for inclusion in formulary Clinisorb is an activated charcoal dressing which adsorb toxins removing malodour from the wound Can be cut to size Cost effective |
06.04.01.01 |
Clinorette® tablets |
|
04.08.01 |
Clobazam |
MHRA Advice Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
13.04 |
Clobetasol Propionate 0.05% Dermovate® |
Potency: very potent
Cream
Ointment
Scalp application |
13.04 |
Clobetasone Butyrate 0.05% cream Eumovate® |
Potency: moderate |
13.04 |
Clobetasone Butyrate 0.05% ointment Eumovate® |
Potency: moderate |
06.05.01 |
Clomifene Citrate |
- For ovulation induction
- On specialist recommendation
- Generic tablets
|
04.03.01 |
Clomipramine |
|
21 |
Clonazepam |
Tablets
Pain - off label use according to WM Cares guideline |
04.08.01 |
Clonazepam tablets |
MHRA Advice Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
02.05.02 |
Clonidine Hydrochloride tablets Catapres® |
|
02.09 |
Clopidogrel 75mg tablets |
|
07.02.02 |
Clotrimazole |
All formulations |
12.01.01 |
Clotrimazole Canesten® |
Only with positive culture/sensitivity data. |
13.10.02 |
Clotrimazole 1% |
cream
powder
solution |
04.02.01 |
Clozapine tablets |
|
13.14.03 |
Coal tar BP 10% w/w in YSP |
|
13.14.03 |
Coal tar BP 2% w/w in YSP |
|
13.14.03 |
Coal tar BP 5% w/w in YSP |
|
13.09 |
Coal Tar Extract 5% (Alcoholic) Alphosyl 2 in 1® |
Over the counter preparation suitable for self-care/purchase if appropriate |
13.05.02 |
Coal tar lotion 5% Exorex® |
|
13.05.02 |
Coal Tar Solution 2.5%, Arachis (peanut) Oil extract of Coal Tar 7.5%, Tar 7.5%, Cade Oil 7.5%, Liqiud Paraffin 35% Polytar Emollient® |
contains peanut oil |
13.14.02 |
Coal tar solution BP 3.3% w/w and propylene glycol 20% w/w in Synalar® gel |
|
13.14.02 |
Coal tar solution BP 5% w/w in betamethasone valerate 0.025% w/w ointment |
|
13.14.03 |
coal tar solution BP 6% w/w / salicylic acid 2% w/w in emulsifying ointment |
|
13.14.03 |
Coal tar solution BP 6% w/w and salicylic acid 6% w/w in Ung. merck |
|
02.02.04 |
Co-amilofruse (furosemide and amiloride) |
Combination products should be avoided, unless compliance is an issue. |
05.01.01.03 |
Co-Amoxiclav oral presentations |
Only when used in line with Antimicrobial guidelines
When used outside Antimicrobial guidelines, on Specialist recommendation.
|
05.01.01.03 |
Co-Amoxiclav injection |
|
A5.08.08 |
Coban, Coban Lite® |
Two layer compression system available in full and reduced compression (Coban Lite). Comprises of a latex free foam padding and cohesive bandage. Type of wound product is suitable for Treatment of venous and mixed aetiology leg ulcers Duration dressing remains on wound before changing 1 to 7 days Frequency of dressing change Daily up to weekly dependant on exudate and oedema management. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Arterial disease Not to be used with other padding or wadding Rationale for inclusion in formulary Two layer compression kit, Once applied the two layers form a band to become a single layer bandage. Bandage technique can be adapted to reduce forefoot oedema (Extra training required) |
04.09.01 |
Co-Beneldopa |
- Capsules
- M/R capsules
- Dispersible tablets
|
04.09.01 |
Co-Careldopa |
|
04.09.01 |
Co-Careldopa and Entacapone Stalevo® |
|
13.14.06 |
Coconut oil 25% w/w in emulsifying ointment |
|
13.06.02 |
Co-Cyprindiol 2000/35 |
Prescribe as generic |
01.06.02 |
Co-danthramer |
Capsules 25/200, 75/1000 Suspension 25/200 in 5ml, Strong suspension 75/1000 in 5ml Co-dantramer strong preferred as per palliative care formulary guidance For constipation in terminally ill patients only |
21 |
Co-danthramer |
Strong suspension |
01.06.02 |
Co-danthrusate |
Capsules 50/60 For constipation in terminally ill patients only |
21 |
Co-danthrusate |
Capsules |
01.04.02 |
Codeine |
Tablets 15mg, 30mg, Syrup 25mg/5ml |
04.07.02 |
Codeine Phosphate |
- tablets
- 25mg/5ml syrup
- Use with caution in patients aged over 65
- Contraindicated in children below the age of 12
|
04.07.02 |
Codeine Phosphate injection |
|
10.01.04 |
Colchicine |
|
09.06.04 |
Colecalciferol oral |
Please see guidance below to support prescribing
Please prescribe generically as listed below
Oral Capsules or Tablets
Colecalciferol 800 unit capsules
Colecalciferol 800 unit tablets
Colecalciferol 1,000unit capsules
Colecalciferol 1,000unit tablets
Colecalciferol 3,200unit capsules
Colecalciferol 4,000unit tablets
Colecalciferol 20,000unit capsules
Colecalciferol 25,000unit tablets
Colecalciferol 40,000unit capsules
Oral Solution
Colecalciferol 2,740units/ml oral drops sugar free
Colecalciferol 10,000units/ml oral drops sugar free
Colecalciferol 10,000units/ml oral solution sugar free
Colecalciferol 15,000units/5ml oral solution
Colecalciferol 25,000units/1ml oral solution unit dose ampoules sugar free
Colecalciferol 50,000units/1ml oral solution unit dose ampoules sugar free
Licensed brands currently available (updated March 2017)
Aviticol 800 IU Capsules
Aviticol 1,000 IU Capsules (Listed in the Drug Tariff)
Aviticol 20,000 IU Capsules
Desunin 800 IU Tablets (Listed in the Drug Tariff)
Desunin 4,000 IU Tablets (Listed in the Drug Tariff)
Fultium-D3 800 IU Capsules (Listed in the Drug Tariff)
Fultium-D3 3,200 IU Capsules (Listed in the Drug Tariff)
Fultium-D3 20,000 IU Capsules (Listed in the Drug Tariff)
Fultium-D3 2740 IU/ml oral drops, solution (Listed in the Drug Tariff)
InVita D3 800 IU Capsules
InVita D3 2,400 IU/ml oral drops, solution
InVita D3 25,000 IU oral solution (Listed in the Drug Tariff)
InVitaD3 50,000 IU oral solution (Listed in the Drug Tariff)
Plenachol 20,000 IU Capsules
Plenachol 40,000 IU Capsules (Listed in the Drug Tariff)
Stexerol-D3 1,000 IU Tablets (Listed in the Drug Tariff)
Stexerol-D3 25,000 IU Tablets (Listed in the Drug Tariff)
STRIVIT-D3 800 IU Capsules
THORENS 10 000 I.U. /ml oral drops, solution (Listed in the Drug Tariff)
THORENS 25 000 I.U. /2.5 ml oral solution
|
02.12 |
Colesevelam Cholestagel® |
- Supported by a RICaD (in development)
|
02.12 |
Colestipol Colestid® |
- Supported by a RICaD (in development)
|
01.09.02 |
Colestyramine |
Powder |
02.12 |
Colestyramine sachets |
Jaundice and Primary Biliary Cholangitis (PBC) |
05.01.07 |
Colistimethate injection |
|
05.01.07 |
Colistimethate for nebulisation |
- See Chapter 3 for respiratory specific indications
|
05.01.07 |
Colistimethate inhaler Colobreathe® |
|
03.13 |
Colistimethate sodium Colistin sulfomethate sodium nebulised |
Commissioned by NHS England for Cystic Fibrosis only New patients Existing patients (initiated prior to April 2013) |
10.03.01 |
Collagenase clostridium histolyticum Xiapex® |
In line with NICE |
01.01.01 |
Co-magaldrox |
When low sodium content is required. ££
Mucogel is most cost effective brand
Use with caution in renal impairment |
07.03.01 |
Combined Hormonal Contraceptive Patches Evra® |
- For patients with poor compliance or absorption problems
|
A5.08.07 |
Comprilan® |
100 % cotton short stretch compression bandage Type of wound product is suitable for Venous leg ulceration Varicosis Management of chronic oedema Management of primary and secondary lymphoedema Deep venous thrombosis Thrombophlebitis Duration dressing remains on wound before changing 1 to 7 days Frequency of dressing change Dependant on exudate levels if wound present or oedema management. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Advanced Peripheral arterial occlusive disease Decompensated cardiac insufficiency Septic phlebitis Phlegmasia coerula doleris Rationale for inclusion in formulary Cotton short stretch bandage. Used by lymphoedema nurse specialists |
03.04.03 |
Conestat Alfa Ruconest® |
Hospital Only- NHSE commissioned |
A5.15 |
Conotrane cream |
Barrier cream Type of wound product is suitable for Intact skin, not to be applied to a wound. To protect the skin from moisture, irritation and chafing. Frequency of use Application at every episode of hygiene. Apply a thin layer sparingly Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not to be used in conjunction with containment products for incontinence due to the inclusion of liquid paraffin in the ingredients, which will repel urine/faeces back onto the skin. Any allergy to the listed ingredients Rationale for inclusion in formulary Dermatology approved
|
13.02.02 |
Conotrane® |
Over the counter preparation suitable for self-care/purchase if appropriate |
07.03.05 |
Copper Intra-uterine devices |
Various |
09.04 |
Corn flour and corn starch |
- For glycogen storage disease
- Slow release CHO to prevent hypoglycaemia in GSD
- Slow release carbohydrate to prevent hypoglycaemia in all types of GSD. Cheaper than glycosade and easier to mix. Used in less severe forms of GSD. Between 1 to 2g/kg body weight is prescribed dependent on age, weight and clinical symptoms of hypoglycaemia. Doses may be given at regular intervals during the day and night or at bedtime only. The dose and frequency of dose should always be advised by the specialist dietitian according to the needs of the patient.
|
05.01.08 |
Co-trimoxazole IV infusion |
|
05.01.08 |
Co-trimoxazole oral presentations |
|
A5.08.03 |
Cotton Stokinette BP |
Sub bandage lining
Type of wound product is suitable for
To be used under retention and compression bandages
Duration dressing remains on wound before changing
As required
Frequency of dressing change
As required
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Not to be used under Coban compression therapy
Not to be used under compression hosiery
Does not conform to a limb shape. If conformity is required, choose Clinifast
Rationale for inclusion in formulary
Cost effective choice when conformity to a limb is not required
|
09.04 |
Cow & Gate Pepti-Junior® |
- Infant and child: Hydrolysate formula
- Whey hydrolysate. Use in infants who have malabsorption problems and require a peptide and MCT containing feed. Eg after gut surgery. Use as tube or oral feed
- Disaccharide and/or whole protein intolerance, or where amino acids and peptides are indicated in conjunction with medium chain triglycerides.
|
08.01.05 |
Crisantaspase Erwinase® |
|
08.01.05 |
Crizotinib Xalkori® |
Hospital only- NHSE commissioned
In line with NICE |
13.03 |
Crotamiton Eurax® |
Over the counter preparation suitable for self-care/purchase if appropriate |
A5.03.04 |
Cutimed ®Sorbact |
DACC coated dressings providing antimicrobial properties, available in a pad, gel, gel sheet, ribbon, round swab and rectangular swab Type of wound product is suitable for Colonised or clinically infected moist wound, suitable for any wound type Duration dressing remains on wound before changing 1-3 days Frequency of dressing change 1-3 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use in combination with oils and creams Known hypersensitivity to ingredients Not for dry wound Not for heavily exuding wounds Rationale for inclusion in formulary Alternative to available antimicrobials |
A5.02.02 |
C-View Post-Op |
Vapour-permeable adhesive film with absorbent pad Type of wound product is suitable for Dry non infected wounds, low exuding wounds, minor burns, protection of intact skin, protection of newly epithelialized wounds Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Up to 7 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Clinically infected wounds, bleeding or exuding wounds Rationale for inclusion in formulary Protection of intact skin, low exuding wounds. Waterproof
|
04.06 |
Cyclizine |
tablets
injection- for palliative care |
11.05 |
Cyclopentolate Hydrochloride 0.5% eye drops |
|
11.05 |
Cyclopentolate Hydrochloride 1% eye drops |
|
11.05 |
Cyclopentolate Hydrochloride single use Minims® |
- Specialist Ophthalmologist Recommendation.
|
08.01.01 |
Cyclophosphamide Tablets |
For oncology |
05.01.09 |
Cycloserine |
|
06.04.02 |
Cyproterone Acetate |
|
08.03.04.02 |
Cyproterone Acetate |
|
09.04 |
Cystine500® |
- To correct cysteine deficiency in homocystinuria
- The only pre-measured sachet of cysteine to correct cysteine deficiency in homocystinuria. The dose and frequency of administration will be determined by the specialist dietitian.
- Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
|
08.01.03 |
Cytarabine–daunorubicin liposomal Vyxeos® |
In line with NICE |
02.08.02 |
Dabigatran |
Following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants.
BSSE APC Primary Care Clinical Pathway for Arial Fibrillation Detection and Management Use following Hip and Knee surgery- full course of treatment supplied on discharge.
For the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Dabigatran in DVT / PE |
08.01.05 |
Dabrafenib with Trametinib |
In line with NICE |
08.01.05 |
Dacarbazine |
|
05.03.03.02 |
Daclatasvir Daklinza® |
In line with NICE |
08.01.05 |
Dacomitinib |
Use in line with NICE |
05.01.07 |
Dalbavancin |
|
09.04 |
Dalia |
- Low protein milk for children and adults with phenylketonuria and other disorders of protein metabolism
- Low protein milk (similar energy content to cow’s milk) for children and adults with phenylketonuria and other disorders of protein metabolism.
|
02.08.01 |
Danaparoid Orgaran® |
|
06.07.02 |
Danazol |
- For hereditary angioedema (off label use)
|
10.02.02 |
Dantrolene capsules |
|
01.06.02 |
Dantron |
For constipation in terminally ill patients only |
21 |
Dantron |
|
06.01.02.03 |
Dapagliflozin Forxiga® |
In line with NICE
See Type 2 diabetes DMMAG Guideline for the choice of oral and non-insulin antihyperglycaemic agents in adults
SLGT2 inhibitors are not to be used in primary care for type 1 diabetes until further local guidance becomes available
for treating Type 2 diabetes in line with NICE
for treating chronic heart failure with reduced ejection fraction
Specialist centres only for treating Type 1 diabetes as per NICE TA 597: Dapagliflozin with insulin for treating type 1 diabetes
|
05.01.10 |
Dapsone |
See Chapter 13 for use in dermatology |
05.01.07 |
Daptomycin injection |
|
08.01.05 |
Daratumumab Darzalex ® |
In line with NICE |
09.01.03 |
Darbepoetin Alfa Aranesp® |
NHSE commissioned for use in renal dialysis
Primary Care commissioned for use in cancer- in line with NICE TA323
|
08.03.04.02 |
Darolutamide Nubeqa® |
In line with NICE |
05.03.01 |
Darunavir Prezista® |
|
08.01.05 |
Dasatinib Sprycel® |
In line with NICE |
A5.05.03 |
Debrisoft® |
£££ Debridement pad to cleanse and debride wounds. Type of wound product is suitable for Acute or chronic wounds with surface debris eg pressure ulcers, leg ulcers, diabetic foot ulcers Hyperkeratosis Duration dressing remains on wound before changing Not applicable Frequency of dressing change At each dressing change or as required Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known sensitivity to polyester Heavy slough and necrotic tissue may require autolytic debridement to soften prior to use Thick hyperkeratosis may take more than one treatment Must be wet with clean warm water prior to use Do not get an emollient on the pad as this blocks the monofilaments Rationale for inclusion in formulary Lifts debris, superficial slough and exudate without damaging new granulation or epithelial cells Removes biofilms Lifts hyperkeratosis and dry flaking skin peri-wound Recommended by NICE Treatment well tolerated Convenient, easy to use, disposable single use pad
|
09.01.03 |
Deferasirox Exjade® |
NHSE commissioned |
09.01.03 |
Deferiprone Ferriprox® |
NHSE commissioned |
08.03.04.02 |
Degarelix |
- Commissioned by CCGs, in line with NICE
- Transfer to Primary Care supported by an ESCA. Click here
to access
|
05.01.03 |
Demeclocycline capsules |
See Chapter 6 for non-infection indications |
06.05.02 |
Demeclocycline capsules |
- in the treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone. UNLICENSED
|
06.06.02 |
Denosumab XGEVA® |
|
06.06.02 |
Denosumab Prolia® |
- Use in postmenopausal osteoporosis is supported by an ESCA, see link below.
|
13.08.02 |
Dermablend® |
- Specialist recommendation
|
13.10.05 |
Dermabond ProPen® |
Hospital only |
13.08.02 |
Dermacolor® |
- First line
- Specialist recommendation
- 100 shades available
- FP10 prescriptions should be endorsed "ACBS"
|
A5.13 |
Dermatonics Once Heel balm |
Cream containing 25% urea Type of wound product is suitable for To moisturise dry skin on the soles of feet For use on adults and children over 12 years of age Frequency of use Reapply daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy or hypersensitivity to any of the ingredients, contains beeswax and lanolin Not to be used on children under 12 Rationale for inclusion in formulary Treatment of dry skin conditions of the foot. Dermatology approved |
13.02.01 |
Dermatonics Once Heel Balm® |
specialist recommendation for epidermolysis bullosa
|
A5.13 |
Dermol 500 Lotion |
Emollient lotion containing an antimicrobial Type of wound product is suitable for For dry and pruritic skin conditions including eczema and dermatitis. Can be applied to skin as an emollient or used as a soap substitute Frequency of use Reapply daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy or hypersensitivity to any of the ingredients, contains benzalkonium chloride, 0.1%, chlorhexidine hydrochloride 0.1%, liquid paraffin, isopropyl myristate. Should not be used unless infection is present or is a frequent complication Rationale for inclusion in formulary Treatment of dry skin requiring antimicrobial properties Dermatology approved
|
13.02.01 |
Dermol 500 lotion ® |
short term use only
Over the counter preparation suitable for self-care/purchase if appropriate |
13.02.01.01 |
Dermol 600® |
Over the counter preparation suitable for self-care/purchase if appropriate |
09.01.03 |
Desferrioxamine Mesilate |
NHSE commissioned |
06.05.02 |
Desmopressin |
Tablets
Melts (60mcg, 120mcg and 240mcg only)£££
Nasal solution
Nasal spray (10mcg/dose) |
07.03.02.01 |
Desogestrel 75mcg |
Prescribe generically
|
09.04.01 |
Desserts |
Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. |
06.03.02 |
Dexamethasone |
Tablets £££
Oral solution SF £££ |
11.04.01 |
Dexamethasone 0.1% eye drops Maxidex® |
|
11.04.01 |
Dexamethasone 0.1% eye drops Single dose units |
- for post corneal implants or OSD
- Use the agent with the lowest acquisition cost
|
11.04.01 |
Dexamethasone 700mcg intravitreal implant Ozurdex® |
For macular oedema secondary to retinal vein occlusion -use in line with NICE
For diabetic macular oedema- use in line with NICE |
04.06 |
Dexamethasone injection |
|
06.03.02 |
Dexamethasone phosphate injection |
|
04.06 |
Dexamethasone tablets |
for resistant nausea and vomitting £££ |
12.01.01 |
Dexamethasone with Antibacterial Sofradex® |
|
11.04.01 |
Dexamethasone with Antibacterials Tobradex® |
|
12.01.01 |
Dexamethasone with neomycin and glacial acetic acid Otomize® |
|
11.04.01 |
Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol® |
- Specialist Ophthalmologist Recommendation.
|
04.04 |
Dexamfetamine |
Please note that commissioning discussion is underway. However the present status is as follows:-
Birmingham and Solihull CCG
Age 6 and over - Solihull practices. Supported with ESCA
Age 16 and over - Birmingham practices. Supported with ESCA
Age under 16 - Birmingham practices
Sandwell and West Birmingham CCG
Age 6 and over. Supported with ESCA. Click here for shared care document for patients seen by Black Country Partnership NHS FT
|
08.01 |
Dexrazoxane Savene® |
|
09.04 |
Dialamine® |
- Protein and carbohydrate
- This is a source of essential amino acids for use in low protein diets with urea cycle disorders. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Hypoproteinaemia, chronic renal failure, wound fistula leakage with excessive protein loss, conditions requiring a controlled nitrogen intake, and haemodialysis. Not suitable for child under 6 months.
|
04.07.02 |
Diamorphine salts |
|
04.01.02 |
Diazepam |
|
04.01.02 |
Diazepam |
|
04.10.01 |
Diazepam |
|
10.02.02 |
Diazepam |
|
04.01.01 |
Diazepam liquid |
Inpatient use and prison settings only |
04.08.02 |
Diazepam rectal tubes |
|
10.01.01 |
Diclofenac |
Short term use only
assess CVD risk
Not first line NSAID
Renal colic and severe acute painful conditions |
10.01.01 |
Diclofenac |
Short term use only
assess CVD risk
Not first line NSAID
For patients with swallowing diffulties
Renal colic and severe acute painful conditions |
11.08.02 |
Diclofenac Voltarol® Ophtha SDU |
|
11.08.02 |
Diclofenac Sodium Voltarol® Ophtha multidose |
|
13.08.01 |
Diclofenac sodium 3% gel |
££ |
05.03.01 |
Didanosine Videx® |
|
08.03.01 |
Diethylstilbestrol |
|
13.04 |
Diflucortolone Valerate 0.3% oily cream |
Potency: very potent |
02.01.01 |
Digoxin Elixir |
Use only if still symptomatic despite optimal treatment of HF with atrial fibrillation.
Take extra caution in the elderly who may be more susceptible to digitalis toxicity.
|
02.01.01 |
Digoxin Injection |
|
02.01.01 |
Digoxin specific antibody fragments Digifab® |
|
02.01.01 |
Digoxin Tablets |
Use only if still symptomatic despite optimal treatment of HF with atrial fibrillation.
Take extra caution in the elderly who may be more susceptible to digitalis toxicity.
|
04.07.02 |
Dihydrocodeine |
tablets
oral solution- for patients with swallowing difficulties |
05.04.02 |
Diloxanide Furoate Diloxanide® |
|
02.06.02 |
Diltiazem |
60mg tablets - FIRST LINE. For administration three times a day. No requirement for brand name prescribing.
Modified- release formulations should be prescribed by brand name.
Brand rationalisation- APC preferred brands:(in alphabetical order, does not suggest order of preference)
Adizem SR capsules and tablets
Adizem XL capsules
Angitil SR capsules
Angitil XL capsules
Tildiem LA capsules
Tildiem Retard tablets |
01.07.04 |
Diltiazem Cream 2% |
Cream
££££
Unlicensed - for use only in patients intolerant of or unresponsive to GTN ointment
Store in fridge
One tube will last a month if used as 2cm application TWICE DAILY
|
08.02.04 |
Dimethyl fumarate Tecfidera® |
For use in relapsing-remitting Multiple Sclerosis- NHSE commissioned
In line with NICE |
13.05.03 |
Dimethyl fumarate Skilarence® |
For use in moderate to severe plaque psoriasis- CCG commissioned In line with NICE |
07.04.04 |
DIMETHYL SULPHOXIDE Bladder Instillation 50% |
Hospital only |
13.10.04 |
Dimeticone |
Over the counter preparation suitable for self-care/purchase if appropriate |
07.01.01 |
Dinoprostone |
|
07.01.01.01 |
Dinoprostone Prostin E2® |
|
08.02.03 |
Dinutuximab |
In line with NICE |
13.14.07 |
Diphenylcyclopropenone in acetone 0.00001-6.0% w/v |
|
02.09 |
Dipyridamole MR capsules Persantin® Retard |
|
02.09 |
Dipyridamole tablets |
|
06.06.02 |
Disodium Pamidronate |
|
21 |
Disodium pamidronate |
All forms |
02.03.02 |
Disopyramide capsules |
|
02.03.02 |
Disopyramide injection |
|
04.10.01 |
Disulfiram Antabuse® |
|
13.05.02 |
Dithranol Dithrocream® |
- All Strengths. Specialist Recommendation
|
13.14.05 |
Dithranol in Lassar’s paste 0.1% w/w |
|
13.14.05 |
Dithranol in Lassar’s paste 0.5% w/w |
|
13.14.05 |
Dithranol in Lassar’s paste 1% w/w |
|
13.14.05 |
Dithranol in Lassar’s paste 10% w/w |
|
13.14.05 |
Dithranol in Lassar’s paste 15% w/w |
|
13.14.05 |
Dithranol in Lassar’s paste 2% w/w |
|
13.14.05 |
Dithranol in Lassar’s paste 4% w/w |
|
13.14.05 |
Dithranol in Lassar’s paste 8% w/w |
|
13.14.05 |
Dithranol pomade 0.4% w/w |
dithranol 0.4% w/w, salicylic acid 2% w/w, emulsifying wax BP 25% w/w, liquid paraffin to 100% |
02.07.01 |
Dobutamine |
|
08.01.05 |
Docetaxel |
In line with NICE |
09.04 |
DocOmega® |
- DHA supplement for low chain fatty acid and low protein diets
- The only ACBS prescribed DHA supplement for low protein diets. The dose and frequency of administration will be determined by the specialist dietitian.
- Nutritional supplement for the dietary management of inborn errors of metabolism for adults and children from birth.
|
01.06.02 |
Docusate Sodium |
Capsules 100mg, Liquid 50mg/5ml
- Solution is utterly unpalatable - only fit for use down tubes)
- Probably acts as a softening laxative as well as a stimulant
- Time to effect is approximately 24 to 48 hours |
01.02 |
Domperidone |
Second line
Domperidone is no longer recommended for the management of heartburn, bloating and stomach discomfort. See the link below for more information |
04.06 |
Domperidone |
tablets- short term use only
suppositories
SF suspension £££ - for patients with swallowing difficulties only |
04.11 |
Donepezil |
- tablets
- orodispersible 10mg tablets sugar free (pack of 28)
|
02.07.01 |
Dopamine |
|
03.07 |
Dornase Alfa Pulmozyme® |
Commissioned by NHS England for Cystic Fibrosis only New patients
For existing patients (initiated pre April 2013)
|
11.06 |
Dorzolamide 2% |
- Specialist Ophthalmologist Recommendation
|
11.06 |
Dorzolamide 2% with Timolol 0.5% |
- Specialist Ophthalmologist Recommendation
|
11.06 |
Dorzolamide 2% with Timolol 0.5% SDU Eye Drops Cosopt® |
- Specialist Ophthalmologist Recommendation
|
11.06 |
Dorzolamide 2% eye drops (SDU) Trusopt® |
- Specialist Ophthalmologist Recommendation
|
13.02.01 |
DoubleBase Gel ® |
Over the counter preparation suitable for self-care/purchase if appropriate |
03.05.01 |
Doxapram Dopram® |
Hospital only |
02.05.04 |
Doxazosin tablets |
Plain tablets
Modified release tablets are non- formulary |
07.04.01 |
Doxazosin tablets |
Plain tablets only
Modified release tablets are non formulary.
|
13.03 |
Doxepin Hcl cream Xepin ® |
|
08.01.02 |
Doxorubicin Hydrochloride Lipid formulation |
|
05.01.03 |
Doxycycline oral |
|
05.01.03 |
Doxycycline injection |
|
13.06.02 |
Doxycycline |
- Topical treatments should be used first line.
- Oral antibiotics should be reserved for acne, if topical treatment is not adequately effective or if it is inappropriate.
Please refer to Antimicrobial guidelines
|
02.03.02 |
Dronedarone tablets Multaq® |
To be used in line with NICE guidance |
03.01.05 |
Drug Delivery Device Haleraid® |
Please note this device is not prescribable, but can be obtained on request from community pharmacies but will incur a small cost. |
03.01.05 |
Drug Delivery Devices |
All spacer devices
|
06.04.01.01 |
Duavive® |
- Specialist recommendation
|
06.01.02.03 |
Dulaglutide Trulicity®▼ |
- injection
- NOT for monotherapy
|
04.03.04 |
Duloxetine Cymbalta® |
|
04.07.03 |
Duloxetine Cymbalta® |
3rd line after gabapentin
low abuse potential , high cost £££
on advice of specialist
not licensed for use in children |
07.04.02 |
Duloxetine |
|
09.04 |
Duocal® Super Soluble |
- Fat and Carbohydrate
- For renal children with fluid restriction
- Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat (or fat and carbohydrate) supplement.
|
A5.02.04 |
Duoderm range of dressings |
The adhesive layer forms a cohesive gel when in contact with wound exudate
Available as Extra thin or Signal (Bordered)
Type of wound product is suitable for
Dry to lightly exuding wounds
Non infected
Acute or Chronic wounds
Duration dressing remains on wound before changing
Up to 7 days maximum
Frequency of dressing change
3-7 days
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Not suitable for infected wounds, full thickness burns or wounds with exposed bone, muscle or tendon or wounds that are likely to macerate, particularly on plantar surface of foot
Not for diabetic foot ulcers
Not for ischaemic wounds
Known product or component sensitivity
Rationale for inclusion in formulary
Conformable, waterproof, aids autolysis. Protect surrounding skin , reduced risk of
blistering. Cost effective
|
08.01.05 |
Dupilumab |
In line with NICE |
08.01.05 |
Durvalumab |
In line with NICE |
06.04.02 |
Dutasteride Avodart® |
- When finasteride has failed or is contraindicated/not tolerated
|
09.04 |
EAA® Supplement |
- Consists of essential amino acids for the treatment of urea cycle disorders
- Essential amino acid supplement for use in urea cycle disorders and the cerebral creatine deficiency syndrome: guanidinoacetate methyltransferase (GAMT) deficiency. The only pre-measured sachet of essential amino acids with added vitamins and minerals for the treatment of urea cycle disorders. This is particularly important as most of our families with UCD do not speak English as their first language so require pre-measured products. Unmeasured use of essential amino acid supplements in UCD could lead to hyperammonaemia, acute brain encephalopathy and ITU admission. The dose and frequency of administration will be determined by the specialist dietitian.
- Nutritional supplement for the dietary management of disorders of protein metabolism including urea cycle disorders in children over 3 years.
|
A5.11 |
Easy-Slide |
Application aid for open toe compression hosiery garments |
A5.01.02 |
Eclypse |
Approved June 2018 to replace Flivasorb® |
11.03.02 |
Econazole 1% eye drops |
|
07.02.02 |
Econazole pessaries Gyno-Pevaryl® |
|
02.08.02 |
Edoxaban |
Following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants.
BSSE APC Primary Care Clinical Pathway for Arial Fibrillation Detection and Management
For treating and for preventing recurrent DVT and PE- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD RICaD: Edoxaban in DVT/PE
|
10.02.01 |
Edrophonium Chloride |
Hospital only |
05.03.01 |
Efavirenz Sustiva® |
|
09.04.02 |
Elemental 028®Extra |
- Less than 1 kcal/mL and less than 5 g protein/100 mL
- Amino acid formula (essential and non-essential amino acids)
- Pts with IBD, multiple allergy
- Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula
|
09.04.02 |
Elemental 028®Extra |
- Less than 1 kcal/mL and less than 5 g protein/100 mL
- Amino acid formula (essential and non-essential amino acids)
- Pts with IBD, multiple allergies. For tube feed and oral feeding. Alter concentration of feed to support individual patient’s nutritional needs.
- Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula
|
09.08.01 |
Eliglustat Cerdelga® |
In line with NICE Highly Specialised Technology guidance- NHSE commissioned |
06.04.01.01 |
Elleste Solo MX® Patch |
- If a 40mcg or 80mcg strength required
|
06.04.01.01 |
Elleste Solo® |
- Elleste Solo® 1mg and 2mg tablets
|
06.04.01.01 |
Elleste-Duet Conti® tablets |
|
06.04.01.01 |
Elleste-Duet® tablets (sequential) |
|
09.01.04 |
Eltrombopag Revolade® |
|
01.05 |
Eluxadoline |
- In line with NICE
- Specialist initiation, transfer of prescribing supported by RICaD.
- RICaD: Eluxadoline
|
06.01.02.03 |
Empagliflozin Jardiance® |
In line with NICE
See Type 2 diabetes DMMAG Guideline for the choice of oral and non-insulin antihyperglycaemic agents in adults
SLGT2 inhibitors are not to be used in primary care for type 1 diabetes until further local guidance becomes available |
05.03.01 |
Emtricitabine Emtriva® |
|
A5.14 |
Emulsifying Ointment |
Emollient ointment containing emulsifying wax, white soft paraffin and liquid paraffin Type of wound product is suitable for For treatment of dry skin conditions Frequency of use Daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy or hypersensitivity to any of the ingredients Rationale for inclusion in formulary Treatment of dry skin Dermatology approved
|
13.02.01 |
Emulsifying Ointment BP |
Over the counter preparation suitable for self-care/purchase if appropriate |
02.05.05.01 |
Enalapril tablets |
For existing patients only. |
08.01.05 |
Encorafenib Braftovi ® |
In line with NICE |
08.01.05 |
Encorafenib with binimetinib |
In line with NICE |
09.04 |
Energivit® |
- Fat and Carbohydrate
- Infant feed - Metabolic disorder pts
- Also protein-free (containing fat, carbohydrate, vitamins and minerals) powder necessary for infants with inborn errors of protein metabolism. It is the only protein-free infant feed for patients with urea cycle disorders and organic acidaemias. It is commonly used in combination with a measured amount of natural protein e.g. expressed breast milk. It will help meet essential energy and nutrient requirements. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- For children requiring additional energy, vitamins, minerals, and trace elements following a protein-restricted diet
|
02.08.01 |
Enoxaparin |
Single use in suspected DVT For all other indications. The APC's view is that on clinical grounds, the status for certain indications approved by APC should be Amber Shared Care, supported by an ESCA. These indications are:
- Deep vein thrombosis (including paediatrics)
- Pulmonary embolism (including paediatrics)
- Intolerance/unsuitable for oral anticoagulants
- Certain cancer patients
- Injectable drug users
- Pregnant women
HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED (ESCAs to be developed). This should not prevent individuals in primary care providing initial prescriptions in urgent situations e.g. pregnancy where there is a high thrombotic risk.
|
02.01.02 |
Enoximone Perfan® |
|
09.04 |
Enshake® |
- Protein, fat, and carbohydrate
- First choice for patients with very high energy requirement eg cystic fibrosis
- In adults with cystic fibrosis, nutritional advice and interventions should be aimed at maintaining a BMI of 22kg/m2 in women and 23kg/m2 in men, as these are associated with better lung function (Nutritional management of CF – Consensus document – 2016)
- Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 1 year; use with caution in child 1–6 years.
|
09.04.02 |
Ensure®Twocal |
- More than 1.5 kcal/mL and 5g (or more) protein/100 mL
- High calorie vegetarian fish oil free
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula ; also haemodialysis and CAPD
|
04.09.01 |
Entacapone |
|
05.03.03 |
Entecavir Baraclude® |
|
08.01.05 |
Entrectinib |
In line with NICE |
08.03.04.02 |
Enzalutamide Xtandi® |
Hospital only- NHSE commissioned
In line with NICE and available from day 91 following publication of TA.
|
13.14.07 |
Eosin solution 2% w/v |
|
A5.14 |
Epaderm ®Ointment |
Emollient ointment containing liquid paraffin, yellow soft paraffin and emulsifying wax Type of wound product is suitable for For use on all dry skin conditions and with dry or wet wrapping techniques Frequency of use Daily or more frequently if required Caution/contraindications Non listed Rationale for inclusion in formulary Treatment of dry skin conditions. Dermatology approved
|
13.02.01 |
Epaderm® ointment |
Over the counter preparation suitable for self-care/purchase if appropriate |
02.07.02 |
Ephedrine |
|
12.02.02 |
Ephedrine nose drops |
Short Term Use Only |
13.02.01 |
Epimax ® cream |
|
21 |
Epinephrine/ adrenaline |
Injection
Topical use for fungating wounds where bleeding is present |
02.02.03 |
Eplerenone tablets |
|
09.01.03 |
Epoetin beta NeoRecormon® |
NHSE commissioned for use in renal dialysis
Primary Care commissioned for use in cancer- in line with NICE TA323
|
02.08.01 |
Epoprostenol Flolan® |
|
03.07 |
Erdosteine |
|
09.06.04 |
Ergocalciferol |
|
07.01.01 |
Ergometrine Maleate |
|
07.01.01 |
Ergometrine Maleate and Oxytocin Syntometrine® |
|
08.01.05 |
Eribulin Halaven® |
In line with NICE
Hospital only- NHSE commissioned |
08.01.05 |
Erlotinib Tarceva® |
in line with NICE and available from day 91 following publication of TA. |
05.01.02.02 |
Ertapenem |
|
06.01.02.03 |
Ertugliflozin Steglatro®▼ |
In line with NICE
See Type 2 diabetes DMMAG Guideline for the choice of oral and non-insulin antihyperglycaemic agents in adults
SLGT2 inhibitors are not to be used in primary care for type 1 diabetes until further local guidance becomes available |
05.01.05 |
Erythromycin tablets |
|
05.01.05 |
Erythromycin Ethyl succinate oral suspension |
|
05.01.05 |
Erythromycin Lactobionate Injection |
|
04.08.01 |
Eslicarbazepine |
|
02.04 |
Esmolol injection |
|
01.03.05 |
Esomeprazole Injection |
|
06.04.01.01 |
Estraderm MX® Patch |
|
07.03.01 |
Estradiol/dienogest Qlaira® |
- Phasic (28-day ‘Every day’ preparation)
- For Synphase failure
|
06.04.01.01 |
Estradot® |
|
08.01.01 |
Estramustine Phosphate capsules |
|
06.04.01.01 |
Estriol® 0.01% |
|
02.11 |
Etamsylate Dicynene® |
|
10.01.03 |
Etanercept Enbrel® |
Hospital only |
13.05.03 |
Etanercept |
use in line with NICE TA 103 |
09.05.01.02 |
Etelcalcetide Parsabiv® |
In line with NICE, NHSE commissioned
Black Triangle |
05.01.09 |
Ethambutol |
Ethambutol liquid 400mg in 5ml (unlicensed) |
07.03.01 |
Ethinylestradiol / levonorgestrel phased pill TriRegol® |
Phasic standard strength (21-day preparation) |
07.03.01 |
Ethinylestradiol 20 mcg / norethisterone 1mg Loestrin 20® |
- Monophasic low strength (21-day preparation)
- For pubertal induction in adolescent patient or premature ovarian failure ONLY
|
07.03.01 |
Ethinylestradiol 20mcg / desogestrel 150mcg Gedarel®20/150/ Lestramyl®20/150 |
Monophasic low strength (21-day preparation) |
07.03.01 |
Ethinylestradiol 20mcg / gestodene 75 mcg Millinette®20/75 |
Monophasic low strength (21-day preparation) |
07.03.01 |
Ethinylestradiol 30 mcg / drospirenone 3 mg |
Monophasic standard strength (21-day preparation)
Brands approved by APC:
Yacella ®
Acondro ®
Dretine ® |
07.03.01 |
Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel®30/150, Lestramyl®30/150 |
Monophasic standard strength (21-day preparation) |
07.03.01 |
Ethinylestradiol 30mcg / gestodene 75 mcg Millinette®30/75 |
Monophasic standard strength (21-day preparation) |
07.03.01 |
Ethinylestradiol 30mcg / levonorgestrel 150mcg |
Monophasic standard strength (21-day preparation)Rigevidon®
Levest®
|
07.03.01 |
Ethinylestradiol 30mcg / levonorgestrel 150mcg Microgynon 30 ED ® |
Monophasic standard strength (28-day ‘Every day’ preparation) |
07.03.01 |
Ethinylestradiol 35 mcg / noresthisterone 500mcg Brevinor® |
Monophasic standard strength (21-day preparation) |
07.03.01 |
Ethinylestradiol 35 mcg / norgestimate 250 mcg Lizinna® |
Monophasic standard strength (21-day preparation) |
06.04.01.01 |
Ethinylestradiol tablets |
- For induction of puberty in female patients who cannot tolerate or are allergic to first-line patches.
2 microgram- unlicensed special
-
Specialist recommendation - 10 microgram ££
|
07.03.01 |
Ethinylestradiol/ Norethisterone Synphase® |
Phasic 21-day preparation
Added to formulary May 2017 as alternative to Trinovum which was discontinued in 2016. |
04.08.01 |
Ethosuximide capsules |
MHRA Advice When prescribing for epilepsy, the potential for clinically relevant differences to exist between different manufacturers’ products is considered to be extremely low. However, consider other patient/carer-related factors, such as negative perceptions about alternative products and/or other issues related to the patient such co-morbid autism, mental health issues, or learning disability. |
07.03.02.02 |
Etonorgestrel 68mg implant Nexplanon® |
|
05.03.01 |
Etravirine Intelence® |
|
13.02.01 |
Eucerin® Intensive lotion 10%urea |
Over the counter preparation suitable for self-care/purchase if appropriate |
08.01.05 |
Everolimus Afinitor® |
In line with NICE
Hospital only-NHSE commissioned |
08.01.05 |
Everolimus Votubia® |
|
02.11 |
Evicel ® |
|
02.12 |
Evolocumab Repatha® |
To be used in line with NICE TA 394 |
06.04.01.01 |
Evorel Conti® patch |
|
06.04.01.01 |
Evorel Sequi® patch |
|
06.04.01.01 |
Evorel® |
|
08.03.04.01 |
Exemestane |
|
02.12 |
Ezetimibe Ezetrol® |
in line with NICE |
02.11 |
Factor VIIa (Recombinant) Eptacog alfa |
|
05.03.02.01 |
Famciclovir |
|
10.01.04 |
Febuxostat Adenuric® |
Second line |
02.06.02 |
Felodipine |
Brand rationalisation - APC preferred brands:-
Cardioplen XL
Felotens XL
|
06.04.01.01 |
Femoston Conti® |
|
06.04.01.01 |
Femoston® (sequential) |
|
06.04.01.01 |
Femseven Conti® patch |
|
06.04.01.01 |
Femseven Sequi® patch |
- 2nd line to Evorel Sequi®
|
02.12 |
Fenofibrate |
tablets
capsules |
21 |
Fentanyl |
Injection |
04.07.02 |
Fentanyl lozenges |
Palliative care only |
04.07.02 |
Fentanyl Nasal Spray |
|
04.07.02 |
Fentanyl patches |
|
04.07.02 |
Fentanyl sublingual tablets |
Palliative care only |
09.01.01.02 |
Ferric Carboxymaltose Ferinject® |
Hospital only |
09.01.01.01 |
Ferric maltol Feraccru® |
- Approved on formulary December 2017
- For the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD), unable to tolerate other oral iron formulations.
- Supported by a RICaD
|
09.01.01.01 |
Ferrous Fumarate liquid Fersamal® |
|
09.01.01.01 |
Ferrous Fumarate tablets |
|
09.01.01.01 |
Ferrous Gluconate |
If patient is intolerant of ferrous sulphate |
09.01.01.01 |
Ferrous Sulphate |
|
03.04.01 |
Fexofenadine |
Second Line
|
05.01.07 |
Fidaxomicin |
|
10.01.03 |
Filgotinib Jyseleca® |
In line with NICE |
09.01.06 |
Filgrastim |
Hospital only |
06.04.02 |
Finasteride 5mg tablets |
In men only |
06.04.02 |
Finasteride 1mg tablets |
- for Hyperandrogenism in women (unlicensed)
- Black listed in NHS primary care
|
13.09 |
Finasteride Propecia® |
for hyperandrogenism in women (unlicensed)
Black listed in NHS primary care Not NHS |
08.02.04 |
Fingolimod |
In line with NICE |
A5.03.04 |
Flaminal ® Forte Gel |
Alginate gel. Moderate to heavily exuding wounds. Contains antimicrobial enzymes.
Type of wound product is suitable for
Colonised wound bed. More suited to sloughy wounds. Can be used on all wound types
Useful for cavity wounds and sinus’s
Requires a secondary dressing
Duration dressing remains on wound before changing
1-7 days
Frequency of dressing change
1-7 days dependent on exudate levels
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Sensitivity to alginate dressings or polyethylene glycol
Full thickness burns
Rationale for inclusion in formulary
1st line antimicrobial in paediatrics
Consider as first line product if signs of colonisation or clinical infection
Does not cause cellular damage |
A5.03.04 |
Flaminal ®Hydro Gel |
Alginate gel. Low to moderate exuding wounds. Contains antimicrobial enzymes
Type of wound product is suitable for
Colonised wound bed. More suited to sloughy wounds. Can be used on all wound types
Useful for cavity wounds and sinus’s
Requires a secondary dressing
Duration dressing remains on wound before changing
1-7 days
Frequency of dressing change
1-7 days dependent on exudate levels
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Sensitivity to alginate dressings or polyethylene glycol
Full thickness burns
Rationale for inclusion in formulary
1st line antimicrobial in paediatrics
Consider as first line product if signs of colonisation or clinical infection
Does not cause cellular damage |
06.01.06 |
Flash glucose monitoring system FreeStyle Libre 2®, FreeStyle Libre® |
|
07.03.04 |
Flat spring diaphragm |
Sizes 55-95mm (rising in 5mm) |
09.04 |
FlavourPac® |
- Flavouring preparations
- For flavouring unpalatable flavouring amino acid supplements or feeds in inborn errors of metabolism
- Essential for flavouring different unflavoured amino acid supplements in inborn errors of metabolism particularly for non PKU conditions. They offer common children’s favourite flavours: e.g. orange or raspberry. Flavourings are important, as amino acid formulations are unpalatable and unacceptable particularly for patients with late diagnosed conditions. They cannot be purchased from a supermarket.
- For use with Vitaflo's range of unflavoured protein substitutes for metabolic diseases; not suitable for child under 3 years.
|
02.03.02 |
Flecainide injection |
|
02.03.02 |
Flecainide tablets |
|
01.06.05 |
Fleet Phospho-soda® |
Oral solution |
09.04.01 |
Flour mixes and egg substitutes |
Essential protein-free basic products. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 1 ordinary egg = 6g protein. 100g flour = 10g protein. |
13.04 |
Flucinolone Acetonide 0.0025% Synalar 1 in 10 Dilution® |
Paeds use only
Potency :Mild
February 2017: aware of unavailability, use alternative mild potency preparation. |
13.04 |
Flucinolone Acetonide 0.025% Synalar Gel® |
£££
Potency:Potent |
05.01.01.02 |
Flucloxacillin injection |
|
05.01.01.02 |
Flucloxacillin oral presentations |
|
05.02 |
Fluconazole |
- Capsules
- Suspension- For patients with swallowing difficulties only
|
07.02.02 |
Fluconazole 150mg oral capsule |
|
05.02 |
Flucytosine |
|
08.01.03 |
Fludarabine Phosphate |
|
06.03.01 |
Fludrocortisone |
|
13.04 |
Fludroxycortide tape previously known as Haelan® |
££ Potency: moderate |
A5.16 |
Fludroxycortide tape |
Adhesive, waterproof, occlusive tape impregnated with 4mg/cm2 fludroxycortide (topical steroid) Type of wound product is suitable for Chronic overgranulation, non acute or weeping. Duration dressing remains on wound before changing Cut the tape to size. Apply for 12 hours at a time, remove and discard. Apply to clean, dry skin that is shorn of any hair. Frequency of dressing change Apply daily for 12 hours at a time. Maximum treatment time 7 days. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Chicken pox Tuberculosis of the skin Hypersensitivity to any components in the tape (steroid fludroxycortide) Facial rosacea Acne vulgaris Perioral dermatitis Perianal and genital pruritis Dermatoses in infants Dermatitis napkin eruption Bacterial, viral and fungal infections Keep away from the eyes Avoid prolonged use on the face Not for untreated bacterial, fungal or viral skin lesions Rationale for inclusion in formulary Treatment of overgranulation |
12.01.01 |
Flumetasone 0.02% with Clioquinol 1% Locorten-Vioform® |
|
04.07.04.02 |
Flunarizine |
Unlicensed medicine |
13.04 |
fluocinolone acetonide 0.025% with clioquinol 3% Synalar C® |
Potency: potent
Cream
Ointment |
11.04.01 |
Fluocinolone intravitreal implant Iluvien® |
|
11.04.01 |
Fluorometholone 0.1% FML® |
- Specialist Ophthalmologist Recommendation.
|
11.99.99.99 |
Fluorouracil |
hospital only |
13.08.01 |
Fluorouracil Efudix® |
|
13.08.01 |
fluorouracil 0.5%, salicylic acid 10% Actikerall® |
For hyperkeratotic lesions |
04.03.03 |
Fluoxetine capsules |
|
04.03.03 |
Fluoxetine liquid |
|
04.02.02 |
Flupentixol Decanoate |
The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
|
04.02.01 |
Flupentixol tablets |
- Supported by ESCA, see link below.
|
04.02.02 |
Fluphenazine Decanoate Modecate® |
The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
- Discontinued by manufacturer by the end of 2018.
|
08.03.04.02 |
Flutamide |
|
03.02 |
Fluticasone and formoterol Flutiform® |
Alternative to Seretide Evohaler/ Seretide 250 Accuhaler
When reviewing/stepping down, consider switch if appropriate |
03.02 |
Fluticasone and salmeterol |
- Combisal® 25/50 and 25/125 metered dose inhaler
- Sereflo® 25/250 metered dose inhaler
- Stalpex® 50/500 dry powder inhaler
Combisal® is a less expensive brand for prescribing salmeterol and fluticasone 25/50 and 25/125 strengths than Seretide Evohaler®. Sereflo® is a less expensive brand for prescribing salmeterol and fluticasone 25/250 strength than Seretide Evohaler®.
Stalpex® 50/500 is a less expensive brand for prescribing salmeterol and fluticasone 50/500 than Seretide Accuhaler®. |
03.02 |
Fluticasone and salmeterol Seretide® |
For paediatric use ONLY (i.e. up to 18 years of age)
- Seretide Evohalers
- Seretide Accuhalers
- Should be prescribed by the intended brand to ensure patients are maintained on the formulation they are used to.
- When reviewing patients on Seretide 250 Accuhaler,consider switch to Fostair or Flutiform if appropriate.
|
12.02.01 |
Fluticasone furoate Avamys® |
previous APC decision reviewed in December 2015.
Approved for use in children and adults. |
03.02 |
Fluticasone furoate & vilanterol Relvar Ellipta® |
- For COPD- 92mcg/22mcg
- For asthma- both strengths
|
03.02 |
Fluticasone inhalers |
For paediatric use ONLY (i.e. up to 18 years of age) Fluticasone Evohaler 50, Fluticasone Accuhaler 50,100
Fluticasone Evohaler 125, Fluticasone Accuhaler 250
|
03.02 |
Fluticasone nebules |
|
12.02.01 |
Fluticasone Propionate Flixonase Nasule® |
- Specialist Recommendations for Nasal Polyps.
|
03.02.03 |
Fluticasone/vilanterol/umeclidinium Trelegy Ellipta® |
COPD Appendix 4 : Criteria for triple therapy and for triple inhaler use in COPD
|
02.12 |
Fluvastatin capsules |
|
09.01.02 |
Folic Acid |
Tablets
SF solution- Lexpec®
|
02.08.01 |
Fondaparinux Arixtra® |
Hospital only |
09.04 |
Food First |
Where clinically appropriate encourage a nutrient dense food and fluid intake for patients at risk of malnutrition. |
09.04.02 |
Food First |
Where clinically appropriate encourage a nutrient dense food and fluid intake for patients at risk of malnutrition. |
09.04 |
Foodlink® Complete |
- More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
- First line product
- Not suitable for CKD 4-5, renal pts.
- Not suitable for lactose intolerance
- Not suitable for bile acid malabsorption or fat maldigestion associated with biliary diseases/conditions
- To be made up with whole milk.
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04 |
Foodlink® Complete with Fibre |
- First line with added fibre
- Not suitable for CKD 4-5, renal pts.
- Not suitable for lactose intolerance
- Not suitable for bile acid malabsorption or fat maldigestion associated with biliary conditions
- To be made up with whole milk.
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04 |
Forceval caps and soluble tabs |
- Special additives for conditions of intolerance
- Vitamin and mineral deficiency and as adjunct in synthetic diets
|
03.01.01.01 |
Formoterol |
|
09.04 |
Fortijuce® |
- More than 1 kcal/mL and less than 5 g protein/100 mL
- Juice style fat free, low K+
- Patients who dislike milky tasting drinks
- Caution advised – not milk free and high sugar content
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula Not suitable for child under 3 years
|
09.04 |
Fortini® |
- More than 1 kcal/ml and less than 4g protein/100ml
- Sip feed for children over 8kg with faltering growth
- Disease-related malnutrition and growth failure in child 1–6 years, body-weight 8–20 kg
|
09.04.02 |
Fortini® 1.0 Multi Fibre |
Child under 12 years
- 1 kcal/mL and less than 4g protein/100 mL
- Standard 1 kcal/mL with fibre
|
09.04 |
Fortini® Compact Multifibre |
- Child: More than 1 kcal/mL and less than 4 g protein/100 mL
- Low volume supplement
- Supporting an unmet paediatric nutritional need
- No other product is current available to meet this need.
|
09.04 |
Fortini® Creamy Fruit |
- Child: More than 1 kcal/mL and less than 4 g protein/100 mL
- High energy fruit pudding for children with faltering growth
|
09.04 |
Fortini® Multifibre |
- Child: More than 1 kcal/mL and less than 4 g protein/100 mL
- Sip feed for children over 8kg with faltering growth, with added fibre
- Disease-related malnutrition and growth failure in child 1–6 years, body-weight 8–20 kg
|
09.04 |
Fortini® Smoothie Multifibre |
- Child: More than 1 kcal/mL and less than 4 g protein/100 mL
- Sip feed for children over 8kg with faltering growth
|
09.04 |
Fortisip® 2kcal |
- More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
- For bolus tube feeding only
- Only on dietetic advice sip feed in small volume.
- Nutritionally complete in 2 bottles.
|
09.04 |
Fortisip® Bottle |
- Restricted for use where fluid volume is a benefit
- Restricted for patients who are lactose intolerant
- Maybe used as an alternative as a bolus feeds
- Low fibre
- Low osmolality.
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
- Not suitable for child under 3 years; use with caution in child 3–5 years.
- Second line choice for 200ml ready-made. If powder is not tolerated or contraindicated
|
09.04 |
Fortisip® Compact |
- More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
- Second line supplements choice.
- Low volume supplement and for bolus feeding
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
- Not suitable for child under 3 years; use with caution in child 3–5 years.
|
09.04 |
Fortisip® Compact Fibre |
- More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
- Second line supplements choice for use when fibre is indicated as advised by dietitian only. Low volume supplement and for bolus feeding
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
- Not suitable for child under 3 years; use with caution in child 3–5 years.
|
09.04 |
Fortisip® Compact Protein |
- More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
- Not to be used without dietetic advice that higher protein is clinically appropriate.
- With added protein
- Low volume supplement and for bolus feeding advised by dietitian only.
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula.
- Not suitable for child under 3 years; use with caution in child 3–5 years.
|
09.04 |
Fortisip® Yogurt Style |
- 1.5 kcal/mL and 5 g (or more) protein/100 mL
- For dysgeusia and flavour fatigue only
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula. Not suitable for child under 3 years
|
05.03.01 |
Fosamprenavir Telzir® |
|
05.03.02.02 |
Foscarnet Sodium Foscavir® |
|
05.01.13 |
Fosfomycin sachets |
- Second line treatment if high risk of resistance
- In line with Antimicrobial guidelines
|
05.01.13 |
Fosfomycin Capsules |
- Second line treatment if high risk of resistance.
- In line with Antimicrobial guidelines
|
04.07.04.02 |
Fremanezumab Ajovy® |
In line with NICE |
02.11 |
Fresh Frozen Plasma |
|
09.04 |
Fresubin® 2kcal |
- More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
- First line choice for 2kcal/ml sip feed
- Small volume required and based on taste preference
- Nutritionally complete in 2 bottles.
- High Cal low Vol
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula; also CAPD, haemodialysis.
- Not suitable for use in child under 1 year; use with caution in child 1–5 years.
|
09.04 |
Fresubin® 2kcal Fibre Drink |
- Used where 2kcal/ml sip feed in small volume with fibre is required
- High Cal low Vol with added fibre
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula ; also CAPD, haemodialysis.Not suitable for use in child under 1 year; use with caution in child 1–5 years.
|
09.04 |
Fresubin® Juicy Drink |
- More than 1 kcal/mL and less than 5 g protein/100 mL
- Juice style fat free, low K+
- Patients who dislike milky tasting drinks
- Caution advised – not milk free and high sugar content
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula ; also CAPD, haemodialysis
|
09.04 |
Fresubin® Thickened |
- 1.5 kcal/mL and 5 g (or more) protein/100 mL
- Used for dysphagia pts only
- Dysphagia or disease-related malnutrition. Not suitable for child under 3 years; use with caution in child 3–4 years.
|
09.04 |
Fresubin® YOcreme |
- 1.5 kcal/mL and 5 g (or more) protein/100 mL
- For dysgeusia and flavour fatigue only
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, preoperative
preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula. Not suitable for child under 3 years
|
09.04.02 |
Fresubin®HP Energy |
- 1.5 kcal/mL and 5g (or more) protein/100 mL
- Only available product with high protein and high MCT (burns pts, tumour pts, and liver pts.)
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula ; also CAPD and haemodialysis
|
09.04.02 |
Fresubin®HP Energy Fibre |
- 1.5 kcal/mL and 5g (or more) protein/100 mL
- Only available product with high protein and high MCT with fibre (burns pts, tumour pts, liver pts)
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula ; also CAPD and haemodialysis
|
09.04 |
Fructose |
- Special additives for conditions of intolerance
- Used as a partial CHO source in modular feeds for infants and children with malabsorption secondary to short bowel syndrome or other malabsorption states
- (Laevulose) For proven glucose/galactose intolerance
|
09.06.07 |
FruitiVits® |
- For patients with inborn errors of metabolism and for enteral feed patients.
- For use in children 3 years and over with inborn errors of metabolism. This is a small volume, flavoured, carbohydrate free vitamin/mineral supplement used in conditions like citrin deficiency. There are no other carbohydrate free preparations available. It cannot be purchased from a supermarket. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Vitamin, mineral, and trace element supplement in children 3–10 years with restrictive therapeutic diets
|
08.03.04.01 |
Fulvestrant Faslodex® |
|
02.02.02 |
Furosemide |
Tablets
Oral solution
Injection
|
21 |
Furosemide |
Injection |
11.03.01 |
Fusidic Acid 1% |
|
13.10.01.02 |
Fusidic Acid 2% |
|
09.04 |
GA Amino 5 |
- Amino acid supplement without lysine – low in tryptophan for infants with GA1 - used for tube feeding in emergencies
- The only pre-measured amino acid supplement without lysine, low in tryptophan for children with GA1 that can be administered via a tube in emergency feeds. It is essential it is easy to use in an emergency and pre-measured is safer, particularly for non-English speaking families. It can also be used in pyridoxine responsive epilepsy.
|
09.04 |
GA Anamix Junior |
- An unthickened amino acid supplement without lysine, low in tryptophan for children with GA1 that can be given as a drink. It can also be used in pyridoxine responsive epilepsy.
|
09.04 |
GA Express 15 (not ACBS approved) |
- Amino acid supplement without lysine and low in tryptophan for children and adults with GA1
- The only low volume, vitamin and mineral amino acid supplement without lysine, low in tryptophan for use in patients > the age of 6 years’ children and adults with GA1 and pyridoxine responsive epilepsy.
|
09.04 |
GA Gel® |
- Amino acid supplement without lysine – low in tryptophan for infants with GA1
- The only weaning (thickened) amino acid supplement without lysine, low in tryptophan for children with GA1. It can also be used in pyridoxine responsive epilepsy.
- Nutritional supplement for dietary management of type 1 glutaric aciduria in children 6 months–10 years.
|
09.04 |
GA1 Anamix® Infant |
- Amino acid supplement without lysine – low in tryptophan for infants with GA1
- The only amino acid supplement without lysine, low in tryptophan for infants with GA1 and pyridoxine responsive epilepsy.
- Nutritional supplement for the dietary management of proven glutaric aciduria (type 1) in children from birth to 3 years.
|
04.07.03 |
Gabapentin |
- 2nd line
- please be aware of the abuse potential associated with this class of agent
Schedule 3 Controlled Drug as of 01/04/2019 |
04.08.01 |
Gabapentin |
- Capsules
- Tablets £££
MHRA Advice It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
Schedule 3 Controlled Drug as of 01/04/2019 |
09.04 |
Galactomin 17® |
- Specialised formulas: Infant and child: Residual lactose formula
- Lactose free feed for use in adults metabolic disease only
- Used as a milk alternative in adults, lactose free with galactosaemia. This is not used for infants by Birmingham Children’s Hospital. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Proven lactose intolerance in pre-school children, galactosaemia, and galactokinase deficiency.
|
09.04 |
Galactomin 19® |
- Specialised formulas: Infant and child: Fructose-based formula
- Disease specific fructose containing formula for infants and children with glucose galactose malabsorption.
- Conditions of glucose plus galactose intolerance
|
04.11 |
Galantamine |
- tablets
- M/R capsules - preferred brands are Gazylan XL® and Galzemic XL®
- Oral solution
|
04.07.04.02 |
Galcanezumab Emgality® |
In line with NICE |
A5.05.01 |
Gamgee |
Sterile or non sterile highly absorbent cotton wool enclosed in an absorbent cotton cover Type of wound product is suitable for Full thickness burns Can be cut to required size Secondary dressing Duration dressing remains on wound before changing Dependent on exudate levels Frequency of dressing change Dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not to be used as a primary dressing Only to be used in UHB burns unit Rationale for inclusion in formulary UHB burns unit only
|
05.03.02.02 |
Ganciclovir Cymevene® |
|
11.03.03 |
Ganciclovir 0.15% ophthalmic gel Virgan® |
- Specialist Ophthalmologist Recommendation.
|
A5.07.02 |
gauze swabs, non-woven swabs |
7.5cm x 7.5cm only
Type of wound product is suitable for
Cleansing wounds via aseptic technique
Duration dressing remains on wound before changing
N/A
Frequency of dressing change
N/A
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Not to be applied to a wound as a dressing
Rationale for inclusion in formulary
Necessity for wound cleansing
Cost effective
Included in Sterile wound packs or used to supplement sterile packs
|
01.01.02 |
Gaviscon Infant |
Oral powder
|
08.01.05 |
Gefitinib Iressa® |
|
09.02.02.02 |
Gelatin Gelofusine® |
For Endoscopy use only |
12.03.01 |
Gelclair® |
Oncology and haematology use only |
08.01.03 |
Gemcitabine Gemzar® |
|
07.01.01 |
Gemeprost |
|
08.02.03 |
Gemtuzumab Mylotarg® |
In line with NICE |
03.13 |
Gentamicin |
Hospital only |
05.01.04 |
Gentamicin |
|
11.03.01 |
Gentamicin 0.3% eye drops |
- Possible 2nd Line after chloramphenicol- specialist opthalmologist recommendation.
|
12.01.01 |
Gentamicin ear drops Genticin® |
Only with positive culture/sensitivity data. |
06.04.01.01 |
Gestone® injection |
|
08.01.05 |
Gilteritinib |
In line with NICE |
08.02.04 |
Glatiramer Acetate Copaxone® |
|
05.03.03.02 |
Glecaprevir–pibrentasvir Maviret® |
In line with NICE
|
06.01.02.01 |
Glibenclamide |
- Use in pregnancy (as per NICE) for patients who do not want to move to insulin but are not responding to metformin
|
06.01.02.01 |
Gliclazide |
|
06.01.02.01 |
Gliclazide M/R |
|
06.01.04 |
Glucagon GlucaGen® HypoKit |
|
06.01.04 |
GlucoGel® |
|
09.04 |
Glucose |
- Special additives for conditions of intolerance
- Used as a partial CHO source in modular feeds for infants and children with malabsorption secondary to short bowel syndrome or other malabsorption states
- (Dextrose monohydrate) For use as an energy supplement in sucrose-isomaltase deficiency
|
21 |
Glucose 4% and sodium chloride 0.18% |
IV infusion |
13.07 |
Glutaraldehyde 10% solution |
Over the counter preparation suitable for self-care/purchase if appropriate |
09.04.01 |
Gluten free foods Breads & mixes |
Department of Health and Social Care (DHSC) guidance –
- GF, GF & Wheat Free (WF) bread
- GF, GF&WF mixes
Follow Coeliac UK prescribing guidance for monthly quantities (based on age) |
01.06.02 |
Glycerol (Glycerin) |
Suppository |
01.07.04 |
Glyceryl Trinitrate 0.4% Rectogesic® |
Ointment |
02.06.01 |
Glyceryl Trinitrate Injection |
Secondary Care use only |
02.06.01 |
Glyceryl Trinitrate MR Bucaal Tabletsq |
|
02.06.01 |
Glyceryl Trinitrate patches |
|
02.06.01 |
Glyceryl Trinitrate SL spray and SL tablets |
|
07.04.04 |
Glycine |
Hospital only |
13.14.07 |
Glycopyrrolate 0.05% w/v in water |
|
13.14.07 |
Glycopyrrolate 2% w/w in cetomacrogol cream |
|
03.01.02 |
Glycopyrronium Seebri breezhaler® |
|
13.12 |
Glycopyrronium |
- Unlicensed
- For specialist initiation for hyperhidrosis
- ££££
|
21 |
Glycopyrronium |
Injection |
04.12 |
Glycopyrronium bromide Sialanar® |
- Approved on formulary December 2017
- Specialist initiation and stabilisation
- £££
|
03.01.04 |
Glycopyrronium/ indacaterol inhaler Ultibro Breezhaler® |
|
09.04 |
Glycosade® |
- Slow release CHO to prevent hypoglycaemia in GSD
- The only specially formulated slow release carbohydrate to prevent hypoglycaemia in severe forms of GSD e.g. Type I and III which allows extended fasting time. The dosage is dependent on age, weight and clinical symptoms of hypoglycaemia. Doses may be given at regular intervals during the day and night or at bedtime only. The dose and frequency of dose should always be advised by the specialist dietitian according to the needs of the patient. Glycosade is in a pre-measured sachet. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- A nutritional supplement for use in the dietary management of glycogen storage disease and other metabolic conditions where a constant supply of glucose is essential. Not suitable for use in children under 2 years.
|
09.04 |
Glytactin Bettermilk 15 |
- A low phenylalanine supplement derived from whey protein for children and adults with phenylketonuria. It is more palatable than amino acid supplements and associated with better utilisation of protein. Very useful for adult patients trying to return to diet or children / adults struggling to take their amino acid product because of its taste. Suitable from aged 4 years
|
09.04 |
Glytactin Bettermilk RTD 15 (original and chocolate) |
- A low phenylalanine supplement derived from whey protein for children and adults with phenylketonuria. It is more palatable than amino acid supplements and associated with better utilisation of protein. Very useful for adult patients trying to return to diet or children / adults struggling to take their amino acid product because of its taste. Suitable from aged 4 years
|
10.01.03 |
Golimumab Simponi® |
Hospital only Available via Home Care |
06.07.02 |
Goserelin |
For assisted conception |
06.07.02 |
Goserelin |
- For endometriosis or breast cancer
- Specialist initiation
|
08.03.04.02 |
Goserelin Zoladex® |
|
08.03.04.02 |
Goserelin Zoladex® LA |
|
A5.09.01 |
Graduated compression hosiery |
Based on assessment |
04.06 |
Granisetron tablets |
|
04.06 |
Granisetron transdermal patch Sancuso® |
for use in oncology patients only |
A5.02.04 |
Granuflex |
Type of wound product is suitable for Hyperkeratosis, granulating wounds, forms cohesive gel on contact with exudate Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change 3-7 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known sensitivity to ingredients - contains pectin and gelatine Not for diabetic foot ulcers or ischaemic wounds Not for infected wounds Rationale for inclusion in formulary Comformable waterproof dressing, aids rehydration. Reduces and softens hyperkeratosis |
03.04.02 |
Grass and Tree Pollen Extract Pollinex® |
|
03.04.02 |
Grass pollen extract Grazax® |
|
09.04 |
GTO oil |
- A cooking oil for dietary treatment of adrenoleukodystrophy. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
|
04.04 |
Guanfacine Intuniv® |
for the treatment of ADHD in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. |
13.05.03 |
Guselkumab Tremfya ® |
Use in line with NICE |
14.04 |
Haemophilus influenzae type B Combined Vaccine Menitorix® |
|
01.07.01 |
Haemorrhoid relief ointment |
Anusol® - other brands also available |
01.07.01 |
Haemorrhoid relief suppositories |
Anusol® - other brands also available |
04.02.02 |
Haloperidol Haldol Decanoate® |
The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
|
04.09.03 |
Haloperidol |
|
04.02.01 |
Haloperidol (oral) |
- tablets
- capsules
- oral liquid sugar-free
- Supported by ESCA, see link below.
|
04.02.01 |
Haloperidol injection |
- For rapid tranquilisation
|
09.04 |
HCU Anamix® Infant |
- Amino acid supplement without methionine for infants with homocystinuria
- The only amino acid supplement without methionine for infants with homocystinuria. It is given to screened infants for HCU. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Nutritional supplement for the dietary management of proven vitamin B6 non-responsive homocystinuria or hypermethioninaemia in children from birth to 3 years.
|
09.04 |
HCU Cooler® 10 |
- Amino acid supplement without methionine for children and adults with homocystinuria
- The only liquid amino acid supplement without methionine for children with homocystinuria aged 3 to 6 years. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements.
|
09.04 |
HCU Cooler® 15 |
- Amino acid supplement without methionine for teenagers and adults with homocystinuria
- The only liquid amino acid supplements without methionine for children with homocystinuria aged 7 to 12 years. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements.
|
09.04 |
HCU Cooler® 20 |
- Amino acid supplement without methionine for teenagers and adults with homocystinuria
- One of two liquid amino acid supplements without methionine for children with homocystinuria aged >12 years. They need the larger sachets (20g protein equivalent) meet their non-methionine protein requirements.
|
09.04 |
HCU Express® 15 |
- Amino acid supplement without methionine for teenagers and adults with homocystinuria
- The only powdered amino acid supplement without methionine that provides 15g protein equivalent per sachet for children with homocystinuria aged 7 to 12 years. Larger sachets are unacceptable for this age group of children and provide in excess of protein requirements.
- A methionine-free protein substitute for use as a nutritional supplement in children over 8 years with homocystinuria
|
09.04 |
HCU Express® 20 |
- Amino acid supplement without methionine for teenagers and adults with homocystinuria
- One of 2 powdered amino acid supplements without methionine that provides 20g protein equivalent per sachet for teenagers with homocystinuria aged >12 years. They need the larger pouches to meet their non-methionine protein requirements. It is important we have a choice of more than 1 product for this age group as adherence is poor.
- A methionine-free protein substitute for use as a nutritional supplement in children over 8 years with homocystinuria.
|
09.04 |
HCU gel® |
- Amino acid supplement without methionine for children with homocystinuria
- The only weaning (thickened) amino acid supplement without methionine for children with homocystinuria.
- A methionine-free protein substitute for use as a nutritional supplement for the dietary management of children 1–10 years with homocystinuria.
|
09.04 |
HCU Lophlex® LQ 20 |
- Amino acid supplement without methionine for teenagers and adults with homocystinuria
- One of 2 powdered amino acid supplements without methionine that provides 20g protein equivalent per sachet for teenagers with homocystinuria aged >12 years. They need the larger pouches to meet their non-methionine protein requirements. It is important we have a choice of more than 1 product for this age group as adherence is poor.
- Nutritional supplement for the dietary management of homocystinuria in children over 3 years.
|
09.06.07 |
Healthy Start Vitamins |
Available free of charge from designated centres |
01.03 |
Helicobacter Stool Antigen Test |
in line with NICE/PHE guidance
check availibility of test in local laboratory. |
01.03 |
Helicobacter Urea Breath Test |
in line with NICE/PHE guidance |
02.08.01 |
Heparin sodium injection |
|
13.13 |
Heparinoid 0.3% Hirudoid® |
|
14.04 |
Hepatitis A vaccine Single Component Avaxim® |
|
14.04 |
Hepatitis A vaccine Single Component Epaxal® |
|
14.04 |
Hepatitis A vaccine Single Component Havrix Monodose® |
|
14.04 |
Hepatitis A vaccine Single Component Vaqta® Paediatric |
|
14.04 |
Hepatitis A vaccine with Hepatitis B vaccine Twinrix® |
|
14.05.02 |
Hepatitis B immunoglobulin |
|
14.04 |
Hepatitis B vaccine Single Component Engerix B® |
|
14.04 |
Hepatitis B vaccine Single Component Fendrix® |
|
14.04 |
Hepatitis B vaccine Single Component HBvaxPRO® |
|
13.11.02 |
Hibitane Obstetric® |
|
13.10.05 |
Histoacryl® |
Hospital only |
09.04 |
Homemade milkshake |
Where clinically appropriate encourage a standardised home-made nutritious drink at least equivalent to a standard 1.5KCal/ml prescribed bottle supplement in terms of calories and protein |
09.04.02 |
Homemade milkshake |
Where clinically appropriate encourage a standardised home-made nutritious drink equivalent to a standard 1.5 KCal/mL prescribed bottle supplement in terms of calories and protein.
|
06.05.01 |
Human Chorionic Gonadotrophin |
|
06.05.01 |
Human Menopausal Gonadotrophins |
|
12.04 |
Human papilloma virus vaccine Gardasil® |
For use by ENT Specialists in recurrent respiratory papillomatosis (RRP) |
14.04 |
Human papilloma virus vaccine Gardasil® |
For use by ENT Specialists only in recurrent respiratory papillomatosis (RRP) |
14.04 |
Human papilloma virus vaccine Cervarix® |
|
14.04 |
Human papilloma virus vaccine Gardasil® |
For national immunisation campaign in adolescent girls ONLY |
11.99.99.99 |
Hyaluronidase Hyalase® |
Hospital only |
02.05.01 |
Hydralazine tablets |
|
01.05.02 |
Hydrocortisone Colifoam® |
July 2020 Manufacturer informed that currerntly there is no active supply chain for ongoing supply from Mylan
Foam enema 125mg /metered application First choice steroid foam enema for IBD However, mesalazine preparations preferred to steroids overall |
06.03.02 |
Hydrocortisone |
Standard release tablets only |
13.04 |
Hydrocortisone |
Potency: mild
Hydrocortisone 0.5% cream & ointment
Hydrocortisone 1% cream & ointment |
13.04 |
Hydrocortisone 0.25% Crotamiton 10% Eurax-Hydrocortisone® |
Potency: mild
Use post scabies once infection has cleared but itch remains present |
13.04 |
Hydrocortisone 0.5% ,chlorhexidine HCl 1% & nystatin Nystaform-HC® |
Potency: mild
Cream
Ointment
Paeds use only
Replacement for discontinued Vioform HC |
13.04 |
Hydrocortisone 1% and oxytetracycline 3% Terra-Cortril® ointment |
Potency: Mild |
13.04 |
Hydrocortisone 1% with Clotrimazole 1% Canesten HC® |
Potency: mild |
13.04 |
Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort Cream® |
Potency: mild |
12.03.01 |
Hydrocortisone 2.5mg buccal tablets |
- Specialist Recommendation
|
10.01.02.02 |
Hydrocortisone acetate Hydrocortistab® |
|
13.04 |
Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H Cream® |
Potency: mild |
12.01.01 |
Hydrocortisone Acetate 1% with Gentamicin 0.3% Gentisone® HC |
Only with positive culture/sensitivity data |
13.04 |
Hydrocortisone Butyrate Locoid ® |
Potency: potent
Cream
Lipocream
Ointment
Scalp lotion |
06.03.02 |
Hydrocortisone sodium succinate Solu-Cortef® |
|
A5.02.02 |
Hydrofilm |
Vapour-permeable adhesive film
Type of wound product is suitable for
Dry non infected wounds, retention of lines, fixation of secondary dressings, protection of intact skin, protection of skin against friction, protection of newly epithelialized wounds
Duration dressing remains on wound before changing
Up to 7 days
Frequency of dressing change
Up to 7 days
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Clinically infected wounds, bleeding or exuding wounds
Rationale for inclusion in formulary
Retention of lines, protection of intact skin, fixation of other dressings. Cost effective
Waterproof
|
13.11.06 |
Hydrogen Peroxide Crystacide® |
|
13.11.06 |
Hydrogen Peroxide 3% Solution (10vols) |
|
13.11.06 |
Hydrogen Peroxide 6% Solution (20vols) |
|
12.03.04 |
Hydrogen Peroxide mouthwash BP |
|
09.04 |
Hydrolysed whey protein maltodextrin powder |
- High-energy supplements: protein
- Hydrolysed protein powder to be used in a modular feed.
|
13.02.01 |
Hydromol Cream® |
Over the counter preparation suitable for self-care/purchase if appropriate |
13.02.01 |
Hydromol ointment ® |
Over the counter preparation suitable for self-care/purchase if appropriate |
13.02.01.01 |
Hydromol® bath and shower |
Over the counter preparation suitable for self-care/purchase if appropriate |
13.14.07 |
Hydroquinone 5% w/w, hydrocortisone 1% w/w and tretinoin 0.1% w/w in a non-aqueous gel 0.3% w/v |
|
13.02.01 |
Hydrous ointment BP |
Over the counter preparation suitable for self-care/purchase if appropriate |
09.01.02 |
Hydroxocobalamin 1mg/ml injection |
|
08.01.05 |
Hydroxycarbamide |
For myeloproliferative disorders.
Supported by an ESCA (in development)
For use in sickle cell- see chapter 9
|
09.01.03 |
Hydroxycarbamide |
For use in sickle cell |
13.05.03 |
Hydroxycarbamide |
|
10.01.03 |
Hydroxychloroquine |
|
10.01.03 |
Hydroxychloroquine |
- Please note: ESCA is not required - Common practice
|
13.05.03 |
Hydroxychloroquine |
|
03.04.01 |
Hydroxyzine |
Tablets
Syrup |
11.08.01 |
HYLO Night® eye ointment |
Brand name changed from VitA POS eye ointment to HYLO Night April 2020 |
04.02.03 |
Hyoscine |
|
01.02 |
Hyoscine Butylbromide Buscopan® |
Tablet 10mg, Injection 20mg/ml |
04.06 |
Hyoscine Hydrobromide |
|
04.06 |
Hyoscine Hydrobromide |
£££ |
15.01.03 |
Hyoscine Hydrobromide |
For hyoscine patch, See chapter 4.6
|
21 |
Hyoscine hydrobromide |
Patches
Drooling in chronic neurological disease |
03.07 |
Hypertonic sodium chloride 7% Resp-Ease® |
Accepted onto formulary December 2016- to replace Nebusal brand. |
11.08.01 |
Hypromellose 0.5% eye drops |
All other strengths are non formulary |
06.06.02 |
Ibandronic Acid 150mg |
|
06.06.02 |
Ibandronic Acid 50mg |
- For skeletal events in metastatic breast cancer.
- Supported by an ESCA, see link below.
|
06.06.02 |
Ibandronic Acid injection |
|
08.01.05 |
Ibrutinib Imbruvica® |
- In line with NICE
- Hospital only- NHSE commissioned
|
07.01.01.01 |
Ibuprofen Pedea® injection |
|
10.01.01 |
Ibuprofen |
|
10.01.01 |
Ibuprofen |
For patients with swallowing difficulties
Paediatric use |
10.03.02 |
Ibuprofen gel |
|
03.04.03 |
Icatibant Firazyr® |
Hospital Only- NHSE commissioned |
13.14.04 |
Ichthammol 1% w/w and zinc oxide 15% w/w in YSP |
|
A5.08.09 |
Ichthopaste |
Zinc and Ichthammol bandage. Type of wound product is suitable for Venous leg ulcers Chronic eczema Dermatitis Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Daily up to weekly dependant on skin and wound management. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use in any cases of sensitivity or allergy to ingredients Rationale for inclusion in formulary For treatment of dermatitis and chronic eczema when venous insufficiency is present. |
08.01.02 |
Idarubicin Hydrochloride Capsules |
|
08.01.05 |
Idelalisib Zydelig® |
NHS England is responsible commissioner for its use in chronic lymphocytic leukaemia(as per NICE TA 359)
|
02.05.01 |
Iloprost nebules Vantavis® |
NHS England commissioned |
08.01.05 |
Imatinib Glivec® |
in line with NICE |
05.01.02.02 |
Imipenem with cilastatin Primaxin® |
|
04.03.01 |
Imipramine |
Tablets |
13.08.01 |
Imiquimod 3.75% Zyclara® |
- £££
- For field changes >25cm2
|
13.07 |
Imiquimod 5% Aldara® |
|
13.08.01 |
Imiquimod 5% Aldara® |
|
14.04 |
Inactivated Influenza Vaccine (Split Virion) |
|
A5.03.02 |
Inadine ® |
Non-adherent dressing impregnated with povidone iodine (10%)
Type of wound product is suitable for
Mild local infection where there is low exudate levels, ischaemic wounds, dry, gangrenous digits with the aim to desiccate and auto-amputate.
Dry-manage fixator sites
Minor burns or skin trauma with local infection
Duration dressing remains on wound before changing
1-3 days depending on uptake of iodine from dressing
Frequency of dressing change
1-3 days depending on uptake of iodine from dressing
Look at colour change of dressing (orange initially to white when all used)
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Iodine allergy or sensitivity
Thyroid disorders
Renal impairment
Not suitable for children, pregnant or lactating women
Rationale for inclusion in formulary
Topical antimicrobial
Non-adherent/pain free use
No damage to granular or epithelial cells
Easy application and removal
Drying properties
Efficacy against bacteria, fungi and viruses
Cost effective. |
02.02.01 |
Indapamide |
Use 2.5mg tablets only |
13.10.05 |
Indermil® |
Hospital only |
20 |
Indigo carmine |
- For use by endoscopy only
|
06.04.01.01 |
Indivina® tablets |
|
07.01.01.01 |
Indometacin Indocid PDA® |
|
10.01.01 |
Indometacin |
- For gout and resistant cases
|
10.01.01 |
Indometacin |
- Special product (100ml)
- For gout and resistant cases
|
14.04 |
Infanrix-IPV® |
|
09.04 |
Infatrini® |
- Child: 1 kcal/ml and less than 4g protein/100ml
- 1 kcal infant feed for faltering growth
- Varying volume size available to support nutritional requirements of the patients.
- Single use only in acute setting – risk of increased waste. Once open must be used within 24 hours.
- Failure to thrive, disease-related malnutrition and malabsorption, in child from birth up to body-weight 8 kg. Up to 18 months.
|
09.04 |
Infatrini® Peptisorb |
- Infant and child: Hydrolysate formula
- Whey hydrolysate. Use in infants (birth – 18 mths) who are unable to tolerate Infatrini (eg gut intolerance) and also require a higher calorie feed for faltering growth. Use as tube or oral feed
- Disease-related malnutrition, intractable malabsorption, proven inflammatory bowel disease, short bowel syndrome, bowel fistula, and intolerance to whole protein feeds
|
01.05.03 |
Infliximab Remicade® |
Infusion
For specialist use only in line with NICE guidance below
Commissioned in paediatrics by NHSE
|
10.01.03 |
Infliximab |
- Hospital only
- Biosimilar brands available:
- Flixabi®
- Inflectra®
- Remsima®
- Zessly®
|
13.05.03 |
Infliximab |
For treatment of adults with psoriasis- use in line with NICE TA134 |
14.04 |
Influenza vaccine |
As per Green Book, Health Service circular, National Flu campaign |
08.02.03 |
Inotuzumab ozogamicin Besponsa ® |
In line with NICE
Hospital only- NHSE commissioned |
09.09 |
Instant Carobel® |
- Used as a feed thickener for infants with GORD and in children with swallowing issues who require thickened fluids
- Used in dysphagic patients or those requiring thickened feeds
- For thickening feeds in the treatment of vomiting
|
06.01.01.01 |
Insulin Actrapid® |
|
06.01.01.01 |
Insulin Humulin® S |
|
06.01.01.01 |
Insulin Insuman® Rapid |
|
06.01.01.01 |
Insulin Aspart NovoRapid® |
|
06.01.01.01 |
Insulin Aspart Fiasp® |
- For use in pregnant women with either gestational diabetes or pre-existing diabetes, after other insulins have been tried and failed to reach post-prandial glucose targets
- As per Effective Shared Care Agreement (ESCA)
|
06.01.01.02 |
Insulin degludec 100 units/mL Tresiba® |
- Specialist use only
- For the treatment of patients with Type 2 diabetes who have nocturnal / severe hypoglycaemia or those with recurrent hypoglycaemic episodes requiring hospital admission
|
06.01.01.02 |
Insulin degludec 100 units/mL Tresiba® |
- To avoid the use of an insulin pump in patients with Type 1 diabetes who have nocturnal/severe hypoglycaemia as defined in NICE TA 151 OR recurrent DKA despite good compliance with current insulin regime
- Specialist initiation
- Supported by a RICaD, see link below.
|
06.01.01.02 |
Insulin detemir Levemir® |
|
06.01.01.02 |
Insulin glargine 100 units/mL Lantus® |
£
Prescribe by brand |
06.01.01.02 |
Insulin glargine 100 units/mL biosimilar Abasaglar® |
- Prescribe by brand as recommended by MHRA.
- Substitution and automatic switching from Lantus® to Abasaglar®CANNOT BE UNDERTAKEN.
|
06.01.01.02 |
Insulin glargine 300 units/mL Toujeo® |
Prescribe by brand
- Reconsidered and approved in April 2017
- Specialist initiation.
- Supported by RICaD
-
For the treatment of adult patients with Type 1 or Type 2 diabetes who have problematic hypoglycaemia OR who are using ≥ 80 units per day of basal analogue insulin (e.g. Abasaglar®, Lantus®, Levemir® or Semglee®)
Transfer of prescribing to Primary Care should not happen (where patients are being managed by a secondary care specialist) until a reduction in problematic hypoglycemia’s (e.g.after 3-4 months) has been demonstrated
|
06.01.01.02 |
Insulin Glargine biosimilar Semglee® |
- First line glargine for new patients initiated on insulin glargine 100 units/mL.
|
06.01.01.01 |
Insulin Glulisine Apidra® |
|
06.01.01.01 |
Insulin Lispro 100 units/mL Humalog 100 units/mL ® |
|
08.02.04 |
Interferon Alfa |
Hospital only
In line with NICE |
08.02.04 |
Interferon Beta Avonex® |
|
08.02.04 |
Interferon Beta Rebif® |
|
08.02.04 |
Interferon Beta Betaferon® |
|
08.02.04 |
Interferon Beta Proleukin® |
|
08.02.04 |
Interferon beta Extavia® |
|
07.03.04 |
Intra-uterine Contraceptive Devices Mini TT ®380 Slimline |
|
07.03.04 |
Intra-uterine Contraceptive Devices Nova-T® 380 |
|
07.03.04 |
Intra-uterine Contraceptive Devices T-Safe® CU 380 A QuickLoad |
|
07.03.02.03 |
Intra-uterine Progestogen Only System Mirena® |
GP will not prescribe for supply. Only prescribe if fitting.
Effective for 5 years |
07.03.02.03 |
Intra-uterine Progestogen Only System Kyleena® |
- Prescribe by brand name to reduce risk of confusion between products.
- Low-dose levonorgestrel releasing IUS effective for 5 years.
|
07.03.02.03 |
Intra-uterine Progestogen Only System Jaydess® |
GP will not prescribe for supply. Only prescribe if fitting.
Effective for 3 years |
06.02.02 |
Iodine and Iodide |
- Potassium iodide tablets 65mg
- Potassium iodate 85mg
- Aqueous Iodine Oral solution
- Also known as Lugol's Iodine
|
A5.03.02 |
Iodoflex® |
Cadexomer dressing containing iodine
Type of wound product is suitable for
Iodine paste in mesh form for chronic infected, sloughy wounds with moderate exudate eg pressure ulcers, leg ulcers, diabetic foot ulcers
Can be used under compression bandaging
MAX Duration dressing remains on wound before changing
Up to 3 days
Frequency of dressing change
Daily for acute infection
Up to 3 days for chronic wounds and infection, depending on exudate levels
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Allergy or sensitivity to iodine
Precaution with large wounds due to absorption. Do not use more than 50g in a single application and no more than 150g in 7 days
Dry necrotic wounds
Thyroid disorders
Renal impairment
Not suitable for children, pregnant or lactating mothers
Concurrent Lithium therapy
Rationale for inclusion in formulary
Anti microbial, broad spectrum, long acting/high absorption capacity
Removes slough and debris to clean the wound bed
Can be moulded to shape of the wound
Alternative to honey products if allergy to bees |
A5.03.02 |
Iodosorb® |
Cadexomer powder or ointment with iodine
Type of wound product is suitable for
Chronic exuding sloughy wounds eg leg ulcers, pressure ulcers, diabetic foot ulcers. Can be used under compression bandaging
Duration dressing remains on wound before changing
Up to 3 days
Frequency of dressing change
Daily for acute infection
Up to 3 days for chronic infection
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Allergy to iodine products
Dry necrotic tissue
Not suitable for Children, pregnant or lactating mothers
Thyroid disorders
Renal impairment
Needs at least twice weekly dressings for iodine to be effective
Rationale for inclusion in formulary
Antimicrobial, broad spectrum, long acting
De-slough and cleans wound debris
Non-adherant. Reduces trauma to wound and pain on dressing changes
Easy application. Can fill cavities or awkward shaped wounds
Alternative to honey based products if allergy to bees |
08.01.05 |
Ipilimumab Yervoy® |
|
03.01.02 |
Ipratropium |
Inhaler
Nebules |
02.05.05.02 |
Irbesartan tablets |
|
09.01.01.01 |
Iron and Folic Acid Pregaday® |
|
09.01.01.02 |
Iron Isomaltoside Monofer® |
Hospital only |
09.01.01.02 |
Iron Sucrose Venofer® |
Hospital use only |
A5.12 |
Irripod |
Sterile sodium chloride solution Type of wound product is suitable for Wound cleansing, for topical irrigation of the eye Duration dressing remains on wound before changing As required Frequency of dressing change As required Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Single use External use only Rationale for inclusion in formulary Cost effective Cleansing of wounds
|
08.01.05 |
Isatuximab |
In line with NICE |
05.02 |
Isavuconazole Cresemba® |
|
09.04 |
Isolecuine50® |
- To correct isoleucine deficiency in MSUD
- The only pre-measured sachet of isoleucine that provides 50 mg/dose to correct isoleucine deficiency in MSUD. A pre-measured sachet is particularly important as most of our families with MSUD do not speak English as their first language so require pre-measured products. The dose and frequency of administration will be determined by the specialist dietitian.
- Nutritional supplement for use in the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
|
09.04 |
Isoleucine 1000 |
- Used as an inpatient only
- Used at the time of diagnosis when on haemofiltration and an isoleucine supplement is necessary.
|
05.01.09 |
Isoniazid |
- RED status also applies to post renal transplant use ( for prophylaxis of TB in renal transplant patients)
Isoniazid liquid 50mg in 5ml (unlicensed) |
06.01.01.02 |
Isophane Insulin Insulatard® |
|
06.01.01.02 |
Isophane Insulin Humulin® I |
|
06.01.01.02 |
Isophane Insulin Insuman® Basal |
|
02.07.01 |
Isoprenaline |
|
02.06.01 |
Isosorbide Dinatrate |
|
02.06.01 |
Isosorbide Mononitrate |
Tablets
|
02.06.01 |
Isosorbide Mononitrate MR |
APC preferred brands:-
Chemydur XL tablets
Monomil XL tablets
|
09.04 |
Isosource Junior (liquid) |
-
Isosource® Junior Mix is a nutritionally complete 1.2kcal/ml standard enteral tube feed, containing some blended food ingredien (rehydrated Chicken meat & vegetables, peach puree, orange juice from concentrate).
- Indicated for: Short bowel syndrome; intractable malabsorption; preoperative preparation of undernourished patients; inflammatory bowel disease; total gastrectomy; dysphagia; bowel fistulae; feeding intolerances, developmental disabilities, disease related malnutrition for children greater than 1 year of age
|
13.06.02 |
Isotretinoin |
Dermatologists only.
Contraindicated in Pregnancy. |
01.06.01 |
Ispaghula Husk |
Granules
- Adequate fluid intake is important to prevent obstruction (6 – 8 cups per day) and should not to be taken immediately before bed
- Unsuitable for frail patients who are likely to drink less than daily required volume of fluid
- Fluid thickens on standing so should be taken as soon as possible as after mixing
- Time to effect is approximately 48 – 72 hours
|
05.02 |
Itraconazole |
|
05.02 |
Itraconazole injection |
|
A5.02.02 |
IV 3000 |
Fixation dressing Type of wound product is suitable for For fixation of intravenous and subcutaneous catheter sites Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Up to 7 days or when wet/soiled Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Sensitivity to any of the product components Not for use on pressure ulcers, burns or donor sites Strips and documentation label are not to be used as suture replacements or primary wound closure methods Rationale for inclusion in formulary Fixation of intravenous and subcutaneous devices |
09.04 |
IVA Anamix® Infant |
- Amino acid supplement without leucine for infants with isovaleric acidaemia
- The only infant amino acid supplement without leucine, for infants with isovaleric acidaemia. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Nutritional supplement for the dietary management of proven isovaleric acidaemia or other proven disorders of leucine metabolism in children from birth to 3 years.
|
02.06.03 |
Ivabradine tablets |
Supported by a RICaD, see link below. |
03.07 |
Ivacaftor Kalydeco® |
In line with NICE |
05.05.06 |
Ivermectin |
- Unlicensed, for crusted scabies, on specialist advice
|
13.06.03 |
Ivermectin 1% cream Soolantra® |
For topical treatment of inflammatory lesions of rosacea (papulopustular) in adults. Alternative treatment option to metronidazole 0.75% cream/gel (see section 13.10.1.2) or azelaic acid 15% gel (see section 13.6.1) |
08.01.05 |
Ixazomib |
In line with NICE
Hospital only - NHSE commissioned. |
13.05.03 |
Ixekizumab Taltz® |
|
A5.17 |
Jelonet® |
Paraffin gauze dressing Type of wound product is suitable for As a primary layer for use with Flamazine® or Flammercerium® Duration dressing remains on wound before changing 24 hours Frequency of dressing change Daily- occasionally alternate day Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy to any ingredients. Rationale for inclusion in formulary Cost effective primary layer
|
09.04.02 |
Jevity® |
- 1 kcal/mL and less than 5 g protein/100 mL
- Pt requires 1 kcal/mL vegetarian feed fish oil free (contains fibre)
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula except bowel fistula. Not suitable for child under 2 years
|
09.04.02 |
Jevity®1.5 kcal |
- 1.5 kcal/mL and 5g (or more) protein/100 mL
- High energy vegetarian feed, fish oil free with fibre
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Jevity®Plus |
- Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
- Pt requires 1.2kcal/mL, fibre, vegetarian feed fish oil free
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Jevity®Plus HP |
- Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
- Pt requires 1.3kcal/mL high protein fibre vegetarian as fish oil free
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Jevity®Promote |
- Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
- Pt requires 1 kcal/mL, fibre, vegetarian feed fish oil free
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.05.02.01 |
Joulies Phosphate Solution |
|
A5.08.04 |
K- Lite |
Lightweight knitted bandage
Type of wound product is suitable for
Designed for use on sprains/strains
Can be used to prevent oedema, would require a wadding bandage to be applied
beneath
It is the second layer of a four layer compression bandage kit
Where there is open skin, a primary dressing must be used
Duration dressing remains on wound before changing
Change in line with primary dressing
Frequency of dressing change
1-7 days
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Known allergy to any components
Not suitable for application of pressure on its own and therefore should be used with other bandage components for the treatment of venous ulcers
Caution over bony prominences where the bandage can cause pressure
Rationale for inclusion in formulary
Cost effective
Essential for providing support to a limb and as part of a bandage compression therapy kit
|
A5.08.07 |
K Soft® |
An absorbent non –woven, sub bandage wadding.
Type of wound product is suitable for
Provides padding , shaping and protection of the limb prior to the application of
compression bandage therapy.
Duration dressing remains on wound before changing
Up to 7 days
Frequency of dressing change
Daily up to weekly dependant on exudate and oedema management.
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Advised not to apply directly to skin as can cause irritation.
Rationale for inclusion in formulary
Essential for protecting a limb, padding and shaping
Forms part of the compression bandage regime. Suitable for use with other formulary products.
|
A5.03.04 |
Kendall AMD® |
Absorbent, non adherent foam disc impregnated with PHMB. Double sided with a centre hole and radial slit Type of wound product is suitable for For use on pin sites, drains and tubes. Duration dressing remains on wound before changing 1-7 days Frequency of dressing change 1-7 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not intended as a primary treatment for infection Do not use as a primary treatment for full thickness burns Not for patients sensitive to PHMB Rationale for inclusion in formulary Provides local exudate management and antimicrobial properties Absorbent Non adherent and semi occlusive For specialist use only |
A5.17 |
Kerlix ® |
Gauze roll containing 0.2% Polyhexamethylene Biguanide (PHMB) Type of wound product is suitable for Colonised or infected wounds, with moderate to heavy exudate Duration dressing remains on wound before changing 3 days Frequency of dressing change 3 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy to PHMB Do not use with Sodium hypochlorite ( Eusol) solutions, as this will deactivate PHM Do not apply gauze circumferentially as it has no stretch, and can become tight restricting circulation Rationale for inclusion in formulary Broad-spectrum antimicrobial agent that reduces bacterial colonization within the dressing and bacterial penetration through the dressing. Can be used in conjunction with Renasys Negative Pressure Therapy
|
13.08.02 |
Keromask® |
- Specialist recommendation
- FP10 prescriptions should be endorsed "ACBS"
|
A5.01.02 |
KerraMaxCare |
Superabsorbent dressing Type of wound product is suitable for Highly exuding wounds as a primary or secondary dressing. Can be used under compression therapy Stackable as no backing present to hold exudate Duration dressing remains on wound before changing 1-7 days. Frequency of dressing change Dependent on level of exudate, usually daily or more frequently Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not cut or tear Rationale for inclusion in formulary Required for heavily exuding wounds. Hospital Use Only
|
A5.16 |
Kerraped |
First consider client's own footwear options.
A shoe to accommodate bandages and offload pressure from the front of the foot
Type of wound product is suitable for
Neuropathic foot ulcers or patients with bulky bandages who cannot wear their own footwear
Duration product remains on wound before changing
As required
Frequency of use
As required
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Ensure correct size is selected
Rationale for inclusion in formulary
Only footwear available for patients with neuropathic ulcers or bulky bandages
|
A5.16 |
KerraPro® |
Silicone pads designed to redistribute pressure from bony prominences. Type of wound product is suitable for Prevention and treatment of category (Stage/Grade) 1 pressure ulcers Duration dressing remains on wound before changing As required. Check skin daily. Frequency of dressing change As required, check skin daily. Pads will last up to 3 months Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Must only be used as part of a pressure ulcer prevention programme Not to be used on a grade 2, 3 4, unstageable or deep tissue injury pressure ulcer unless directed by a clinical specialist Known sensitivity to silicone Do not use as a wound dressing Do not apply directly onto broken skin If skin macerates beneath, ensure the area is being checked and washed daily and consider utilising a cotton stockinette to reduce humidity Rationale for inclusion in formulary Cost effective Available in a large range of shapes and sizes Accessible pressure ulcer prevention medical device Reusable on the same patient for up to 3 months by washing with soap and water and thoroughly drying
|
09.04 |
KetoCal® 2.5:1 Liquid |
|
09.04 |
KetoCal® 3:1 |
- Specialised formulas for specific clinical conditions
- High fat, low carbohydrate, nutritionally complete formula for infants and children from birth to 6 yrs, or as a supplementary feed for children over 6 years and adults on a ketogenic diet. May also be used in cooking
- Enteral feed or nutritional supplement as part of ketogenic diet in management of drug resistant epilepsy or other conditions for which a ketogenic diet is indicated in children from birth to 6 years; as a nutritional supplement in children over 6 years.
|
09.04 |
KetoCal® 4.1 |
- Specialised formulas for specific clinical conditions
- High fat, low carbohydrate powdered formula for children on a ketogenic diet as oral or tube feed, or used in cooking or as a supplementary feed for adults on a ketogenic diet
- Enteral feed or nutritional supplement as part of ketogenic diet in management of epilepsy resistant to drug therapy, in children over 1 year, only on the advice of secondary care physician with experience of ketogenic diet.
|
09.04 |
KetoCal® 4:1 LQ |
- Specialised formulas for specific clinical conditions
- High fat, low carbohydrate nutritionally complete liquid for children over 1 year of age and adults on a ketogenic diet, suitable for oral or tube feeding
- Enteral feed or nutritional supplement as part of ketogenic diet in management of drug resistant epilepsy or other conditions for which a ketogenic diet is indicated in children 1–10 years; as a nutritional supplement in children over 10 years.
|
13.10.02 |
Ketoconazole 2% |
££ |
13.09 |
Ketoconazole 2% shampoo |
Over the counter preparation suitable for self-care/purchase if appropriate |
11.08.02 |
Ketorolac Acular® |
|
21 |
Ketorolac |
Injection |
09.04 |
KeyOmega® |
- Long chain fatty acid supplementation in very low fat diets
- Nutritional supplement for the dietary management of inborn errors of metabolism.
|
A5.02.03 |
kliniderm Foam Silicone |
- November 2016: approved for use, replacing Mepilex®
Polyurethane foam with adhesive silicone wound contact layer Type of wound product is suitable for Suitable for acute and chronic wounds including leg ulcers, pressure ulcers, superficial and partial thickness burns, donor sites, post operative wounds and skin abrasions. Suitable for low to moderately exuding wounds for patients with fragile skin Available in border and non border Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change 1-7 days – dependant on exudate level Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known product or component sensitivity eg Silicone Rationale for inclusion in formulary Wound contact surface is coated with a layer of soft silicone which reduces trauma to delicate tissue. Range of shapes and sizes available.
|
06.04.01.01 |
Kliofem® tablets |
|
06.04.01.01 |
Kliovance® |
|
A5.08.02 |
Knit -band® |
Cellulose contour bandage used for retention of non adhesive dressing products
Type of wound product is suitable for
Retention bandage
Duration dressing remains on wound before changing
Change in line with dressing change
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Take care to apply joint below to joint above. Always use a primary dressing
Rationale for inclusion in formulary
Most cost effective choice.
|
A5.08.06 |
Ko-Flex® |
A water resistant vapour permeable cohesive bandage
Type of wound product is suitable for
Venous ulceration, oedema, Managing sprains and strains and following orthopaedic
surgery
Forms part of the K four bandage system
Duration dressing remains on wound before changing
1 to 7 days
Frequency of dressing change
Dependant on exudate levels if wound present or oedema management .
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Not recommended on those patients with an ABPI lower than 0.8.
Contains latex
Rationale for inclusion in formulary
Cohesive bandage that can be used alongside other formulary products
Forms the 4th layer of a four layer compression bandage system
|
A5.03.04 |
Kytocel® |
Absorbent gelling fibre wound dressing
Type of wound product is suitable for
Moderate to heavily exuding chronic and acute wounds that are sloughy and clinically infected. Haemostatic properties for minor bleeds in superficial wounds Autolytic debridement properties
Duration dressing remains on wound before changing
1-3 days
Frequency of dressing change
1-3 days, dependent on exudate levels
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Allergy to Shellfish (Chitin) Full thickness burns Heavily bleeding wounds Dry wounds
Rationale for inclusion in formulary
Cost effective Alternative to available antimicrobials Can be used on heavily exuding wounds |
02.04 |
Labetalol injection |
|
02.04 |
Labetalol tablets |
Specific indication- Pregnancy |
04.08.01 |
Lacosamide |
- Tablets
- Syrup
- Supported by an ESCA, see link below.
|
01.06.04 |
Lactulose |
Solution |
05.03.01 |
Lamivudine Epivir® |
|
05.03.01 |
Lamivudine Zeffix® |
|
04.02.03 |
Lamotrigine |
|
04.08.01 |
Lamotrigine |
- Tablets
- Dispersible tablets
MHRA Advice Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history.
|
03.04.03 |
Lanadelumab Takhzyro® |
Use in line with NICE
Highly specialist allergy centre- NHSE commissioned |
08.03.04.03 |
Lanreotide Somatuline® LA |
Palliative Care use only Oncology Acromegaly
|
08.03.04.03 |
Lanreotide Somatuline Autogel® |
Palliative Care use only Oncology Acromegaly
|
01.03.05 |
Lansoprazole |
Capsules 15mg, 30mg
- Capsules are more cost effective than tablets
- Can be opened and beads swallowed without crushing, or can be mixed with food or drink
|
01.03.05 |
Lansoprazole dispersible |
Orodispersible tablets 15mg, 30mg
Orodispersible tablets cost twice as much as capsules
Restricted Second choice - for use in patients with swallowing difficulties or who are on enteral tube feeding.
Also licensed to be given via a NG tube or oral syringe if diluted in 5-10 ml water
|
09.05.02.02 |
Lanthanum |
- Specialist Recommendation
- No ESCA
- Common Practice
NHSE commissioned when used for renal dialysis in most circumstances |
08.01.05 |
Lapatinib Tyverb® |
|
08.01.05 |
Larotrectinib Vitrakvi® |
In line with NICE |
A5.10 |
LarvE |
Free range: Biomonde Larvae 100/200 or BioBag Biosurgical treatment for the debridement and cleansing of wounds consisting of aseptically produced living larvae. The BioBag is presented in the five (5) configurations listed below. The larvae are Lucilia sericata contained in a sterile polyester net bag with a sterile PVA spacer cube, presented in a sterile transport container. BioBag 50 at least 50 larvae 25 x 40mm 1 8x8x10 BioBag 100 at least 100 larvae 50 x 40mm 1 12x12x10 BioBag 200 at least 200 larvae 60 x 50mm 1 25x10x10 BioBag 300 at least 300 larvae 120 x 60mm 2 25x10x10 BioBag 400 at least 400 larvae 100 x 100mm 2 25x10x10 Free range larvae, larvae and 30 x 30 flat retention net plus kit pack, larvae and 40 x 60cm boot retention net plus kit pack. Additional 100 or 200 larvae available. Type of wound product is suitable for The BioMonde Larval Debridement Therapy Products are indicated for debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds. Duration dressing remains on wound before changing and frequency of dressing change An application of BioBag can be left in place for up to 4 days, dependent on the condition of the wound. If the wound is not sufficiently debrided after 4 days, the treatment can be repeated with a fresh application of BioBag. The treatment should be stopped as soon as the wound is sufficiently debrided or if no improvement is observed after 3 or more applications. The total number of treatment cycles will depend on the characteristics of the wound, the response of the patient to LDT and the aim of the therapy. Most ulcers are completely debrided within 1 to 6 treatment cycles. If exudate production is excessive, the secondary dressing may be changed as required while leaving the BioBag undisturbed. Frequent removal of the outer dressing will also help to control the odour associated with the liquefied necrotic tissue Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Larvae should not be used in patients with known hypersensitivities to fly larvae, polyester, PVA (polyvinyl alcohol) or the components of the media on which the larvae are raised (including soya protein, yeast protein, potato starch and bovine protein) as this may result in dermatitis or more severe immunological reactions in susceptible individuals. If treatment is undertaken then these patients should be under strict medical supervision for the duration of the treatment with immediate access to care. Patients with life or limb-threatening, rapidly advancing infections should not be treated with as LDT may interfere with the close and frequent observation that these patients require. Should not be used as first line therapy of infected tendon and bone. These wounds should be treated surgically and/or with antibiotics before using LDT. Should not be used to treat wounds which are not directly exposed to the outside. Wounds should never be allowed to close over the larvae either intentionally or unintentionally. Should not be used on wounds with an inadequate blood supply as this ultimately reduces the ability of the wound to heal. LDT will enlarge the wound as necrotic tissue is debrided but the resulting clean wound is at risk from re-infection. Although some mild bleeding is common during LDT, larvae should not be used on wounds that have a tendency to bleed or wounds close to an exposed major blood vessel, especially if considered to be necrotic as this can lead to rupture of the blood vessels which could be life-threatening. If LDT is attempted, the patient must remain under strict medical supervision for the duration of the treatment. Should not be used on patients with an inborn or medication-induced coagulopathy or in patients being treated with anticoagulants. If these patients are treated with LDT, they should remain under strict medical supervision for the duration of the treatment. Should never be used in sterile body cavities. Should be used with caution on wounds over adjacent exposed organs or leading to a body cavity, and only under close medical supervision for the duration of the treatment. Data are not available concerning the antibiotic / antiseptic activity of maggots and therefore any infected wound should receive standard antibiotic care. Rationale for inclusion in formulary Only available larval therapy on prescription. Rapid debridement of chronic wounds Can be utilised in the community |
11.06 |
Latanoprost 0.005% with Timolol 0.5% |
- Specialist Ophthalmologist Recommendation
|
11.06 |
Latanoprost eye drops |
- Specialist Ophthalmologist Recommendation
- 1st Line
|
11.06 |
Latanoprost PF Eye Drops Monopost |
Specialist Ophthalmologist Recommendation
1st Line PF option |
11.06 |
Latanoprost with Timolol preservative free Fixapost® |
- Specialist Ophthalmologist Recommendation
|
05.03.03.02 |
Ledipasvir- sofosbuvir Harvoni® |
In line with NICE |
10.01.03 |
Leflunomide |
Supported by ESCA, see link below. |
08.02.04 |
Lenalidomide |
In line with NICE |
09.01.06 |
Lenograstim |
Hospital only |
08.01.05 |
Lenvatinib Kisplyx ® |
In line with NICE |
05.03.02.02 |
Letermovir |
Use in line with NICE |
08.03.04.01 |
Letrozole |
|
06.07.02 |
Leuprorelin |
- For endometrosis or breast cancer
- Specialist initiation
|
08.03.04.02 |
Leuprorelin Acetate Prostap® SR |
|
08.03.04.02 |
Leuprorelin Acetate Prostap® 3 |
|
05.05.02 |
Levamisole |
Unlicensed |
04.08.01 |
Levetiracetam Desitrend® |
- Paediatrician initiation.
- For patients up to and including 16 years of age unable to swallow tablets and in whom the liquid formulation is not appropriate or tolerated.
MHRA Advice It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
|
04.08.01 |
Levetiracetam |
- Tablets
- SF oral solution
- Coated granules in sachets (see Desitrend®)
MHRA Advice It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors
|
05.01.12 |
Levofloxacin tablets |
- For multi resistant organisms, on advice of specialist
|
05.01.12 |
Levofloxacin infusion |
|
11.03.01 |
Levofloxacin Oftaquix |
- Amber £££ 2nd line
- Use SDU if using 1or 2 hourly or if significant OSD/toxicity.
|
04.06 |
Levomepromazine |
palliative care only |
04.02.01 |
Levomepromazine injection |
|
04.02.01 |
Levomepromazine tablets |
- Supported by ESCA, see link below.
|
07.03.05 |
Levonogrestrel Levonelle® 1500 |
|
07.03.02.01 |
Levonorgestrel 30mcg Norgeston® |
|
06.02.01 |
Levothyroxine |
|
15.02 |
Lidocaine laryngojet® |
Hospital only
Dental use under review |
12.03.01 |
Lidocaine 10% mouth spray |
Hospital only |
15.02 |
Lidocaine 2.5% with Prilocaine 2.5% EMLA® |
|
15.02 |
Lidocaine 4% cream LMX® |
Paediatrics only |
15.02 |
Lidocaine 5% ointment |
|
04.07.03 |
Lidocaine 5% patch Versatis® |
Approved only in patients who have been treated in line with NICE CG173 Neuropathic pain in adults: pharmacological management in non-specialist settings but are still experiencing neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia)
|
02.03.02 |
Lidocaine hydrochloride |
|
15.02 |
Lidocaine injection |
|
15.02 |
Lidocaine with Adrenaline Lignospan® |
|
15.02 |
Lidocaine with Adrenaline Xylocaine® |
|
15.02 |
Lidocaine2% with Chlorhexidine 0.25% Instillagel® |
|
A5.11 |
LimbO Waterproof protector |
Waterproof protector, non slip latex free with a flexible seal at the opening Type of wound product is suitable for Used to keep arm, PICC, leg and foot dressings dry, can be fully submerged in water Rationale for inclusion in formulary Multiple sizing for legs and arms |
01.06.07 |
Linaclotide Constella▼® |
- For moderate to severe IBS-Constipation.
- For patients who have not responded adequately to or cannot tolerate all other suitable treatment options BUT BEFORE other agents with higher costs.
|
06.01.02.03 |
Linagliptin Trajenta® |
In line with NICE |
05.01.07 |
Linezolid oral formulations |
- On advice from microbiologist for MRSA
|
05.01.07 |
Linezolid infusion |
|
06.02.01 |
Liothyronine |
Tablets - Supported by an ESCA (being developed)
-
Injection
|
20 |
Lipiodol |
|
09.04 |
Lipistart® |
- Specialised formulas: Infant and child: MCT-enhanced formula
- Essential for infants/children with long chain fatty acid oxidation disorders who need a high intake of MCT but require normal proportions of carbohydrate e.g. CPT1 and CPT2 deficiency. High carbohydrate formulas are unnecessary.
- Also essential for infants/children with long chain fatty acid oxidation disorders who need a high intake of MCT but require normal proportions of carbohydrate e.g. CPT1 deficiency (i.e. high carbohydrate formulas may be unnecessary). There should always be 2 powdered high MCT formulae in the formulary in case of supply issues. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Dietary management of fat malabsorption, long-chain fatty acid oxidation disorders, and other disorders requiring a high MCT, low LCT formula.
|
13.02.01 |
Liquid and White Soft Paraffin Ointment (50:50) |
Over the counter preparation suitable for self-care/purchase if appropriate |
A5.13 |
Liquid paraffin / white soft paraffin 50:50 |
Emollient ointment containing liquid paraffin and white soft paraffin To assist the skin in retaining moisture Type of wound product is suitable for For use on all dry skin conditions including eczema and psoriasis Frequency of use Daily or more frequently if required Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy or hypersensitivity to any of the ingredients Rationale for inclusion in formulary Treatment of dry skin conditions. Dermatology approved
|
09.04 |
Liquigen® |
- High-energy supplements: fat
- Used as a source of MCT when required for children and adults with LCT intolerance and on a low LCT diet and for adults and children on a ketogenic diet - ££
- Also this is used as a milk replacement and as part of module tube feeds for patients with long chain fatty acid disorders such as LCHADD and VLCADD who require ≥10% fat calories from long chain fat and a diet supplemented with MCT. It is essential to provide essential energy on fat restricted diets if MCT is tolerated by the patient. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Steatorrhoea associated with cystic fibrosis of the pancreas, intestinal lymphangiectasia, intestinal surgery, chronic liver disease, liver cirrhosis, other proven malabsorption syndromes, ketogenic diet in epilepsy, and in type 1 lipoproteinaemia. Not suitable for child under 1 year
|
06.01.02.03 |
Liraglutide Saxenda® |
- Injection
- For weight loss/ obesity
- Use according to NICE guidance
The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place.
Prescribe by brand (Saxenda ®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes |
06.01.02.03 |
Liraglutide Victoza® |
- Injection
- For the treatment of type 2 diabetes ONLY.
- Use according to NICE guidance
THIS IS FOR DIABETES ONLY. Prescribe by brand (Victoza®) to avoid patients inadvertently receiving a different product licensed for obesity. |
04.04 |
Lisdexamfetamine |
Please note that commissioning discussion is underway. However the present status is as follows:-
Birmingham and Solihull CCG
Age 6 and over - Solihull practices. Supported with ESCA
Age 16 and over - Birmingham practices. Supported with ESCA
Age under 16 - Birmingham practices
Sandwell and West Birmingham CCG
Age 6 and over. Supported with ESCA. Click here for shared care document for patients seen by Black Country Partnership NHS FT
|
02.05.05.01 |
Lisinopril tablets |
|
04.02.03 |
Lithium Carbonate M/R tablets Priadel® |
- Supported by an ESCA, see link below.
- APC preferred brand is Priadel
|
04.02.03 |
Lithium Citrate liquid |
- Supported by an ESCA, see link below.
- APC preferred brand Priadel
|
A5.03.01 |
L-Mesitran ® |
A hydro active gel dressing containing medical grade honey available without or with an adhesive film border. L- Mesitran has anti bacterial properties and can debride and reduce malodour.
Type of wound product is suitable for
Burns, chronic wounds, necrotic/sloughy wounds, surgical wounds, diabetic ulcers with caution, donor sites, fungating wounds.
Max Duration dressing remains on wound before changing
3-7 days
Frequency of dressing change
3- 7 days, dependent on exudate level
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Known sensitivity to dressing and any of its components use with caution in patients with bee venom allergy
Not suitable for full thickness burns/deep narrow cavities
Caution must be exercised when applying to diabetic patients. Blood glucose levels must be monitored.
Rationale for inclusion in formulary
Desloughing, Antimicrobial, Deodorising |
09.04 |
Locasol ® |
- Specialised formulas: Infant and child: Low calcium formula
- Use in children with high blood calcium levels eg Noonan’s syndrome
- Conditions of calcium intolerance requiring restriction of calcium and vitamin D intake
|
04.03.01 |
Lofepramine |
Tablets
Suspension |
04.10.03 |
Lofexidine BritLofex® |
|
08.01.01 |
Lomustine capsules |
|
01.04.02 |
Loperamide |
- Capsule 2mg, Syrup 1mg/5ml
Capsules are more cost effective than tablets
- Loperamide melts (orodispersible) tablets are reserved for high output stoma patients only
- Not to be used if C.diff is suspected
Caution in patients with a history of recent or repeated antibiotic use as increased risk of C.diff infection in this group
|
09.04 |
Lophlex® |
- A supplement without phenylalanine for teenagers and adults with phenylketonuria
- One of 2 powdered amino acid supplement without phenylalanine for teenagers and adults with phenylketonuria that will meet their higher amino acid requirements. This age group need the larger sachets (20g protein equivalent) to meet their non-phenylalanine protein requirements. It is important we have a choice of more than 1 product for this age group as compliance is reported to be poor and the potential outcome of poor compliance is poor executive functioning. The 2 different products have a different degree of sweetness and range of flavours.
- Nutritional supplement for the dietary management of proven phenylketonuria in children over 8 years and adults including pregnant women.
|
05.03.01 |
Lopinavir and Ritonavir Kaletra® |
|
09.04 |
Loprofin SnoPro |
- Specialised formulas for specific clinical conditions
- Low protein, low potassium, low Phosphate milk substitute , used as a milk replacement in children with renal disease and IMD
- Nutritional supplement for the dietary management of phenylketonuria, chronic renal failure and other inborn errors of amino acid metabolism.
|
09.04 |
Loprofin® PKU Drink |
- Low protein milk for children and adults with phenylketonuria and other disorders of protein metabolism
- Low energy protein milk for children and adults with phenylketonuria and other disorders of protein metabolism who are overweight
- Nutritional supplement for the dietary management of phenylketonuria in children over 1 year and adults.
|
09.04 |
Loprofin® Sno-Pro |
- Specialised formulas for specific clinical conditions
- Low protein, low potassium, low Phosphate milk substitute , used as a milk
replacement in children with renal disease and IMD
- Nutritional supplement for the dietary management of phenylketonuria, chronic renal failure and other inborn errors of amino acid metabolism.
|
03.04.01 |
Loratadine |
OTC preparation suitable for self-care/purchase if appropriate |
04.01.02 |
Lorazepam |
|
04.01.02 |
Lorazepam |
Oct 2018: supply issues with injection |
21 |
Lorazepam |
Tablets |
09.04 |
Lorenzo’s oil |
- For dietary treatment of adrenoleukodystrophy. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
|
08.01.05 |
Lorlatinib Lorviqua® |
In line with NICE |
02.05.05.02 |
Losartan tablets |
|
11.04.01 |
Loteprednol Etabonate 0.5% Lotemax® |
|
09.04 |
Low fat 1+ module |
- Specialised formulas: Infant and child: MCT-enhanced formula
- Children and adults with a fatty acid disorder
- Also fat free preparation. Used by patients with long chain fatty acid oxidation disorders who cannot tolerate MCT and require a very low-fat diet. Suitable for children and adults with a fatty acid disorder. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
|
03.01.05 |
Low range peak flow meter |
|
06.04.01.01 |
Lubion® Injection |
|
03.15 |
Lumacaftor-ivacaftor Orkambi® |
In line with NICE |
09.01.04 |
Lusutrombopag Mulpleo® |
|
08.03.04.03 |
Lutetium (177Lu) oxodotreotide |
In line with NICE
Hospital only - NHSE commissioned |
A5.09.02 |
Lymphoedema garments |
Based on assessment |
02.05.01 |
Macitentan Opsumit® |
NHS England commissioned |
01.06.04 |
Macrogol Laxido® |
Oral powder
Prescribe as Laxido |
01.06.05 |
Macrogols Klean-Prep® |
Oral powder |
01.06.05 |
Macrogols Moviprep® |
Oral powder sachet |
09.05.01.03 |
Magnaspartate ® sachets |
|
09.05.01.03 |
Magnesium citrate tablets |
|
09.05.01.03 |
Magnesium Glycerophosphate oral |
|
09.05.01.03 |
Magnesium Sulphate |
Hospital only |
13.10.05 |
Magnesium Sulphate Paste BP |
Over the counter preparation suitable for self-care/purchase if appropriate |
01.01.01 |
Magnesium Trisilicate Mixture BP |
Suspension
High sodium content
Use with caution in renal impairment |
A5.11 |
Magnide |
Application aid for closed toe stockings/ compression garments |
13.10.04 |
Malathion |
Over the counter preparation suitable for self-care/purchase if appropriate |
02.02.05 |
Mannitol infusion |
|
03.07 |
Mannitol inhalation Bronchitol ® |
Hospital only |
05.03.01 |
Maraviroc |
|
09.04 |
Maxijul® Super Soluble |
- High-energy supplements: carbohydrate
- High calorie modular powder, to be added to other food, drink and feeds e.g. faltering growth, to increase carbohydrate content.
- Also used as an additional energy supplement when IMD patients require a modified, low protein or low-fat feed or are on a glucose polymer based energy supplement and require other Nutricia products such as Monogen or Nutrini fibre, so it can be delivered using the same home delivery service so less burdensome for families. It is also used as a core ingredient for glucose based emergency feeds. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement.
|
09.04 |
MCT Procal® |
- Protein, fat, and carbohydrate
- Used in children and adults on a ketogenic diet as an energy source for use with long chain fatty acid disorders and in metabolic disorders.
- Used in liver/hepatobiliary disease/conditions
- Essential for use with log chain fatty acid disorders such as LCHADD, VLCADD, CACT. It provides a pre-measured source of MCT energy at breakfast, midday and evening to ensure patients do not become energy depleted when performing usual daytime activities. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Dietary management of disorders of long-chain fatty acid oxidation, fat malabsorption, and other disorders requiring a low LCT, high MCT supplement.
- Not suitable for child under 1 year.
|
14.04 |
Measles, Mumps and Rubella Vaccine, Live (MMR) |
|
05.05.01 |
Mebendazole |
|
01.02 |
Mebeverine Hydrochloride |
Tablet 135mg
Prescribe standard release tablets only; modified release (MR) preparations are non-formulary
|
06.07.04 |
Mecasermin Increlex® |
NHSE commissioned. |
A5.15 |
MediHoney barrier cream |
Barrier cream containing active Medihoney. Helps to reduce inflammation Type of wound product is suitable for Treatment of incontinence related lesions Treats blistered skin Prevention and treatment of maceration and excoriation Treats candidiasis and intertrigo Frequency of use At each episode of hygiene Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Patch test before use Rationale for inclusion in formulary Suitable for neonates and children Treats fungal infections as well as incontinence associated lesions Reduces inflammation Can be applied to broken skin |
09.04 |
Medium-chain Triglyceride (MCT) Oil |
- High-energy supplements: fat
- Used as a source of energy for children and adults requiring a low LCT/ High MCT diet
- Also this is used as a MCT cooking oil to improve diet palatability in patients with long chain fatty acid disorders such as LCHADD and VLCADD who require ≥10% fat calories from long chain fat. It is used to make MCT margarine, add to toast or to cook potatoes and other vegetables. It is essential to provide essential energy on fat restricted diets if MCT is tolerated by the patient. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Nutritional supplement for steatorrhoea associated with cystic fibrosis of the pancreas, intestinal lymphangiectasia, intestinal surgery, chronic liver disease and liver cirrhosis, other proven malabsorption syndromes, ketogenic diet in management of epilepsy, type 1 hyperlipoproteinaemia
|
06.04.01.02 |
Medroxyprogesterone Acetate |
Climanor®
Provera® |
07.03.02.02 |
Medroxyprogesterone Acetate Depo-Provera® |
|
07.03.02.02 |
Medroxyprogesterone acetate Sayana Press® |
Suitable for self-injection in patients who have had appropriate training |
08.03.02 |
Medroxyprogesterone Acetate |
|
10.01.01 |
Mefenamic Acid |
For dysmenorrhoea |
A5.07.03 |
Mefix |
Permeable, aperture non woven, synthetic adhesive tape
For securing dressings.
Frequency of dressing change
Determined by wound type and dressing change
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
None listed
Rationale for inclusion in formulary
Available on drug tariff. Different availability of sizes in comparison to Clinipore for
difficult to dress areas. Some stretch and flexibility to improve conformity and adhesion. Can be used to secure dressings rather than bandages.
|
05.04.01 |
Mefloquine Lariam® |
Private prescription in Primary Care |
08.03.02 |
Megestrol Acetate |
|
04.01.01 |
Melatonin |
|
04.01.01 |
Melatonin Circadin ® |
|
08.01.01 |
Melphalan Tablets |
|
04.11 |
Memantine |
|
09.06.06 |
Menadiol Sodium Phosphate |
|
14.04 |
Meningococcal A, C, W135, and Y conjugate vaccine |
|
14.04 |
Meningococcal group B Vaccine Bexsero® |
|
14.04 |
Meningococcal group C conjugate vaccine |
|
13.03 |
Menthol in Aqueous cream |
Over the counter preparation suitable for self-care/purchase if appropriate |
05.04.04 |
Mepacrine Hydrochloride |
|
13.15 |
Mepacrine Hydrochloride |
For Discoid lupus erythematosus (DLE) |
A5.04.02 |
Mepiform |
Silicone sheet for scar treatment Type of wound product is suitable for Not for use on open wounds- to be applied on healed scar only. This is not a dressing but a scar treatment Duration dressing remains on wound before changing 23 hours Frequency of dressing change Daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use on open or infected wounds. Do not use on skin affected by acne. Discontinue use if a rash or itching occur. Rationale for inclusion in formulary Scar therapy Silicone sheets have been shown to soften, flatten scarring aiding movement, nerve sensations and function. Cost effective. |
A5.02.03 |
Mepitel |
Soft polymer non-adherent dressing without pad Type of wound product is suitable for Primary wound contact layer, non adherent, traumatic and chronic wounds Requires secondary dressing Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Up to 7 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Heavily bleeding wounds Any sensitivity to silicone Rationale for inclusion in formulary Non-adherent primary wound contact layer to protect skin tears, fragile skin, primary contact layer for use under topical negative pressure |
03.14 |
Mepolizumab (Nucala®) |
In line with NHSE |
A5.01.02 |
Mepore |
Type of wound product is suitable for
Post operative closed surgical wounds or simple wounds with up to light amounts of exudate.
Can be used as a protective dressing for sutured post operative wounds. Can be used as a protective dressing for newly epithelialized wounds. Can be used for small traumatic wounds.
Duration dressing remains on wound before changing
Up to 7 days
Frequency of dressing change
1-7 days. If daily change is required - review product choice
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Known product or component sensitivity
Rationale for inclusion in formulary
Sutured surgical wounds for protection. Can be used as a protective dressing for newly epithelialized wounds. Can be used for small traumatic wounds. |
04.07.02 |
Meptazinol Meptid® |
|
09.08.01 |
Mercaptamine Cystagon® |
|
01.05.03 |
Mercaptopurine |
Tablet 50mg Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults – unlicensed but in line with national guidelines For use in Inflammatory Bowel Disease (IBD) as per effective shared care agreement (ESCA). See link below. |
08.01.03 |
Mercaptopurine Tablets |
Red for cancer indications
See section 01.05.03 for use in IBD |
09.04 |
Meritene shake |
- Prescribed for liver patients, at request of UHB liver/dietetic team only
- Liver/hepatobiliary and pancreatic conditions.
- Supported by RICaD
|
03.13 |
Meropenem |
Hospital only |
05.01.02.02 |
Meropenem |
|
01.05.01 |
Mesalazine Mezavant® XL |
For initiation by Consultant Gastroenterologists only, for patients non-compliant with other oral mesalazine preparations. |
01.05.01 |
Mesalazine tablets, MR tablets, granules, suppositories, enemas |
Octasa is preferred brand of choice UHB NHS FT Other brands – Pentasa, Asacol, Asacol MR, Salofalk (granules/enema), Mezavant XL. |
01.05.01 |
Mesalazine Salofalk® |
Granules and enemas |
01.05.01 |
Mesalazine Octasa® |
Octasa is currently the preferred brand - name changed from Mesren® in Nov/Dec 2012 Both strengths are more cost effective compared to Asacol®. Mesalazine should be prescribed by brand. |
08.01 |
Mesna |
|
07.03.01 |
Mestranol 50mcg/norethisterone 1mg Norinyl-1® |
- Monophasic standard strength (21-day preparation)
- For patients who need high oestrogen
- For patients on anticonvulsant treatment
|
A5.15 |
Metanium ointment |
Barrier preparation Type of wound product is suitable for For relief of the symptoms of nappy rash Frequency of use Spread the ointment thinly so the skin texture can be clearly seen through it. Repeat at each nappy change. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not to be used on adults in conjunction with containment products for incontinence due to the inclusion of light liquid and white paraffin in the ingredients, which will repel urine/faeces back onto the skin. Any allergy to the listed ingredients Overdose is unlikely when Metanium Nappy Rash Ointment is used as instructed for treating nappy rash. However, as this product contains titanium salicylate, accidental ingestion or excessive topical application could lead to symptoms of salicylate poisoning. Rationale for inclusion in formulary Dermatology approved |
13.02.02 |
Metanium® |
- specialist recommendation
Over the counter preparation suitable for self-care/purchase if appropriate |
02.07.02 |
Metaraminol |
|
06.01.02.02 |
Metformin |
|
06.01.02.02 |
Metformin M/R |
Only for patients intolerant of slowly titrated standard release metformin |
06.01.02.02 |
Metformin oral solution SF |
For patients with swallowing difficulties £££ |
04.07.02 |
Methadone |
For use in opioid dependence, see section 4.10.3 |
21 |
Methadone |
All forms |
03.09.01 |
Methadone Hydrochloride Methadone® Linctus |
Palliative care only |
04.10.03 |
Methadone injection |
|
04.10.03 |
Methadone oral solution |
|
04.10.03 |
Methadone tablets |
|
05.01.13 |
Methenamine Hippurate |
|
01.05.03 |
Methotrexate |
- Tablets 2.5mg (2.5mg tablets preferred as per NPSA alert)
Cytotoxic- do not crush and disperse in water
- Parenteral injection:Metoject®PEN is the APC preferred brand.
- Unlicensed liquid may be available if required
For use in active Crohn's disease (unlicensed indication supported by APC) as per effective shared care agreement (ESCA). See link below.
|
04.13 |
Methotrexate |
Specialist use only for neurological conditions |
13.05.03 |
Methotrexate |
- supported by ESCA, see link below
|
08.01.03 |
Methotrexate 2.5mg Tablets |
Red for cancer indications
See section 13.05.03 for psoriasis, 01.05.03 for Crohn's disease, 03.12 for interstitial lung disease and 10.01.03 for rheumatology indications. |
10.01.03 |
Methotrexate 2.5mg tablets |
Supported by ESCA, see link below. Should only be prescribed as 2.5mg tablets (Local agreement following National Patient Safety Agency alert) |
03.12 |
Methotrexate tablets |
- Supported by ESCA , see link below.
- 2.5mg tablets
|
09.01.03 |
Methoxy Polyethylene Glycol-Epoetin Beta Mircera® |
NHSE commissioned for use in renal dialysis
Primary Care commissioned for use in cancer- in line with NICE TA323
|
13.05.02 |
Methoxypsoralen |
|
13.08.01 |
Methyl-5-Aminolevulinate Metvix® |
|
02.05.02 |
Methyldopa tablets |
|
04.04 |
Methylphenidate Modified-Release tablets/capsules |
Please note that commissioning discussion is underway. However the present status is as follows:-
Birmingham and Solihull CCG
Age 6 and over - Solihull practices. Supported with ESCA
Age 16 and over - Birmingham practices. Supported with ESCA
Age under 16 - Birmingham practices
Sandwell and West Birmingham CCG
Age 6 and over. Supported with ESCA. Click here for shared care document for patients seen by Black Country Partnership NHS FT
|
04.04 |
Methylphenidate tablets |
Please note that commissioning discussion is underway. However the present status is as follows:-
Birmingham and Solihull CCG
Age 6 and over - Solihull practices. Supported with ESCA
Age 16 and over - Birmingham practices. Supported with ESCA
Age under 16 - Birmingham practices
Sandwell and West Birmingham CCG
Age 6 and over. Supported with ESCA. Click here for shared care document for patients seen by Black Country Partnership NHS FT
|
10.01.02.02 |
Methylprednisolone Acetate Depo-Medrone® |
|
06.03.02 |
Methylprednisolone acetate injection Depo-Medrone® |
|
10.01.02.02 |
Methylprednisolone Acetate/ Lidocaine Depo-Medrone® with Lidocaine |
|
06.03.02 |
Methylprednisolone sodium succinate injection Solu-Medrone ® |
|
06.03.02 |
Methylprednisolone tablets |
In line with NICE |
02.05.01 |
Metirosine |
|
01.02 |
Metoclopramide |
Not recommended for patients aged 20 years and below due to risk of dystonic reactions See MHRA guidance below for restrictions on use in younger patients
|
04.06 |
Metoclopramide |
tablets
SF solution- £££-for patients with swallowing difficulties only |
04.06 |
Metoclopramide injection |
in palliative care
other indications
|
10.01.03 |
Metoject® |
Metoject is APC preferred brand in view of additional patient safety characteristics. Supported by ESCA, see link below. Check cytotoxic disposal arrangements locally |
02.02.01 |
Metolazone |
Specialist recommendation (unlicensed) Use with local trust approval. Available from "special-order" manufacturers or specialist-importing companies. |
02.04 |
Metoprolol tartrate |
Tablets
Modified Release tablets |
02.04 |
Metoprolol tartrate injection |
|
05.01.11 |
Metronidazole Suppositories |
|
05.01.11 |
Metronidazole infusion |
|
05.01.11 |
Metronidazole |
Tablets
Suspension ££ |
07.02.02 |
Metronidazole Zidoval® |
0.75% vaginal gel |
13.10.01.02 |
Metronidazole 0.75% Anabact® |
for wounds |
13.10.01.02 |
Metronidazole 0.75% Rozex® |
For acne rosacea |
13.10.01.02 |
Metronidazole 0.75% Acea® |
For acne rosacea |
A5.16 |
metronidazole 0.75% gel Anabact® |
Type of wound product is suitable for Malodourous fungating wounds. Requires a secondary dressing Duration preparation remains on wound before changing Apply 1-2 times daily following cleansing Frequency of use 1-2 times daily for a maximum of 8 weeks. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Avoid exposure to strong sunlight or UV light Not to be used on a patient with known sensitivity to any components Avoid contact with eyes Not for use of any other aetiology of wound as odour control. Rationale for inclusion in formulary Odour control for fungating tumours |
06.07.03 |
Metyrapone Metopirone® |
|
02.03.02 |
Mexiletine hydrochloride |
unlicensed Use with local trust approval. Available from "special-order" manufacturers or specialist importing companies.
|
05.02.04 |
Micafungin |
|
07.02.02 |
Miconazole Gyno-Daktarin® |
- 2% intravaginal cream
- 1.2g ovule (vaginal capsule) - discontinued by manufacturer 2018
|
11.03.02 |
Miconazole 1% eye drops |
|
13.10.02 |
Miconazole 2% |
|
12.03.02 |
Miconazole oral gel |
|
04.08.02 |
Midazolam buccal liquid Buccolam® |
|
02.07.02 |
Midodrine Bramox® |
- Transfer to Primary Care supported by an ESCA.
- Click here for ESCA
|
08.01.05 |
Midostaurin Rydapt® |
In line with NICE
NHSE commissioned |
08.02.04 |
Mifamurtide |
In line with NICE |
07.01.02 |
Mifepristone Mifegyne® |
|
05.01.03 |
Minocycline |
|
07.04.02 |
Mirabegron Betmiga® |
for patients not tolerating/ with contra-indications to antimuscarinics
in line with NICE |
04.03.04 |
Mirtazapine |
tablets
orodispersible tablets ££ |
21 |
Mirtazapine |
Tablets, oral solution
For pain |
01.03.04 |
Misoprostol Cytotec® |
Tablet 200mg For specialist initiation only |
07.01.01 |
Misoprostol |
oral
PV |
11.99.99.99 |
Mitomycin C |
Hospital only |
08.01.05 |
Mitotane Lysodren® |
|
09.04 |
MMA/PA amp 5 |
- Methionine, threonine and valine free, and low isoleucine aa supplement
- The only pre-measured sachet of methionine, threonine, valine free and low isoleucine amino acid supplement for patients with propionic acidaemia and methyl malonic acidaemia reliant on tube feeding. A pre-measured sachet is particularly important as most of our families with MSUD do not speak English as their first language so require pre-measured products.
|
09.04 |
MMA/PA Anamix® Infant |
- Amino acid supplement without methionine, threonine, valine and isoleucine for infants with propionic acidaemia and methyl malonic acidaemia
- The only infant amino acid supplement without methionine, threonine, valine and isoleucine for patients with propionic acidaemia and methyl malonic acidaemia
- Nutritional supplement for the dietary management of proven methylmalonic acidaemia or propionic acidaemia in children from birth to 3 years.
|
04.03.02 |
Moclobemide tablets |
|
04.04 |
Modafinil |
|
09.04 |
Modjul® Flavour System |
- Flavouring preparations
- For flavouring unpalatable flavouring amino acid supplements or feeds in inborn errors of metabolism
- Essential for flavouring different unflavoured amino acid supplements in inborn errors of metabolism- particularly for non PKU conditions. They offer alternative flavours to Vitaflo pacs. This is important as amino acid formulations are unpalatable and unacceptable particularly for patients with late diagnosed conditions. They cannot be purchased from a supermarket.
- For use with unflavoured SHS products based on peptides or amino acids; not suitable for child under 6 months.
|
09.04 |
Modulen IBD® |
- Specialised formulas for specific clinical conditions
- For treatment of Crohn’s Disease
- Crohn's disease active phase, and in remission if malnourished
|
13.04 |
Mometasone Furoate 0.1% |
Potency: potent Cream Ointment Scalp lotion ££ |
12.02.01 |
Mometasone Furoate nasal spray |
|
09.04 |
Monogen® |
- Specialised formulas: Infant and child: MCT-enhanced formula
- Used in infants who require high MCT feed eg following chylothorax and in inborn errors of metabolism where MCT is required
- Also essential for infants/children with long chain fatty acid oxidation disorders who need a high intake of MCT and high intake of carbohydrate e.g. LCHADD and trifunctional protein deficiency (i.e. lower carbohydrate formulas are inappropriate). There should always be 2 powdered high MCT formulae in the formulary in case of supply issues. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Long-chain acyl-CoA dehydrogenase deficiency (LCAD), carnitine palmitoyl transferase deficiency (CPTD), primary and secondary lipoprotein lipase deficiency, chylothorax, and lymphangiectasia
|
03.03.02 |
Montelukast |
|
04.07.02 |
Morphine |
suppositories
100mg/100ml PCA
5mg/5ml intrathecal injection
pre-filled syringes |
04.07.02 |
Morphine |
tablets
M/R tablets
M/R capsules
Oral solution
injection |
21 |
Morphine |
Injection
Topical use for painful wounds where systemic opioids are effective but dose limited due to side-effects |
05.01.12 |
Moxifloxacin |
|
02.05.02 |
Moxonidine tablets |
|
09.04 |
MSUD Amino 5 |
- Amino acid supplement without leucine, valine and isoleucine for infants/children with MSUD
- The only pre-measured amino acid supplement, without leucine, valine, isoleucine for infants/children with maple syrup urine disease used for emergency regimens and tube feeds. This is particularly important as most of our families with MSUD do not speak English as their first language.
|
09.04 |
MSUD Anamix® Infant |
- Amino acid supplement without leucine, valine and isoleucine for infants with MSUD
- The only infant amino acid supplement without leucine, valine, isoleucine for maple syrup urine disease.
- Nutritional supplement for the dietary management of proven maple syrup urine disease in children from birth to 3 years.
|
09.04 |
MSUD Anamix® Junior |
- Amino acid supplement without leucine, valine and isoleucine for children with MSUD
- The only infant amino acid supplement without leucine, valine, isoleucine for maple syrup urine disease.
- Nutritional supplement for the dietary management of maple syrup urine disease in children 1–10 years.
|
09.04 |
MSUD Anamix® Junior LQ |
- Amino acid supplement without leucine, valine and isoleucine for children with MSUD. Can be used in adults
- An unthickened powdered amino acid supplement without leucine, valine, isoleucine for children aged 1 to 10y with maple syrup urine disease which can be given as a drink.
- Nutritional supplement for the dietary management of maple syrup urine disease in children 1–10 years.
|
09.04 |
MSUD cooler® 10 |
- Amino acid supplement without leucine, valine and isoleucine for children and adults with MSUD
- An oral liquid amino acid supplement without leucine, valine, isoleucine formulated for children aged 3 to 6 years with maple syrup urine disease. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements
|
09.04 |
MSUD cooler® 15 |
- Amino acid supplement without leucine, valine and isoleucine for teenagers with MSUD
- An oral liquid amino acid supplement without leucine, valine, isoleucine for children aged 7 to 12 years with maple syrup urine disease. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements.
|
09.04 |
MSUD cooler® 20 |
- Amino acid supplement without leucine, valine and isoleucine for teenagers and adults with MSUD
- One of 2 oral flavoured liquid amino acid supplements without leucine, valine, isoleucine for teenagers over 12 years of age and adults. This age group need the larger pouches to meet their non-leucine protein requirements. It is important we have a choice of more than 1 product as compliance is poor. It is essential that patients are offered choice of more than 1 protein substitute.
|
09.04 |
MSUD express® 15 |
- Amino acid supplement without leucine, valine and isoleucine for teenagers and adults with MSUD
- The only powdered amino acid supplement without leucine, valine, isoleucine for 7 to 12-year olds with maple syrup urine disease. Larger sachets are unacceptable for this age group of children and provide in excess of protein requirements.
- Nutritional supplement for the dietary management of maple syrup urine disease in children over 8 years and adults.
|
09.04 |
MSUD express® 20 |
- Amino acid supplement without leucine, valine and isoleucine for teenagers and adults with MSUD
- The only powdered amino acid supplement without leucine, valine, isoleucine for teenagers and adults with maple syrup urine disease that will met their higher BCAA-free amino acid requirements. This age group need the larger sachets (20g protein equivalent) to meet their non-methionine protein requirements
- Nutritional supplement for the dietary management of maple syrup urine disease in children over 8 years and adults.
|
09.04 |
MSUD Gel® |
- Amino acid supplement without leucine, valine and isoleucine for children with MSUD
- The only weaning (thickened) amino acid supplement without leucine, valine, isoleucine for infants/young children with maple syrup urine disease.
- Nutritional supplement for the dietary management of maple syrup urine disease in children 1–10 years.
|
09.04 |
MSUD Lophlex® LQ 20 |
- Amino acid supplement without leucine, valine and isoleucine for teenagers and adults with MSUD
- One of 2 oral flavoured amino acid supplement without leucine, valine, isoleucine for teenagers over 12 years of age and adults with maple syrup urine disease. They need the larger pouches to meet their BCAA-free amino acid requirements. It is important we have a choice of more than 1 product for this age group as compliance is poor. It is essential that patients are offered choice of more than 1 protein substitute.
- Nutritional supplement for the dietary management of maple syrup urine disease in children over 3 years.
|
09.06.07 |
Multivitamin preparations Abidec® |
contains arachis ( peanut) oil |
09.06.07 |
Multivitamin preparations Dalivit® |
|
09.06.07 |
Multivitamin Supplement Paravit-CF® |
Capsule, liquid.
- Specialist initiation or recommendation for GP initiation by specialist in cystic fibrosis.
|
13.10.01.01 |
Mupirocin 2% |
Please refer to Primary care antimicrobial guidelines |
12.02.03 |
Mupirocin 2% in White Soft Paraffin Bactroban Nasal® |
|
09.06.07 |
Mutivitamins |
|
04.13 |
Mycophenolate |
Specialist use only for neurological conditions |
13.05.03 |
Mycophenolate |
supported by ESCA (to be developed) |
08.02.01 |
Mycophenolate Mofetil |
Renal Post transplant- new patients
Renal Post transplant-patients initiated pre April 2013
- For use in connective tissue diseases (Rheumatology)Click here
|
08.02.01 |
Mycophenolate Sodium Myfortic® |
|
10.02.01 |
Mycophenolate mofetil |
- For use in connective tissue diseases
- For specialist initiation and dose stabilisation.
- Supported by an ESCA.
|
20 |
N acetyl cysteine |
|
A5.01.01 |
N/A Ultra |
Type of wound product is suitable for
For flat granulating and epithelising wound for non to heavy exudate levels where
adherence may occur. To be used as a primary dressing with a secondary for absorption.
Duration dressing remains on wound before changing
7 days maximum
Frequency of dressing change
1-7 days, depending on levels of exudate
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Known product or component sensitivity eg silicone
Use with care if wound is bleeding heavily
Rationale for inclusion in formulary
To be used to reduce adherence to wound bed
|
03.07 |
N-Acetylcysteine nebulised |
Hospital only |
02.06.04 |
Naftidrofuryl Oxalate capsules |
|
01.06.06 |
Naldemedine Rizmoic®
| Tablets
For treating opioid-induced constipation- use in line with NICE. |
04.10.01 |
Nalmefene |
Restricted to Specialist Substance Misuse Services only
Reach Out Recovery (CRI) in Birmingham. Single point of contact 24/7 Tel: 0121 227 5890 Link Reach Out Recovery website
Swanswell in Sandwell Tel: 0121 553 1333 Link to Swanswell website
SIAS in Solihull Tel:0121 301 3600 Link to SIAS website
The Nalmefene for reducing alcohol consumption technology appraisal (TA325) recommends this drug as a possible treatment for people with alcohol dependence who:
• are still drinking more than 7.5 units per day (for men) and more than 5 units per day (for women) 2 weeks after an initial assessment and
• do not have physical withdrawal symptoms and
• do not need to either stop drinking straight away or stop drinking completely
The guidance also recommends that nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.
|
01.06.06 |
Naloxegol Moventig ® |
£££
For treating opioid-induced constipation- use in line with NICE.
|
04.10.03 |
Naloxone |
Used to reverse opioid overdose. |
04.10.01 |
Naltrexone |
- Useful as an adjunct in the treatment of alcohol dependence after a successful withdrawal.
|
04.10.03 |
Naltrexone Nalorex® |
|
06.04.03 |
Nandrolone Deca-Durabolin® |
Hospital only |
10.01.01 |
Naproxen |
NOT Enteric Coated tablets |
08.02.04 |
Natalizumab Tysabri® |
In line with NICE |
09.04 |
Neocate® Junior |
- Infant and child: Amino acid-based formula
- Replacement for Neocate Active and Neocate Advance on the formulary.
- Use in children over 12 mths who require amino acid based feed / have multiple food allergies.
- Used as tube or oral feed, provides complete nutritional support
- For the dietary management of proven whole protein allergy, short bowel syndrome, intractable malabsorption and other gastrointestinal disorders where an amino acid diet is recommended, for children from 1 year onwards
- ACBS Indications: Proven whole protein intolerance, short bowel syndrome, intractable malabsorption, or other gastro-intestinal disorders where an elemental diet is indicated
|
09.04 |
Neocate® LCP |
- Infant and child: Amino acid-based formula
- Use in infants ( birth – 12 months) who have multiple food allergies / faltering growth / require amino acid based feed as unable to tolerate standard or peptide feed. Used as tube and oral feed.
- Cows' milk allergy, multiple food protein intolerance, and conditions requiring an elemental diet
- ACBS Indications: Proven whole protein intolerance, short bowel syndrome, intractable malabsorption, or other gastro-intestinal disorders where an elemental diet is indicated
|
09.04 |
Neocate® Syneo |
- Infant and child: Amino acid-based formula - ACBS Indications:Proven whole protein intolerance, short bowel syndrome, intractable malabsorption, or other gastro-intestinal disorders where an elemental diet is indicated
- Contains Bifidobacterium breve M-16V to combat gut flora dysbiosis, shown by infants with allergies.
- Use in infants ( birth – 12 months) who have multiple food allergies / faltering growth / require amino acid based feed as unable to tolerate standard or peptide feed. Used as tube and oral feed.
- Not suitable for premature infants or infants who maybe immunocompromised. Not for use in postpyloric tube feeding.
Not recommended for infants with central venous catheter or SHORT BOWEL SYNDROME without full consideration of risks/benefits and monitoring by/on advice of a specialist.
- Cows' milk allergy, multiple food protein intolerance, and conditions requiring an elemental diet
|
05.01.04 |
Neomycin Sulphate |
|
10.02.01 |
Neostigmine injection |
Hospital only |
10.02.01 |
Neostigmine tablets |
|
09.04 |
Nepro® |
- Specialised formulas for specific clinical conditions
- Used for renal in and outpatients – adults only Useful on occasion due to reduced Vitamin A content – adults only
- Enteral feed or nutritional supplement in patients with chronic renal failure who are on haemodialysis or CAPD, or with cirrhosis, or other conditions requiring a high energy, low fluid, low electrolyte diet.Not suitable for child under 1 year; use with caution in child 1–5 years.
|
08.01.05 |
Neratinib Nerlynx® |
In line with NICE |
05.03.01 |
Nevirapine |
|
02.06.03 |
Nicorandil tablets |
Specialist initiation |
09.06.02 |
Nicotinamide |
|
13.06.01 |
Nicotinamide 4% gel |
|
04.10.02 |
Nicotine replacement therapy |
|
02.06.02 |
Nifedipine |
Standard release capsules
and
Modified Release preparations: Brand rationalisation- APC preferred brands:-
Adipine MR tablets
Adipine XL tablets
Coracten SR capsules
Coracten XL capsules |
07.01.03 |
Nifedipine |
|
21 |
Nifedipine |
m/r tablets and capsules
Hiccup, tenesmus - off label use according to WM Cares guideline |
08.01.05 |
Nilotinib Tasigna® |
In line with NICE |
02.06.02 |
Nimodipine Nimotop® |
|
03.11 |
Nintedanib Ofev®
| Hospital only- NHSE commissioned
In line with NICE and available from day 91 following publication of TA.
|
08.01.05 |
Nintedanib Vargatef ® |
- Hospital only- NHSE commissioned
- In line with NICE and available from day 91 following publication of TA.
|
08.01.05 |
Niraparib |
|
05.01.07 |
Nitazoxanide |
Hospital use only |
05.01.13 |
Nitrofurantoin |
|
08.02.03 |
Nivolumab Opdivo® |
In line with NICE Hospital only- NHSE Commissioned |
02.07.02 |
Noradrenaline / Norepinephrine |
|
06.04.01.02 |
Norethisterone |
Generic tablets
Utovlan®
Noriday® - if used in HRT - Specialist initiation
|
07.03.02.01 |
Norethisterone Noriday® |
Alternative to discontinued Micronor® |
08.03.02 |
Norethisterone |
|
05.01.12 |
Norfloxacin |
|
14.05 |
Normal immunoglobulin |
List of brands available for use:
- Intratect (5%)
- Gammaplex
- Subgam
- Hizentra
- Privigen
- Gamunex (10%)
- Iqymune
- Gammanorm
- Octagam 10%
- Panzyga
- Cuvitru
- Subcuvia
|
14.05.01 |
Normal immunoglobulin for Intramuscular use |
|
14.05.01 |
Normal immunoglobulin for Subcutaneous use |
|
06.04.01.01 |
Novofem® tablets |
|
10.02 |
Nusinersen |
|
09.09 |
Nutilis® Clear |
- Recommended by SALTs for patients with dysphagia requiring thickened fluids
- For thickening of liquids or foods in dysphagia. Not suitable for children under 3 years.
- Gum based products are generally preferred as they thicken to a more stable end point (unlike starch based products, they do not continue thickening over time) and provide a smoother texture, which improves acceptability and palatability for patients.
|
09.04 |
Nutilis® Complete Stage 1 |
- Used for dysphagia pts only
- Where first line pre-thickened product – Slo Milkshake – is not suitable
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
- Not suitable for child under 3 years; use with caution in child 3–5 years.
|
09.04 |
Nutramigen® 1 with LGG |
- Specialised formulas: Infant and child: Hydrolysate formula
- Casein hydrolysate. Use in infants (from birth – 6 mths) who have cow’s milk protein intolerance / allergy. Tube or oral feed.
- Nutramigen has all the fat as LCT and CHO as glucose polymer and is more suitable for CMPI
- If patient has a cow’s milk protein intolerance / allergy GP may initiate Nutramigen® Lipil 1 and refer to dietetics – in line NICE CG 116
- Disaccharide and/or whole protein intolerance where additional medium chain triglycerides are not included.
|
09.04 |
Nutramigen® 2 with LGG |
- Specialised formulas: Infant and child: Hydrolysate formula
- Casein hydrolysate. Use in infants from 6 mths who have cow’s milk protein intolerance/ allergy and soya intolerance/allergy. Tube or oral feed. If patient has a cow’s milk protein intolerance / allergy GP may initiate Nutramigen® Lipil 2 and refer to dietetics – in line NICE CG 116
- Established disaccharide and/or whole protein intolerance (where additional chain triglycerides are not indicated) Not suitable for child under 6 months.
|
09.04 |
Nutramigen® Puramino |
- Infant and child: Amino acid-based formula
- Use in infants (birth – 12 months) who have multiple food allergies / faltering growth / require amino acid based feed. Unlike other products contains 33% MCT fat so useful in children requiring amino acid feed who also have fat malabsorption. Used as tube and oral feed.
- For use in the management of severe protein intolerance, multiple food intolerance and other gastro-intestinal disorders where an amino acid based diet is specifically indicated for infants and young children.
- ACBS Indications: Proven whole protein intolerance, short bowel syndrome, intractable malabsorption, or other gastro-intestinal disorders where an elemental diet is indicated
|
09.04 |
Nutricrem® |
- More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
- Lactose free diet
- Low energy per serving as a semi-solid supplement where low volume is required only.
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
- Not suitable for child under 3 years; use with caution in child 3–6 years.
|
09.04 |
Nutrini® |
- Child: 1 kcal/ml and less than 4g protein/100ml
- 1 kcal feed without fibre, used in children 8-20kg. Up to 6 years.
- Also essential low protein tube feed for children with inborn errors of protein metabolism (e.g. organic acidaemias, urea cycle disorders) aged 2 to 10y due to its low protein and amino profile as a source of natural protein. It is used when IMD children cannot tolerate fibre. To change to an alternative enteral feed with children with metabolic disorders would potentially require hospital admission to ensure stabilisation with a new enteral feed. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–6 years, body-weight 8–20 kg
|
09.04 |
Nutrini® Energy |
- Child: 1.5 kcal/mL and more than 4 g protein/100 mL
- 1.5kcal/ml tube feed for children over 8kg
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–6 years, body-weight 8–20 kg
|
09.04 |
Nutrini® Energy Multi Fibre |
- Child: 1.5 kcal/mL and more than 4 g protein/100 mL
- 1.5kcal/ml tube feed for children over 8kg with added fibre
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–6 years, body-weight 8–20 kg
|
09.04.02 |
Nutrini® Low Energy Multi Fibre |
Child under 12 years
- Low energy with fibre. 8-20kg
- Less than 1 kcal/mL and less than 4g protein/100 mL
- Paediatric ACBS indications: Disease-related malnutrition, intractable malabsorption, growth failure, pre-operative preparation of malnourished patients, dysphagia, short-bowel syndrome, bowel fistula except bowel fistula, in child 1–6 years, body-weight 8–20 kg
|
09.04 |
Nutrini® Multi Fibre |
- Child: 1 kcal/ml and less than 4g protein/100ml
- 1 kcal feed with fibre, used in children 8-20kg. Up to 6 years.
- Also, used in low protein tube feeds for children with inborn errors of protein metabolism (e.g. organic acidaemias, urea cycle disorders) aged 2 to 10y due to its protein and amino acid profile. It provides a source of natural protein. It is used in IMD children who can tolerate fibre. To change to an alternative enteral feed with children with metabolic disorders would potentially require hospital admission to ensure stabilisation with a new enteral feed. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–6 years, body-weight 8–20 kg
|
09.04 |
Nutrini® Peptisorb |
- Hydrolysate formula
- 1.0kcal/ml polymeric feed used 8 -20kg where hydrolysed protein is required
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–6 years, body-weight 8–20 kg Follow trust guidance on use of acidic tube feeds.
|
09.04 |
Nutrini® Peptisorb Energy |
- Child: 1.5 kcal/mL and more than 4 g protein/100 mL
- 1.5kcal/ml hydrolysed protein feed used in children over 8kg where whole protein is not tolerated. Additional information re pH of the product?
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–6 years, body-weight 8–20 kg
|
09.04.02 |
Nutriprem® 1 |
Child under 12 years
- Less than 1 kcal/mL and less than 4g protein/100 mL
- Low birth - weight formula
- For premature infant up to 2kg
|
09.04.02 |
Nutriprem® 2 |
Child under 12 years
- Less than 1 kcal/mL and less than 4g protein/100 mL
- Post discharge formula for pre-term infants
- Catch-up growth in pre-term infants (less than 35 weeks at birth) and small for gestational-age infants up to 6 months corrected age.
|
09.04.02 |
Nutriprem® 2 |
Child under 12 years
- Less than 1 kcal/mL and less than 4g protein/100 mL
- Post discharge formula for pre-term infants for immunocompromised infants
- Catch-up growth in pre-term infants (less than 35 weeks at birth) and small for gestational-age infants up to 6 months corrected age.
|
09.04.02 |
Nutrison Peptisorb® |
- 1 kcal/mL and less than 5 g protein/100 mL
- Peptide-based formula
- Pts with malabsorption
- Short bowel syndrome, intractable malabsoprtion, proven inflammatory bowel disease, bowel fistula.
- Follow Trust guidance on use of acidic tube feeds
|
09.04.02 |
Nutrison® |
First line
- 1 kcal/mL and less than 5 g protein/100 mL
- Standard 1 kcal/mL, No fibre
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Nutrison® Soya |
- 1 kcal/mL and less than 5 g protein/100 mL
- Soya protein formula
- Dietary restriction or intolerance to standard feeds
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Nutrison® Soya Multi Fibre |
- 1 kcal/mL and less than 5 g protein/100 mL
- Soya protein formula
- Dietary restriction or intolerance to standard feeds requiring fibre
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Nutrison®1000 Complete Multi Fibre |
- Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
- 1000 kcal/L, nutritionally complete in 1 litre, low volume
- Disease related malnutrition in patients with low energy and/or low fluid
requirements
|
09.04.02 |
Nutrison®1200 Complete Multi Fibre |
- Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
- 1200 kcal/L, nutritionally complete in 1 litre, low volume
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Nutrison®800 Complete Multi Fibre |
- Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
- 800 kcal/L, nutritionally complete in 1 litre, low volume
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula except bowel fistula
- Not suitable for child under 6 years; not recommended for child 6-12 years
|
09.04.02 |
Nutrison®Concentrated |
- More than 1.5 kcal/mL and 5g (or more) protein/100 mL
- High calorie (2000 kcal/L), low volume, low potassium
- First line in CF and renal patients
|
09.04.02 |
Nutrison®Energy |
- 1.5 kcal/mL and 5g (or more) protein/100 mL
- High energy feed
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Nutrison®Energy Multi Fibre |
- 1.5 kcal/mL and 5g (or more) protein/100 mL
- High energy feed with fibre
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Nutrison®MCT |
- Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
- Pts with chyle leaks following upper GI surgery
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Nutrison®Multi Fibre |
First line
- 1 kcal/mL and less than 5 g protein/100 mL
- Standard 1 kcal/mL, With fibre
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Nutrison®Protein Plus |
- Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
- Lower calorie, high protein feed. Fibre free
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Nutrison®Protein Plus Multi Fibre |
- Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
- Lower calorie, high protein feed. Added fibre
|
05.02 |
Nystatin oral suspension |
|
12.03.02 |
Nystatin 100,000units/ml suspension |
Do not Prescribe as Sugar Free (SF) |
A5.05.02 |
Oakmed Option Wound Manager |
Wound drainage system consisting of a hydrocolloid adhesive wafer and a drainable drainage bag Type of wound product is suitable for Complex abdominal wounds, moderate to large fistula’s, orthopaedic wounds or fungating wounds with high levels of exudate, that are unmanaged with conventional dressings. Max Duration dressing remains on wound before changing Empty drainage bag as required. If no port for drainage, change as required. Frequency of dressing change As long as adhesive remains intact whilst being mindful of skin integrity Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known product component sensitivity to hydrocolloid (Gelatine and Pectin) Low to moderate exuding wounds Do not use if a conventional dressing can manage the exudate levels Rationale for inclusion in formulary Various size selection with drainage ports and windows For highly exuding wounds that conventional dressings cannot manage the exudate levels |
01.09.01 |
Obeticholic acid Ocaliva® |
In line with NICE |
08.02.03 |
Obinutuzumab Gazyvaro® |
In line with NICE
Hospital only- NHS England commissioned |
08.02.03 |
Ocrelizumab |
In line with NICE |
11.08.02 |
Ocriplasmin Jetrea® |
|
12.02.03 |
Octenidine hydrochloride Octenisan® md Nasal gel |
Classed as a medical device Listed in drug tariff- 6ml tube
Added to formulary as alternative to Bactroban® nasal ointment in view of supply issues. |
13.01 |
Octenisan® |
For MRSA skin decolonisation , if chlorhexidine sensitivity is a problem |
13.11.02 |
Octenisan® antimicrobial wash lotion |
MRSA skin decolonisation, if chlorhexidine sensitivity is a problem |
01.09 |
Octreotide |
Injection For specialist gastroenterologist initiation for intestinal secretions |
08.03.04.03 |
Octreotide Sandostatin® |
Palliative Care use only Oncology Acromegaly
|
08.03.04.03 |
Octreotide Sandostatin Lar® |
Palliative Care use only Oncology Acromegaly
|
21 |
Octreotide |
Injection |
06.04.01.01 |
Oestrogel® |
|
07.02.01 |
Oestrogens, Topical Gynest® |
|
07.02.01 |
Oestrogens, Topical Estring® |
|
07.02.01 |
Oestrogens, Topical Ovestin® |
|
07.02.01 |
Oestrogens, Topical Vagifem® |
|
08.02.03 |
Ofatumumab Arzerra® |
NHS England is responsible commissioner for its use in untreated chronic lymphocytic leukaemia (as per NICE TA 344)
|
05.01.12 |
Ofloxacin |
|
11.03.01 |
Ofloxacin Eye drops 0.3% |
|
01.07.03 |
Oily phenol injection BP |
|
04.02.01 |
Olanzapine (oral) |
- tablets
- orodispersible tablets
- Supported by ESCA, see link below.
|
04.02.02 |
Olanzapine Embonate ZypAdhera® |
The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED. |
08.01.05 |
Olaparib Lynparza ®
|
- Hospital only- NHSE commissioned
- In line with NICE and available from day 91 following publication of TA.
|
12.01.03 |
Olive Oil Ear Drops |
|
11.04.02 |
Olopatadine Opatanol® |
2nd line £££ |
03.14 |
Omalizumab Xolair® |
- For specialist use only in line with NICE guidance below
- NHS England is the responsible commissioner for use in Asthma
- Clinical Commissioning Groups are the responsible commissioners for use in urticaria
|
13.05.03 |
Omalizumab |
In line with NICE |
05.03.03.02 |
Ombitasvir-paritaprevir-ritonavir Viekirax® |
In line with NICE |
01.03.05 |
Omeprazole |
Capsules 10mg, 20mg
Capsules are more cost effective than tablets
Most brands of capsules can be opened and beads swallowed without crushing, or can be mixed with food or drink
|
01.03.05 |
Omeprazole dispersible Losec MUPS |
Orodispersible tablets 10mg, 20mg
££- Orodispersible tablets are very significantly more expensive than capsules.
For use in swallowing difficulties or via nasogastric tubes when beads in the capsule are too large and lansoprazole orodispersible are not acceptable (e.g. children with fine bore NG tubes). |
01.03.05 |
Omeprazole IV |
IV Infusion 40mg vial- Hospital use only |
A5.07.05 |
Omnistrip® |
Adhesive wound closure strip Type of wound product is suitable for For atraumatic closure of minor wounds or surgical incisions Require a secondary dressing Duration dressing remains on wound before changing As necessary, up to 14 days Frequency of dressing change As necessary Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) None Rationale for inclusion in formulary Cost effective Essential for closure of minor injuries
|
04.06 |
Ondansetron |
- tablets
- melt tablets
- suppositories
- injection
- SF syrup - swallowing difficulties only
hyperemesis in pregnancy (off label) palliative care (off label) Chemotherapy
|
04.09.01 |
Opicapone Ongentys® |
- Second-line therapy to entacapone, in patients who fail to respond to, or are intolerant of, entacapone, in situations where apomorphine therapy has been considered.
- Supported by an ESCA, see link below
|
12.03.01 |
Orabase Protective Paste |
|
12.03.01 |
Orahesive Powder |
|
01.04 |
Oral Rehydration Salts |
Powder Follow Scriptswitch advice for most cost-effective prescribing option |
09.02.01.02 |
Oral Rehydration Salts |
|
04.05.01 |
Orlistat capsules |
Orlistat 60mg capsules - Over the counter preparation suitable for self-care/purchase if appropriate |
05.03.04 |
Oseltamivir Tamiflu® |
PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza |
08.01.05 |
Osimertinib |
In line with NICE |
09.04.02 |
Osmolite® |
- 1 kcal/mL and less than 5 g protein/100 mL
- Pt requires 1 kcal/mL, vegetarian feed fish oil free (Nil fibre)
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Osmolite®1.5 kcal |
- 1.5 kcal/mL and 5g (or more) protein/100 mL
- High energy vegetarian fish oil free (Nil fibre)
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.04.02 |
Osmolite®Plus |
- Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
- Alternative standard feed, vegetarian fish oil free (1200 kcal/L) (Nil fibre)
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
09.05.02.02 |
Osvaren® |
- Specialist Recommendation
|
08.01.05 |
Oxaliplatin |
|
06.04.03 |
Oxandrolone Tablets 2.5 mg |
|
04.01.02 |
Oxazepam |
|
04.08.01 |
Oxcarbazepine |
- Tablets
- Oral suspension
MHRA Advice Care should be taken when switching between oral formulations.The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history.
|
07.04.02 |
Oxybutynin immediate release tablets |
2.5mg and 5mg tablets only
3mg tablets are non-formulary |
07.04.02 |
Oxybutynin Modified release tablets |
|
07.04.02 |
Oxybutynin Hydrochloride patch Kentera® |
- for patients who cannot tolerate oral agents
|
13.12 |
Oxybutynin immediate release tablets |
For hyperhidrosis (off label use) after trial of aluminium salts |
04.07.02 |
Oxycodone |
- capsules
- M/R tablets
- SF solution
- For patients who do not tolerate morphine
|
21 |
Oxycodone |
Injection |
04.07.02 |
Oxycodone injection |
|
03.06 |
Oxygen |
Short term use in palliative care
Long term use- requires specialist assessment
|
05.01.03 |
Oxytetracycline |
|
13.06.02 |
Oxytetracycline |
- Topical treatments should be used first line.
- Oral antibiotics should be reserved for acne, if topical treatment is not adequately effective or if it is inappropriate.
Please refer to Antimicrobial guidelines
|
07.01.01 |
Oxytocin |
|
08.01.05 |
Paclitaxel |
In line with NICE |
08.01.05 |
Paclitaxel - Albumin Bound Formulation Abraxane® |
In line with NICE |
09.04 |
Paediasure® |
- Child: 1 kcal/ml and less than 4g protein/100ml
- 1 kcal per ml low carbohydrate sip feed for children
- Paediatric ACBS indications: Disease-related malnutrition, intractable malabsorption, growth failure, pre-operative preparation of malnourished patients, dysphagia, short-bowel syndrome, bowel fistula in child 1–10 years, body-weight 8–30 kg
|
09.04 |
Paediasure® Plus |
- Child: 1.5 kcal/mL and more than 4 g protein/100 mL
- Lower Carbohydrate , 1.5kcal/ml sip feed, used in children with CHO intolerance
- Paediatric ACBS indications: Disease-related malnutrition, intractable malabsorption, growth failure, pre-operative preparation of malnourished patients, dysphagia, short-bowel syndrome, bowel fistula in child 1–10 years, body-weight 8–30 kg
|
09.04 |
Paediasure® Plus Fibre |
- Child: 1.5 kcal/mL and more than 4 g protein/100 mL
- Lower Carbohydrate , 1.5kcal/ml sip feed, used in children with CHO intolerance with added fibre
- Paediatric ACBS indications: Disease-related malnutrition, intractable malabsorption, growth failure, pre-operative preparation of malnourished patients, dysphagia, short-bowel syndrome, bowel fistula in child 1–10 years, body-weight 8–30 kg. Not suitable for use in child under 1 year.
|
09.04 |
Paediasure® Peptide |
- Child: 1 kcal/ml and less than 4g protein
- Peptide based sip feed used in pts with gut failure
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula and growth failure in child 1–10 years, body-weight 8–30 kg
|
09.04 |
Paediatric Seravit® |
- Vitamin and Mineral supplements
- Used in children and low weight adults on very restricted diets who are not meeting vitamin and mineral requirements and in enteral feed patients.
- For use in infants - unflavoured vitamin and mineral supplement given to infants and young children on low protein or low-fat diets who require vitamin and mineral supplementation. There are no other powdered preparations available that meet the requirements of infants on very limited diets with inherited metabolic disorders of metabolism. It cannot be purchased from a supermarket. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient
- Vitamin, mineral, and trace element supplement in infants and children with restrictive therapeutic diets
|
09.06.07 |
Paediatric Seravit® |
- Used in children and low weight adults on very restricted diets who are not meeting vitamin and mineral requirements and in enteral feed patients.
- For use in infants - unflavoured vitamin and mineral supplement given to infants and young children on low protein or low-fat diets who require vitamin and mineral supplementation. There are no other powdered preparations available that meet the requirements of infants on very limited diets with inherited metabolic disorders of metabolism. It cannot be purchased from a supermarket. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Vitamin, mineral, and trace element supplement in infants and children with restrictive therapeutic diets
|
08.01.05 |
Palbociclib Ibrance® |
In line with NICE
Hospital only - NHSE commissioned |
04.02.02 |
Paliperidone Trevicta® |
The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
|
04.02.02 |
Paliperidone Xeplion® |
The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
|
05.03.05 |
Palivizumab Synagis® |
|
04.06 |
Palonosetron Aloxi® |
|
01.09.04 |
Pancreatin Pancrex® V |
Powder Counsel patient on need for adequate hydration |
01.09.04 |
Pancreatin Creon® products |
Counsel patient on need for adequate hydration
|
01.09.04 |
Pancreatin Nutrizym 22® |
Specialist dietician recommendation only |
08.01.05 |
Panitumumab Vectibix® |
|
08.01.05 |
Panobinostat Farydak®
| Hospital only- NHSE commissioned
In line with NICE and available from day 91 following publication of TA.
|
04.07.01 |
Paracetamol |
|
04.07.01 |
Paracetamol |
tablets
SF suspension
500mg soluble tablets- high sodium content.Only for patients with swallowing difficulties. |
04.07.01 |
Paracetamol Perfalgan® |
|
04.07.01 |
Paracetamol and codeine Co-codamol ®15/500 |
£££
Limited evidence.
For elderly community who would not tolerate separate ingredients or to support a step down review. |
04.07.01 |
Paracetamol and codeine Co-codamol® 30/500 |
- Use with caution in patients aged over 65
- Contraindicated in children below the age of 12
|
04.07.01 |
Paracetamol and codeine Co-codamol ®15/500 |
£££
Limited evidence.
High sodium content.
For elderly community who would not tolerate separate ingredients or to support a step down review. |
04.07.01 |
Paracetamol and codeine Co-codamol® 30/500 |
£££
High sodium content
Use in chronic pain only, and for patients with swallowing difficulties. |
04.08.02 |
Paraldehyde |
- Rectal solution 50% in olive oil
|
06.06.01 |
Parathyroid Hormone |
Injection |
05.04.05 |
Paromomycin suspension |
Unlicensed |
04.03.03 |
Paroxetine tablets |
|
09.04.01 |
Pasta |
Essential protein-free basic products. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 100g pasta = 10g protein. |
09.02.01.01 |
Patiromer Veltassa® |
Use in line with NICE |
08.01.05 |
Pazopanib Votrient® |
|
14.04 |
Pediacel® |
|
08.01.05 |
Pegaspargase Oncaspar® |
Hospital only- NHSE Commissioned In line with NICE and available from day 91 following publication of TA.
|
09.01.06 |
Pegfilgrastim |
Hospital only. |
08.02.04 |
Peginterferon Alfa |
Hospital only
In line with NICE
|
08.02.04 |
Peginterferon beta-1a Plegridy ® |
As per NICE |
08.01.05 |
Pembrolizumab Keytruda® |
NHS England is responsible commissioner in line with NICE (see links below)
|
08.01.03 |
Pemetrexed Alimta® |
|
04.02.01 |
Penfluridol (Oral) |
|
09.08.01 |
Penicillamine |
- Wilson disease: Specialist Recommendation with ESCA (in development)
|
10.01.03 |
Penicillamine |
Supported by ESCA, see link below. |
11.03.01 |
Penicillin 500o units in 1 ml eye drops |
Unlicensed
Hospital use only- Ophthalmologists |
05.04.08 |
Pentamidine Isetionate Pantacarinat® |
|
07.04.03 |
Pentosan polysulfate elmiron ® |
In line with NICE |
01.02 |
Peppermint Oil |
Capsule E/C 0.2ml
|
01.02 |
Peppermint water |
unlicensed
For specialist use only |
01.01.02 |
Peptac |
Suspension |
09.04.02 |
Peptamen® |
- 1 kcal/mL and less than 5 g protein/100 mL
- Peptide-based formula
- Where hydrolysate is required
- Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula
|
09.04 |
Peptamen® Junior |
- Hydrolysate Formula
- Ready to use, neutral pH, 1kcal/ml
- Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula, in child 1–10 years
|
09.04 |
Peptamen® Junior |
- Hydrolysate Formula
- Powdered preparation only Used in children requiring hydrolysate, ability to concentrate or dilute to meet specific calorie density requirements
- Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula, in child 1–10 years
|
09.04 |
Peptamen® Junior Advance |
- Child: 1.5 kcal/mL and more than 4 g protein/100 mL
- 1.5kcal/ml hydrolysed protein feed used in children over 8kg where whole protein is not tolerated. Increased MCT for use in liver failure.
- Intractable malabsorption, short-bowel syndrome, bowel fistula, and proven inflammatory bowel disease in child 1–10 years
|
09.04.02 |
Peptamen®AF |
Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
Used in critical care settings |
09.04.02 |
Peptamen®HN |
- Less than 1.5 kcal/mL and 5g (or more) protein/100 mL
- Step down from Peptamen® AF
- Intolerance to other feed
- Hydrolysate 1300 kcal/L nutritionally complete in 1 litre
- For patients with malabsorption where requirements (high protein/low volume) cannot be met with a standard 1Kcal/ml MCT peptide feed. Used in liver/hepatobiliary disease/conditions
- Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula. Not suitable for child under 3 years
|
04.08.01 |
Perampanel tablets |
- Supported by an ESCA, see link below.
MHRA Advice When prescribing for epilepsy the patient should be assessed to make a clinical judgement if the same manufacturer’s product/brand is necessary taking into account factors such as seizure frequency and treatment history. Also take into account patient/carer-related factors such as their negative perceptions about alternative products and/or other issues related to the patient such co-morbid autism, mental health issues, or learning disability.
|
02.06.03 |
Perhexiline tablets |
|
04.02.01 |
Pericyazine (oral) |
- £££
- Supported by ESCA, see link below.
|
02.05.05.01 |
Perindopril erbumine tablets |
|
13.10.04 |
Permethrin 5% Lyclear® Dermal Cream |
Over the counter preparation suitable for self-care/purchase if appropriate |
04.02.01 |
Perphenazine (oral) |
- £££
- Supported by ESCA, see link below.
|
08.01.05 |
Pertuzumab Perjeta® |
In line with NICE
|
04.07.02 |
Pethidine injection |
|
02.08.02 |
Phenindione tablets |
|
04.08.01 |
Phenobarbital |
- Tablets
- Elixir
MHRA Advice Patients being treated for epilepsy should be maintained on a specific manufacturer's product.
|
13.14.07 |
Phenol 2% w/w in compound zinc paste BP |
|
02.05.04 |
Phenoxybenzamine Hydrochloride capsules |
Check availibility |
05.01.01.01 |
Phenoxymethylpenicillin oral presentations |
|
02.07.02 |
Phenylephrine |
|
11.05 |
Phenylephrine Hydrochloride Minims® Phenylephrine Hydrochloride |
|
04.08.01 |
Phenytoin |
- Capsules
- Suspension
MHRA Advice Patients being treated for epilepsy should be maintained on a specific manufacturer's product.
|
09.04 |
Phlexy-10® Exchange System |
- Tablets maybe used in pregnancy, when suffering from morning sickness
- Nutritional supplement for the dietary management of phenylketonuria.
|
09.04 |
Phlexy-Vits® |
- Vitamin and mineral supplement for teenagers and adults with phenylketonuria and other inborn errors of protein metabolism
- The only suitable low volume (powder and tablets) comprehensive vitamin and mineral supplement for teenagers and adults that has been formulated for patients with phenylketonuria and other inborn errors of protein metabolism requiring very restrictive diets. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- For use as a vitamin and mineral component of restricted therapeutic diets in children over 11 years and adults with phenylketonuria and similar amino acid abnormalities.
|
03.09.01 |
Pholcodine Linctus, BP |
Over the counter preparation suitable for self-care/purchase if appropriate |
09.05.02.01 |
Phosphate supplements Phosphate-Sandoz® |
|
01.06.04 |
Phosphates (Rectal) Fletchers phosphate enema, fleet ready to use enema |
Enema |
09.06.06 |
Phytomenadione Konakion® MM |
|
09.06.06 |
Phytomenadione Konakion® MM Paediatric |
|
09.06.06 |
Phytomenadione 1mg |
|
A5.06.01 |
PICO products |
Disposable and portable system designed to kick start wound healing. Required components: One PICO device, 2 dressings per kit. Type of wound product is suitable for Acute, chronic, dehisced, partial thickness burns, flaps, grafts and traumatic wounds. Consider standard interactive dressings first. Duration dressing remains on wound before changing Twice a week dressing change, PICO device weekly change Frequency of dressing change Determined by exudate levels. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) It should not be used on: Confirmed and untreated osteomyelitis Malignancy in wound bed or wound margins Exposed blood vessels Organs Unexplored fistulae Necrotic wounds Anastomotic sites Emergency airway aspiration Pleural, mediastinal or chest tube drainage and surgical suction Rationale for inclusion in formulary These devices promote patient mobility at a cost effective price and is available on drug tariff which other comparable models are not. |
01.06.05 |
Picolax® |
Oral powder |
21 |
Pilocarpine |
Eye drops all strengths
Oral use - for dry mouth where routine oral mouth care and saliva substitutes have failed |
11.06 |
Pilocarpine 1%,2% and 4% eye drops |
- Specialist Ophthalmologist Recommendation
|
12.03.05 |
pilocarpine Hydrochloride tablets Salagen® |
Licensed for treatment of xerostomia following irradiation for head and neck cancer; dry mouth and dry eyes in Sjögren's syndrome.
Effective only in patients who have residual salivary gland function. |
11.06 |
Pilocarpine preservative free |
Hospital only |
13.05.03 |
Pimecrolimus Elidel® |
|
06.01.02.03 |
Pioglitazone |
|
05.01.01.04 |
Piperacillin and Tazobactam |
|
04.09.03 |
Piracetam |
|
04.02.03 |
Pirenzipine (unlicensed) |
Hospital only |
03.11 |
Pirfenidone Esbriet® |
Hospital only - NHSE commissioned |
05.01.01.05 |
Pivmecillinam Hydrochloride |
- In line with Antimicrobial guidelines
- Only on microbiology advice
|
04.07.04.02 |
Pizotifen |
Tablets
Elixir |
09.04.01 |
Pizza bases |
Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who do not tolerate very little natural protein. One regular pizza likely to provide 20g + protein. |
09.04 |
PKU Air 15 |
- A liquid amino acid which is lower in calories for children and adults with phenylketonuria
|
09.04 |
PKU Air 20 |
- A supplement which is lower in calories for children and adults with phenylketonuria
|
09.04 |
PKU Anamix first spoon |
- A supplement without phenylalanine for children with phenylketonuria
- One of 2 powdered weaning (thickened) amino acid supplement without phenylalanine for infants/young children with phenylketonuria. The consistency can be adjusted to suit the developmental age of the older baby/toddler. This is our preferable product because it has added long chain fatty acids.
- Nutritional supplement for the dietary management of proven phenylketonuria in children from 6 months to 5 years.
|
09.04 |
PKU Anamix® Infant |
- A supplement without phenylalanine for infants with phenylketonuria
- The only infant amino acid supplement without phenylalanine for infants with phenylketonuria
- Nutritional supplement for the dietary management of proven phenylketonuria in children from birth to 3 years.
|
09.04 |
PKU cooler 10® |
- A supplement without phenylalanine for children and adults with phenylketonuria
- An oral liquid amino acid supplement without phenylalanine formulated for children aged 3 to 6 years with phenylketonuria. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements. The 3 different products have a different degree of sweetness and range of flavours.
- Nutritional supplement for the dietary management of phenylketonuria in children over 3 years
|
09.04 |
PKU cooler 15® |
- A supplement without phenylalanine for children and adults with phenylketonuria
- One of three oral liquid amino acid supplements without phenylalanine for children aged 7 to 12 years with phenylketonuria. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements.
|
09.04 |
PKU cooler 20® |
- A supplement without phenylalanine for teenagers and adults with phenylketonuria
- One of 3 liquid amino acid supplement without phenylalanine for teenagers and adults (>12 years of age) with phenylketonuria that will meet their higher amino acid requirements. This age group need the larger sachets (20g protein equivalent) to meet their non-phenylalanine protein requirements. It is important there is a choice of more than 1 product for this age group as compliance is poor and the potential outcome of poor compliance. The 3 different products have a different degree of sweetness and range of flavours.
- Nutritional supplement for the dietary management of phenylketonuria in children over 3 years.
|
09.04 |
PKU Explore 10 |
|
09.04 |
PKU Explore 5 |
|
09.04 |
PKU express15® |
- A supplement without phenylalanine for teenagers and adults with phenylketonuria
- The only powdered amino acid supplement without phenylalanine for 7 to 12-year olds with phenylketonuria. Larger sachets are unacceptable for this age group of children and provide in excess of protein requirements.
- Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 3 years.
|
09.04 |
PKU express20® |
- A supplement without phenylalanine for teenagers and adults with phenylketonuria
- One of 2 powdered amino acid supplement without phenylalanine for teenagers and adults with phenylketonuria that will meet their higher amino acid requirements. This age group need the larger sachets (20g protein equivalent) to meet their non-phenylalanine protein requirements. It is important there is a choice of more than 1 product for this age group as compliance is poor. The 2 different products have a different degree of sweetness and range of flavours.
- Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 3 years.
|
09.04 |
PKU Lophlex |
- A supplement without phenylalanine for teenagers and adults with phenylketonuria
- One of 2 powdered amino acid supplement without phenylalanine for teenagers and adults with phenylketonuria that will meet their higher amino acid requirements. This age group need the larger sachets (20g protein equivalent) to meet their non-phenylalanine protein requirements. It is important we have a choice of more than 1 product for this age group as compliance is reported to be poor and the potential outcome of poor compliance is poor executive functioning. The 2 different products have a different degree of sweetness and range of flavours.
- Nutritional supplement for the dietary management of proven phenylketonuria in children over 8 years and adults including pregnant women.
|
09.04 |
PKU Lophlex® LQ 10 |
- A supplement without phenylalanine for children and adults with phenylketonuria
- One of three liquid amino acid supplement without phenylalanine formulated for children aged 3 to 6 years with phenylketonuria. Larger pouches are unacceptable for this age group of children and provide in excess of protein requirements. The 3 different products have a different degree of sweetness and range of flavours.
- Nutritional supplement for the dietary management of phenylketonuria in children over 4 years and adults including pregnant women.
|
09.04 |
PKU Lophlex® LQ 20 |
- A supplement without phenylalanine for teenagers and adults with phenylketonuria
- One of 3 liquid amino acid supplements without phenylalanine for teenagers and adults (>12 years of age) with phenylketonuria that will met their higher amino acid requirements. This age group need the larger sachets (20g protein equivalent) to meet their non-phenylalanine protein requirements. It is important there is a choice of more than 1 product for this age group as compliance is poor. The 3 different products have a different degree of sweetness and range of flavours.
- Nutritional supplement for the dietary management of phenylketonuria in children over 4 years and adults including pregnant women.
|
09.04 |
PKU Sphere 15 |
A low phenylalanine supplement derived from whey protein for children and adults with phenylketonuria. It is more palatable than amino acid supplements and associated with better utilisation of protein. Very useful for adult patients trying to return to diet or children / adults struggling to take their amino acid product because of its taste. Suitable from aged 4 years |
09.04 |
PKU Sphere 20 |
A low phenylalanine supplement derived from whey protein for children and adults with phenylketonuria. It is more palatable than amino acid supplements and associated with better utilisation of protein. Very useful for adult patients trying to return to diet or children / adult struggling to take their amino acid product because of its taste. Suitable from aged 4 years |
09.04 |
PKU Start® |
- For use in the dietary management of phenylketonuria.
- Amino acid supplement. Without phenylalanine for infants with phenylketonuria.
|
14.04 |
Pneumococcal polysaccharide conjugate vaccine (adsorbed) Synflorix® |
|
14.04 |
Pneumococcal polysaccharide conjugate vaccine (adsorbed) Prevenar 13® |
|
14.04 |
Pneumococcal polysaccharide vaccine (23-valent) Pneumovax ® |
|
13.07 |
Podophyllotoxin Condyline® |
|
13.07 |
Podophyllotoxin Warticon® |
|
13.07 |
Podophyllum |
|
08.01.05 |
Polatuzumab Polivy ® |
In line with NICE |
14.04 |
Poliomyelitis Vaccine Inactivated (Salk) |
The polio vaccine is only given as part of combined products:
● diphtheria/tetanus/acellular pertussis/inactivated polio vaccine/
Haemophilus influenzae type b (DTaP/IPV/Hib)
● diphtheria/tetanus/acellular pertussis/inactivated polio vaccine (DTaP/
IPV or dTaP/IPV)
● tetanus/diphtheria/inactivated polio vaccine (Td/IPV). |
09.04 |
Polycal® |
- High-energy supplements: carbohydrate
- Ready to use. Requires no specific instruction to prepare e.g. energy supplement/ used as pre and post bolus with patients with glycogen storage disease to prevent hypoglycaemia, also used in fatty acid oxidation disorders
- There is no other liquid glucose supplement on ACBS prescription.
- Also energy supplements/ used as pre-and post-bolus tube feeds with patients with glycogen storage disease to prevent hypoglycaemia. Also use as a quick access, liquid energy supplement in patients with fatty acid oxidation disorders. There is no other liquid glucose supplement on ACBS prescription. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement.
|
A5.07.01 |
Polyfield Nitrile Patient Pack primary care and BCHC, other Trusts as per contract |
Sterile dressing pack Type of wound product is suitable for To be used on all wounds requiring aseptic dressing procedures Duration dressing remains on wound before changing Single use Frequency of dressing change Determined by wound type Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) None listed Rationale for inclusion in formulary Available on drug tariff, cost effective and incorporates a measure guide which would be an additional cost with other packs
|
A5.02.05 |
PolyMem |
Foam dressing that contains a cleansing agent and glycerol Type of wound product is suitable for Low to moderately exuding wound including skin tears, and other traumatic wounds, superficial and partial thickness wounds, burns, donor and graft sites and radiotherapy induces reactions Duration dressing remains on wound before changing 2-7 days Frequency of dressing change Up to 7 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Sensitivity to ingredients contained within the dressing Not for full thickness burns Not for ischaemic wounds Not for diabetic foot wounds Not in conjunction with solutions containing hypochlorite Rationale for inclusion in formulary Suitable for fragile and sensitive skin, Soft and comformable, Easy to redress awkward areas Wide range of sizes including digit shaped dressings |
14.04 |
Polysaccharide vaccine for injection Typhim Vi®, Typherix® |
|
14.04 |
Polysaccharide vaccine with hepatitis A vaccine |
|
09.02.01.01 |
Polystyrene Sulphonate Resins |
|
13.09 |
Polytar Plus® |
Over the counter preparation suitable for self-care/purchase if appropriate |
13.09 |
Polytar® |
Over the counter preparation suitable for self-care/purchase if appropriate |
08.02.04 |
Pomalidomide Imnovid® |
|
08.01.05 |
Ponatinib Iclusig® |
In line with NICE |
03.05.02 |
Poractant Alfa Curosurf® |
Hospital only |
05.02 |
Posaconazole |
|
09.05.02.01 |
Potassium acid phosphate |
|
09.02.01.01 |
Potassium Chloride efferevescent tablets Sando-K® |
|
09.02.01.01 |
Potassium Chloride MR tablets Slow-K® |
|
09.02.01.01 |
Potassium Chloride SF syrup Kay-Cee-L® |
- Specialist Recommendation
|
07.04.03 |
Potassium Citrate |
|
13.11.06 |
Potassium Permanganate tablets |
|
13.11.04 |
Povidone-Iodine preparations |
|
04.09.01 |
Pramipexole IR tablets |
|
02.09 |
Prasugrel Efient® |
|
02.12 |
Pravastatin tablets |
|
05.05.05 |
Praziquantel tablets |
UNLICENSED, on specialist advice only |
01.05.02 |
Prednisolone |
Tablets 5mg, EC 2.5mg, 5mg, Soluble 25mg
Plain tablets are first line option.
EC tablets are more expensive than plain tablets without any substantial evidence that they confer any GI benefits
25mg tablets are more expensive per mg than 5mg tablets.
Soluble tablets are significantly more expensive than normal tablets which can be crushed & dispersed (unlicensed).
For short term use in acute exacerbation or 'flare-ups'of relevant conditions |
01.05.02 |
Prednisolone |
Retention Enema (20mg/100ml single dose pack, Predsol®) Foam Enema ££- Predfoam® discontinued, generic replacement is very expensive Suppositories - (5mg, Predsol®) For short term use in acute exacerbation or 'flare-ups'of relevant conditions |
06.03.02 |
Prednisolone |
Plain tablets |
10.01.02.01 |
Prednisolone |
|
10.01.02.01 |
Prednisolone |
for use in children or patients with swallowing difficulties |
11.04.01 |
Prednisolone 0.5% eye drops |
- Specialist Ophthalmologist Recommendation .
|
11.04.01 |
Prednisolone 1% eye drops Pred Forte® |
- Specialist Ophthalmologist Recommendation.
- For Anterior Uveitis in A&E-prednisolone acetate 1% as the drug of choice unless the patient has a preference for dexamethasone 0.1%
|
11.04.01 |
Prednisolone preservative free eye drops 0.5% |
- Specialist Ophthalmologist recommendation
- Use in patients with severe Chronic Allergic Eye Disease who present to A&E with a flare up.
|
03.12 |
Prednisolone tablets |
- Plain tablets (not enteric coated)
|
10.01.04 |
Prednisolone tablets |
Second line gout treatment |
04.03.04 |
Pregabalin |
- for generalised anxiety disorder
- ££
Schedule 3 Controlled Drug as of 01/04/2019 |
04.07.03 |
Pregabalin |
- 4th line after duloxetine
- on advice of specialist if duloxetine is unsuitable
- please be aware of the abuse potential associated with this class of agent
- From 17th July 2017, clinicians can now return to normal practice when prescribing pregabalin and no longer need to specify a brand name when prescribing for neuropathic pain.
Schedule 3 Controlled Drug as of 01/04/2019 |
04.08.01 |
Pregabalin |
- Capsules
MHRA Advice For patients being treated for epilepsy, it is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors.
Schedule 3 Controlled Drug as of 01/04/2019 |
21 |
Pregabalin |
Capsules, oral solution |
06.04.01.01 |
Premarin® |
|
06.04.01.01 |
Premique® low dose |
|
05.04.01 |
Primaquine |
Private prescription in Primary Care |
04.08.01 |
Primidone |
- Tablets
MHRA Advice Patients being treated for epilepsy should be maintained on a specific manufacturer's product.
|
04.09.03 |
Primidone |
|
10.01.04 |
Probenecid |
|
05.01.01.01 |
Procaine Penicillin G Injection |
|
09.04 |
Pro-Cal® Shot |
- Protein, fat, and carbohydrate
- Used where energy and protein is required in small volume – only on recommendation of dietitian
- Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement.
- Not suitable for child under 3 years.
|
09.04 |
Pro-Cal® Singles |
- Protein, fat, and carbohydrate
- Used where energy and protein is required in small volume, where measured doses are required – only on recommendation of dietitian
- Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years.
|
08.01.05 |
Procarbazine |
|
04.06 |
Prochlorperazine |
tablets
buccal tablets
syrup
injection |
04.02.03 |
Procyclidine |
|
04.09.02 |
Procyclidine |
Tablets
SF syrup
|
04.09.02 |
Procyclidine |
Injection |
13.10.05 |
Proflavine Cream, BPC |
Hospital only |
06.04.01.02 |
Progesterone Crinone® |
|
06.04.01.02 |
Progesterone Cyclogest® |
Recurrent miscarriage (off label use) Fertility (off label use)
|
06.04.01.02 |
Progesterone (micronised) Utrogestan® |
|
05.04.01 |
Proguanil Hydrochloride |
Private prescription in Primary Care |
05.04.01 |
Proguanil Hydrochloride with Atovaquone |
Private prescription in Primary Care |
06.04.01.01 |
Progynova® |
- Progynova® 1mg and 2mg tablets
|
03.04.01 |
Promethazine |
|
04.06 |
Promethazine Hydrochloride |
|
04.01.01 |
Promethazine Hydrochloride |
|
A5.03.04 |
Prontosan Wound Gel 30ml |
A gel containing betaine, a surfactant to remove biofilm and debris and PHMB to help control bacterial bioburden. Type of wound product is suitable for Cleansing, decontamination and moisturising of acute and chronic wounds including 1st and 2nd degree burns. Duration dressing remains on wound before changing Apply at each dressing change Frequency of dressing change As determined by the wound and exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) None Rationale for inclusion in formulary Gel to cleanse and decontaminate wounds Antimicrobial Breaks down biofilms in chronic wounds |
A5.03.04 |
Prontosan Wound Irrigation Solution |
Wound irrigation solution containing betaine a surfactant to remove biofilm and debris and PHMB to help control bacterial bioburden.
Type of wound product is suitable for
Cleansing, decontamination and moisturising of acute and chronic wounds including 1st and 2nd degree burns.
Duration dressing remains on wound before changing
Apply at each dressing change
Frequency of dressing change
As determined by the wound and exudate levels
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
None
Rationale for inclusion in formulary
Solution to cleanse and decontaminate wounds
Antimicrobial
Breaks down biofilms in chronic wounds
Can be used as an irrigation fluid with VAC Veraflow |
A5.12 |
Prontosan Wound Irrigation solution |
See under antimicrobials
|
02.03.02 |
Propafenone hydrochloride |
|
13.12 |
Propantheline |
- For hyperhidrosis (licensed indication)
- Specialist recommendation
|
02.04 |
Propranolol |
Tablets
Modified Release capsules |
04.07.04.02 |
Propranolol |
|
04.09.03 |
Propranolol |
|
13.14.01 |
Propylene glycol 20% w/w in aqueous cream |
|
13.14.02 |
Propylene glycol 40% w/w in Dermovate® cream |
|
06.02.02 |
Propylthiouracil |
|
A5.15 |
Proshield plus ® |
Skin protectant Type of wound product is suitable for To treat injured skin associated with incontinence where a dressing seal cannot be achieved Frequency of use Apply at each episode of hygiene Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) External use only Avoid contact with eyes Known allergic sensitivity to any of the components Keep out of reach of children Do not apply to pressure ulcers or leg ulcers Not to be used as a first line barrier cream Not to be used to protect peri wound Not to be used as an emollient Rationale for inclusion in formulary For treatment of incontinence lesions where a standard dressing seal cannot be achieved
|
A5.15 |
ProShield® |
Skin cleanser for use in patients with chronic diarrhoea or incontinence of urine. Type of wound product is suitable for To cleanse intact or injured skin from contamination of urine or faeces Frequency of use Apply at each episode of hygiene Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) External use only Avoid contact with eyes Known allergic sensitivity to any of the components Keep out of reach of children Rationale for inclusion in formulary For skin cleansing related to incontinence. Only skin cleanser available on drug tarrif |
09.04 |
Prosource® Jelly |
- High-energy supplements: protein
- Liver/hepatobiliary disease/conditions.
- Other patients groups, based on clinical assessment.
- Pts requiring increased protein in a low volume
- Hypoproteinaemia. Not recommended for child under 3 years
|
09.04 |
Prosource® Liquid |
- Protein and carbohydrate
- Pts requiring low volume, low cal, low CHO protein supplement (10g/30ml) for oral and tube feeders. Useful in allergy to milk and soya proteins. For high protein requirements.
- Liver/hepatobiliary disease/conditions.
- Biochemically proven hypoproteinaemia.
- Not recommended for child under 3 years.
|
09.04 |
ProSource® Plus |
- Protein and carbohydrate
- Pts requiring low volume, low cal, low CHO protein supplement (15g/30ml) for oral and tube feeders.
- Useful in allergy to milk and soya proteins.
- Liver/hepatobiliary disease/conditions.
- Hypoproteinaemia.
- Not recommended for child under 3 years
|
09.04 |
ProSource® TF |
- Protein and carbohydrate
- Pts requiring low volume, low cal, low CHO protein supplement (11g/30ml) specifically formulated for tube feeders. Useful in allergy to milk and soya proteins. Low osmolality.
- Liver/hepatobiliary disease/conditions.
|
02.08.03 |
Protamine Sulphate |
|
02.11 |
Prothrombin complex injection |
|
09.04 |
Protifar® |
- High-energy supplements: protein
- High protein modular powder, to be added to other food, drink and feeds in a range of conditions
- Nutritional supplement for use in biochemically proven hypoproteinaemia.
|
06.05.01 |
Protirelin TRH |
|
09.04 |
ProZero® |
- Low protein milk replacer in children and adults with inborn errors of protein metabolism on low protein diets
- A protein-free milk in children and adults with inborn errors of protein metabolism on low protein diets. It contains equal calories per 100 ml to cow’s milk. It is particularly suitable for MSUD patients. Available in 1 litre /250 ml cartons. The dose and frequency of administration will be determined by the specialist dietitian
- A protein-free nutritional supplement for the dietary management of inborn errors of metabolism in children over 6 months and adults.
|
01.06.07 |
Prucalopride Resolor ® |
For use in men and women for chronic constipation. |
03.10 |
Pseudoephedrine Hydrochloride |
Over the counter preparation suitable for self-care/purchase if appropriate |
05.01.09 |
Pyrazinamide |
Pyrazinamide liquid 500mg in 5ml (unlicensed) |
10.02.01 |
Pyridostigmine Bromide |
|
09.06.02 |
Pyridoxine Hydrochloride |
|
05.04.01 |
Pyrimethamine Darprim® |
|
04.02.01 |
Quetiapine Modified-release preparations |
- Supported by ESCA, see link below.
- Rationale for prescribing rather than first line antipsychotics to be provided with ESCA.
APC preferred brands Biquelle XL, Sondate XL, Zaluron XL Choose most cost-effective option.
|
04.02.01 |
Quetiapine tablets |
- Supported by ESCA, see link below.
|
06.07.01 |
Quinagolide |
|
05.04.01 |
Quinine dihydrochloride |
Injection |
05.04.01 |
Quinine sulphate |
Tablets |
10.02.02 |
Quinine sulphate |
Short term use only- MHRA guidance |
14.05 |
Rabies immunoglobulin |
- Use in line with protocol
|
16.02 |
Radium-223 Xofigo®
| Hospital only- NHSE commissioned In line with NICE and available from day 91 following publication of TA.
|
06.04.01.01 |
Raloxifene Hydrochloride |
In line with NICE
- Generic
- Evirex® £££
- Evista® £££
- Ostiral® £££
- Razylan® £££
|
05.03.01 |
Raltegravir Isentress ® |
|
08.01.03 |
Raltitrexed Tomudex® |
|
02.05.05.01 |
Ramipril capsules |
|
11.08.02 |
Ranibizumab Lucentis® |
Use in line with NICE |
01.03.01 |
Ranitidine |
Prescribe standard release tablets only; modified release (MR) preparations are non-formulary.
The supply disruption recommendations relating to H2As as a result of the issues around ranitidine are likely to remain prevalent for the foreseeable future. Where a patient has previously been prescribed ranitidine, the most likely course of action will be to step up to PPIs or down to antacids/alginates. H2As should be reserved as an option of last resort for patients who do not respond to other treatments and combinations.
Please reserve H2As for exceptional cases in order to preserve supplies. Where an H2A is indicated, please use the lowest dose of the least costly agent available in your locality. You will need to liaise with local community pharmacists to establish availability in your area as national availability will not necessarily translate to local availability |
01.03.01 |
Ranitidine Effervescent tablet |
For use in patients with swallowing difficulties or via nasogastric tubes only.
The supply disruption recommendations relating to H2As as a result of the issues around ranitidine are likely to remain prevalent for the foreseeable future. Where a patient has previously been prescribed ranitidine, the most likely course of action will be to step up to PPIs or down to antacids/alginates. H2As should be reserved as an option of last resort for patients who do not respond to other treatments and combinations.
Please reserve H2As for exceptional cases in order to preserve supplies. Where an H2A is indicated, please use the lowest dose of the least costly agent available in your locality. You will need to liaise with local community pharmacists to establish availability in your area as national availability will not necessarily translate to local availability |
21 |
Ranitidine |
Injection
Bowel obstruction
Off label use according to wmcare guideline’ |
01.03.01 |
Ranitidine IV |
Injection 50mg/2ml
For specialist use only |
02.06.03 |
Ranolazine Ranexa® |
Supported by RICaD, see link below. |
04.09.01 |
Rasagiline Azilect® |
|
10.01.04 |
Rasburicase Fastertec® |
|
13.14.07 |
Reflectant (Dundee) sunscreens |
coffee, coral pink, beige |
08.01.05 |
Regorafenib Stivarga® |
In line with NICE
NHS E commissioned |
01.01 |
Remote Control Panasonic® |
Control the TV and costs £20 to replace
MR tabs restricted for use in xyz |
09.04 |
Renapro® |
- Specialised formulas for specific clinical conditions
- For patients with high protein needs, low volume, low phosphate requirements.
- Used in renal patients.
- Used in liver/hepatobiliary diseases/conditions.
|
09.04 |
Renapro® shot |
- For patients with high protein needs, low phosphate requirements.
- Used for renal patients.
- Used in liver/hepatobiliary diseases/conditions
|
09.04 |
Renastart® |
- Specialised formulas for specific clinical conditions
- Used in infants and children with renal disease when low Potassium and Low phosphate feed is required, can be given orally or as a tube feed
- Dietary management of renal failure in child from birth to 10 years.
|
09.04 |
Renastart® |
- Used in infants and children with renal disease when low Potassium and Low phosphate feed is required, can be given orally or as a tube feed
- Dietary management of renal failure in child from birth to 10 years.
|
09.04 |
Renastep® Liquid |
- ACBS criteria: For the dietary management of renal failure from 3 years of age.
- Patients with renal failure from 3 years of age.
- Use under medical supervision.
- Not suitable for use as a sole source of nutrition.
- Suitable from 3 years of age onwards.
- Regular monitoring of nutritional status and electrolyte levels is required.
- For enteral use only
|
A5.06.01 |
Renasys products |
The use of sub atmospheric pressure to promote or assist wound healing or to remove fluids from a site. Required components: Pump, Dressings foam or gauze, tubing and canister. Type of wound product is suitable for Acute, chronic and traumatic wounds. Can be used as a adjunct to surgery and for salvage procedures such as wound dehiscence. Benefits are that it removes excess fluid that may contain bacterial pathogens, reduces soft tissue oedema, promotes granulation and provides a moist wound healing environment. Consider standard interactive dressings first. Duration dressing remains on wound before changing Every three days Frequency of dressing change Determined by exudate levels. Different canister sizes available Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) It should not be used on: Grossly infected or bleeding wounds Malignancy Exposed blood vessels Organs Unexplored fistulae Extensive necrotic wounds Caution with foam, document the number inserted, ensure all pieces are retrieved. Rationale for inclusion in formulary It removes excess fluid that may contain bacterial pathogens, reduces soft tissue oedema, promotes granulation and provides a moist wound healing environment. Both companies products are included due to different contracting arrangements. Can be used on large open wounds to increase speed of wound healing |
09.06.07 |
Renavit® |
- For renal patients as per APC formulary
- Dietary management of water-soluble vitamin deficiency in adults with renal failure on dialysis.
- Dietary management of water-soluble vitamine deficiency in adults with renal failure on dialysis
|
09.04 |
Renilon® 7.5 |
- More than 1.5 kcal/mL and 5 g (or more) protein/100 mL
- Low potassium, low phosphate sip feed
- Dietetic advice
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
- Not suitable for child under 3 years; use with caution in child 3–5 years.
|
06.01.02.03 |
Repaglinide |
|
14.04 |
Repevax® |
|
03.14 |
Reslizumab Cinqaero® |
- For specialist use only in line with NICE
- NHS England is the responsible commissioner for use in Asthma
|
09.04 |
Resource® Junior |
- Child: More than 1 kcal/mL and less than 4 g protein/100 mL
- First Choice Alternative to Fortini, for patients who have taste fatigue - long term use
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula. Not suitable for use in child under 3 years
|
09.04 |
Resource® Optifibre |
- High-fibre supplements
- A fibre source added to oral and tube feeds
- This is added to low protein tube feeds for patients with propionic acidaemia, methyl malonic acidaemia to provide a source of fibre. Children with these conditions become easily constipated leading to metabolic instability and hospital admissions so an additional source extra to fibre content of existing enteral feeds is essential. this product cannot be purchased from the supermarket and is essential. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula except dysphagia
- Not suitable for child under 5 years
|
09.09 |
Resource® ThickenUp Clear |
- Recommended by SALTs for patients with dysphagia requiring thickened fluids Gum based products are generally preferred as they thicken to a more stable end point (unlike starch based products, they do not continue thickening over time) and provide a smoother texture, which improves acceptability and palatability for patients.
|
09.04.02 |
Resource®Energy |
- 1.5 kcal/mL and 5g (or more) protein/100 mL
- Paediatrics and specialists adults use only
- Standard ACBS indications: Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
|
02.10.02 |
Reteplase |
Hospital only |
14.04 |
Revaxis® |
|
05.03.05 |
Ribavirin |
Capsules
Tablets
Inhalation |
08.01.05 |
Ribociclib Kisqali® |
In line with NICE Hospital only - NHSE commissioned |
09.06.02 |
Riboflavin |
- Specialist Recommendation
- Inherited metabolic disease
|
05.01.09 |
Rifabutin |
|
05.01.09 |
Rifampicin infusion |
|
05.01.09 |
Rifampicin oral presentations |
|
13.06.02 |
Rifampicin |
|
05.01.09 |
Rifampicin and Isoniazid Rifinah® 300 |
|
05.01.09 |
Rifampicin and Isoniazid Rifinah® 150 |
|
05.01.09 |
Rifampicin and Isoniazid and Pyrazinamide Rifater® |
|
05.01.09 |
Rifampicin with ethambutol, isoniazid and pyrazinamide Voractiv® |
|
05.01.07 |
Rifaximin |
- In line with NICE
- Supported by RICaD, see link below.
|
05.03.01 |
Rilpivirine hydrochloride Edurant® |
|
04.09.03 |
Riluzole Rilutek® |
- Supported by an ESCA, see link below.
|
13.05.02 |
Risankizumab |
Use in line with NICE |
06.06.02 |
Risedronate |
- The need for continued bisphosphonate treatment should be re-evaluated periodically particularly after 5 or more years of use
|
04.02.02 |
Risperidone Risperdal Consta® |
The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.
|
04.02.01 |
Risperidone (oral) |
- tablets
- liquid
- Supported by ESCA, see link below.
|
05.03.01 |
Ritonavir Norvir® |
|
08.02.03 |
Rituximab |
NHSE is the responsible commissioner.In line with NICE |
10.01.03 |
Rituximab (rheumatology) MabThera® |
Hospital only |
02.08.02 |
Rivaroxaban |
Following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants.
BSSE APC Primary Care Clinical Pathway for Arial Fibrillation Detection and Management
For the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Rivaroxaban in DVT /PE
For preventing adverse outcomes after acute management of ACS use in line with NICE TA335. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Rivaroxaban post ACS
For preventing atherothrombotic events in people with coronary or peripheral artery disease use in line with NICE TA607 Use following Hip and Knee surgery- full course of treatment supplied on discharge. |
04.11 |
Rivastigmine |
- capsules
- patches - preferred brand is Alzest®
|
04.07.04.01 |
Rizatriptan |
Tablets
Orodispersible tablets SF- reserve for patients who are vomiting due to migraine
Wafer/oral lyophilisates SF £££
|
03.03.03 |
Roflumilast Daxas® |
In line with NICE Specialist initiation- transfer of prescribing supported by RICaD
RICaD: Roflumilast for treating COPD |
09.01.04 |
Romiplostim Nplate® |
|
04.09.01 |
Ropinirole M/R tablets |
|
04.09.01 |
Ropinirole tablets |
- For use in Restless Legs - Supported by an ESCA, see link below.
|
02.12 |
Rosuvastatin tablets |
|
14.04 |
Rotavirus vaccine Rotarix® |
|
04.09.01 |
Rotigotine patches |
|
08.01.05 |
Rucaparib Rubraca® |
In line with NICE |
04.08.01 |
Rufinamide |
- Tablets
- Supported by an ESCA, see link below.
MHRA advises that when prescribing for epilepsy the patient should be assessed to make a clinical judgement if the same manufacturer’s product/brand is necessary taking into account factors such as seizure frequency and treatment history. Also take into account patient/carer-related factors such as their negative perceptions about alternative products and/or other issues related to the patient such co-morbid autism, mental health issues, or learning disability.
|
08.01.05 |
Ruloxitinib Jakavi®
| Hospital only- NHS England is responsible commissioner
In line with NICE and available from day 91 following publication of TA (see links below)
|
09.04 |
S.O.S® |
- High-energy supplements: carbohydrate
- Individual dose sachets, to be made as needed –pre measured dose to be made up by parents.
- Essential for use in an emergency regimen in inborn errors of metabolism / module in tube feed for low amino acid or fat diets / energy supplement.
- Also essential core ingredient in emergency feeds for inborn errors of metabolism / or used as an Individual carbohydrate module in tube feeds for low amino acid or fat diets / or as an energy supplement. Particularly important to use with non-English speaking families and vulnerable families as it is supplied in pre-measured sachets. Research as shown that it is safer to use than conventional glucose polymer powders. The dose and type of product should always be advised by the specialist dietitian according to the needs of the patient.
- For use as an emergency regimen in the dietary management of inborn errors of metabolism in adults and children from birth.
|
02.05.05 |
Sacubitril valsartan Entresto ®
| |
03.01.01.01 |
Salbutamol |
Inhaler
oral preparations
Nebules
|
07.01.03 |
Salbutamol |
|
03.01.01.01 |
Salbutamol IV |
|
13.07 |
Salicylic Acid Salatac® |
Over the counter preparation suitable for self-care/purchase if appropriate |
13.14.06 |
Salicylic acid 10% w/w in emulsifying ointment |
|
13.07 |
Salicylic Acid 16.7% with Lactic Acid 16.7% Salactol® |
Over the counter preparation suitable for self-care/purchase if appropriate |
13.14.06 |
Salicylic acid 2% w/w and sulphur 2% w/w in aqueous cream |
|
13.14.06 |
Salicylic acid 2% w/w in emulsifying ointment |
|
13.14.06 |
Salicylic acid 20% w/w in emulsifying ointment |
|
13.14.02 |
Salicylic acid 5% w/w / propylene glycol 47.5% w/w in Dermovate® cream |
|
13.07 |
Salicylic Acid Ointment Verrugon® |
Over the counter preparation suitable for self-care/purchase if appropriate |
12.03.05 |
Saliveze® Oral spray |
Approved for
- Palliative Care
- Dental practitioners
- May be prescribed under ACBS for patients with dry mouth post radiotherapy or sicca syndrome
|
12.03.05 |
Salivix® pastilles |
Approved for
- Palliative Care
- Dental practitioners
- only effective in patients who have residual salivary gland function.
|
03.01.01.01 |
Salmeterol |
- Soltel® is a less expensive brand for patients >12 years of age N.B. Soltel® is contraindicated in patients with peanut or soya allergy
- Prescribe by brand to ensure patients receive the device they are used to.
- Check licensed indication (differences among brands).
- Be aware of differences in excipients among the different brands.
|
09.05.01.01 |
Sandocal-1000® |
|
06.04.01.01 |
Sandrena® gel |
|
09.04.01 |
Sapropterin Dihydrochloride Kuvan® |
|
05.03.01 |
Saquinavir Invirase® |
|
08.02.04 |
Sarilumab Kevzara® |
In line with NICE Commissioned by CCGs. |
09.04.01 |
Savoury meals and mixes |
Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein-. 1 ordinary meal is likely to provide ≥25g protein. |
09.04 |
Scandishake® Mix |
- Protein, fat, and carbohydrate
- Second choice for patients with very high energy requirement eg cystic fibrosis
- In adults with cystic fibrosis, nutritional advice and interventions should be aimed at maintaining a BMI of 22kg/m2 in women and 23kg/m2 in men, as these are associated with better lung function (Nutritional management of CF – Consensus document – 2016)
- Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years.
|
01.07.02 |
Scheriproct® suppositories |
Scheriproct ointment and suppositories |
A5.11 |
Seal-Tight Wound care protector |
Waterproof protector, non slip latex free Type of wound product is suitable for Used to keep leg and foot dressings dry, can be fully submerged in water Rationale for inclusion in formulary Multiple sizing for leg including extra large limb No adjustments required
|
13.05.02 |
Sebco® |
|
13.05.03 |
Secukinumab |
Use in line with NICE |
04.09.01 |
Selegiline Hydrochloride |
- Tablets
- Oral lyophilisate reserved for patients with swallowing difficulties in Parkinson's disease
|
09.05.05 |
Selenium capsules/tablets Selenase® |
- Specialist Recommendation
|
13.09 |
Selenium Sulphide Selsun® |
Over the counter preparation suitable for self-care/purchase if appropriate |
06.01.02.03 |
Semaglutide Ozempic®, Rybelsus ®▼ |
- tablets (Rybelsus®)
- injection (Ozempic®)
Semaglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing; manufacturer advises to record the brand name and batch number after each administration.
Caution - retinopathy. Do not use in patients with pre-proliferative/proliferative retinopathy (R2/R3 grade) or maculopathy (M1) or who are undergoing or awaiting eye laser or intravitreal treatments. Ensure all patients are up-to-date with their retinopathy screening programme prior to initiation of semaglutide, and that they attend their annual screening whilst on treatment. |
01.06.02 |
Senna |
Tablets 7.5mg; Syrup 7.5mg/5ml
- Syrup is currently more cost effective than tablets
- Time to effect approximately 8 to 12 hours
|
04.03.03 |
Sertraline tablets |
|
09.05.02.02 |
Sevelamer |
- Specialist Recommendation
- No ESCA
- Common Practice
|
02.05.01 |
Sildenafil Revatio® |
NHS England commissioned |
07.04.05 |
Sildenafil tablets GENERIC |
no restrictions on quantity to be supplied to ensure adequate trial of treatment
SLS criteria no longer apply
For use in digital ulceration, see chapter 10 |
10.04 |
Sildenafil tablets GENERIC |
Use in digital ulceration is commissioned by NHS England
All prescribing retained in Secondary Care
Off label use |
A5.16 |
Silver nitrate |
NOT 1ST LINE TREATMENT ONLY TO BE USED IN A CLINIC SETTING OR BY A CLINICAL SPECIALIST Type of wound product is suitable for For treatment of chronic overgranulation, non acute or weeping. Duration product remains on wound before changing Apply moistened caustic pencil tip for 1-2 mins, whilst protecting the surrounding skin with soft paraffin. Frequency of use Maximum treatment: 3 applications Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Keep away from the eyes Not suitable for use on the face, ano-genital region or large areas Not for untreated bacterial, fungal or viral skin lesions Can cause chemical burns Rationale for inclusion in formulary Treatment of overgranulation |
13.07 |
Silver Nitrate 95% with Potassium Nitrate 5% AVOCA® |
Over the counter preparation suitable for self-care/purchase if appropriate |
13.07 |
Silver Nitrate applicators ( 40% ,75% and 95%) |
Over the counter preparation suitable for self-care/purchase if appropriate |
13.07 |
Silver Nitrate caustic applicator |
|
13.10.01.01 |
Silver Sulfadiazine Flamazine® |
For infected burns |
A5.17 |
silver sulfadiazine 1% Flamazine® |
Type of wound product is suitable for Partial thickness & full thickness burn injuries. Sloughy burn wounds or areas of graft loss Duration preparation remains on wound before changing 24-48 hours Frequency of use Daily- occasionally alternate day Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy to any ingredients. Not to use in pregnancy or breast feeding Take care if: suffer kidney or liver problems, deficiency of the enzyme known as glucose 6- phosphate dehydrogenase. Taking tablets prescribed for epilepsy Rationale for inclusion in formulary Prevent and treat bacterial infections in burns, skin graft donor sites. |
A5.17 |
Silver sulfadiazine 1.0g & Cerium nitrate 2.2g Flammercerium® |
Type of wound product is suitable for Partial thickness & full thickness burn injuries. Duration preparation remains on wound before changing 24-48 hours Frequency of use Daily- occasionally alternate day Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy to any ingredients. Not to use in pregnancy or breast feeding, infants or babies under the age of 2 years. Take care if: suffer kidney or liver problems, deficiency of the enzyme known as glucose 6- phosphate dehydrogenase. Taking tablets prescribed for epilepsy Rationale for inclusion in formulary Prevent and treat bacterial infections in burns
|
01.01.01 |
Simeticone |
Drops For use in infantile colic
For Endoscopy use
|
03.09.02 |
Simple Linctus, BP |
Over the counter preparation suitable for self-care/purchase if appropriate |
03.09.02 |
Simple Linctus, Paediatric BP |
Over the counter preparation suitable for self-care/purchase if appropriate |
02.12 |
Simvastatin tablets |
|
08.02.04 |
Siponimod Mayzent® |
In line with NICE |
08.02.02 |
Sirolimus Rapamune® |
Post transplant- if prescribing is NOT established with GP before 1st April 2013
Post transplant- if prescribing IS established with GP before 1st April 2013
|
06.01.02.03 |
Sitagliptin Januvia® |
In line with NICE |
09.04 |
Slo drinks milkshakes |
- 1.5 kcal/ml and 5g (or more) protein/100ml
- First line For dysphagia pts only
- Not suitable for CKD 4-5, renal pts.
- Not suitable for lactose intolerance
- Not suitable for bile acid malabsorption or fat maldigestion associated with biliary diseases/conditions
- To be made up with whole milk.
- Contains 24g protein per serving as served.
|
09.09 |
SLO Drinks® |
- Used in a complex specific patient group advised by a SALT specialist
- Nutritional supplement for patient hydration in the dietary management of dysphagia. Not suitable for children under 3 years.
|
09.04 |
SMA LF® Lactose Free Formula (previous name SMA® LF) |
- Specialised formulas: Infant and child: Residual lactose formula
- Can be purchased over the counter.
- Only prescribable for patients who currently do not pay for formula feeds (eg healthy start scheme)
- For infants with lactose intolerance
- Proven lactose intolerance
|
09.04.02 |
SMA® PRO Gold Prem 2 |
Child under 12 years
- Less than 1 kcal/mL and less than 4g protein/100 mL
- Post discharge formula for pre term infants
- Powder feed
- Partially hydrolysed
- For catch-up growth in preterm infants and small for gestational age babies on discharge from hospital until 6 months corrected age. It may be used as the sole source of nutrition until complementary feeding commences.
|
09.04.02 |
SMA® PRO High Energy |
Child under 12 years
- Less than 1 kcal/mL and less than 4g protein/100 mL
- High energy feed for faltering growth
- Single use only in acute setting – risk of increased waste.
- Once open must be used within 24 hours
- Disease-related malnutrition, malabsorption, and growth failure in infancy.
|
10.01.03 |
Sodium Aurothiomalate Myocrisin® |
Supported by ESCA, see link below. |
07.04.03 |
Sodium Bicarbonate |
|
12.01.03 |
Sodium Bicarbonate 5% ear drops |
|
09.02.01.03 |
Sodium Bicarbonate capsules |
- Specialist Recommendation
|
03.01.05 |
Sodium Chloride |
|
09.02.01.02 |
Sodium Chloride |
Sodium chloride M/R Tablets
Sodium chloride 5mmol solution
Sodium chloride 1mmol/mL oral solution. Amber Specialist recommendation
|
11.08.01 |
Sodium Chloride Minims® Saline |
Hospital only. Diluent for impregnated dye strips |
03.07 |
Sodium chloride 0.9% |
|
07.04.04 |
Sodium Chloride 0.9% Catheter Patency Solutions |
|
21 |
Sodium chloride 0.9% |
IV infusion |
13.11.01 |
Sodium Chloride 0.9% irrigation sachets |
|
11.08.01 |
Sodium Chloride 0.9% Solutions |
Hospital only- Theatre use |
11.08.01 |
Sodium Chloride 5% eye ointment |
- Specialist Ophthalmologist Recommendation
|
11.08.01 |
Sodium Chloride 5% PF drops Moorfields |
- Specialist Ophthalmologist Recommendation
|
12.02.02 |
Sodium Chloride Nose drops 10ml |
|
07.04.04 |
Sodium Citrate |
Hospital only |
01.06.04 |
Sodium Citrate (Rectal) |
Micro-enema
Microlette®, Relaxit® and Micralax® |
06.06.02 |
Sodium Clodronate |
- For the management of osteolytic lesions, bone pain and hypercalcaemia associated with multiple myeloma or breast cancer.
- Supported by an ESCA, see link below.
|
11.04.02 |
Sodium Cromoglicate 2% eye drops |
|
11.04.02 |
Sodium Cromoglicate 2% eye drops preservative free |
- Specialist Ophthalmologist recommendation as Catacrom
|
09.01.01.01 |
Sodium Feredetate SF Elixir Sytron® |
|
09.05.03 |
Sodium Fluoride Mouthwash, BP |
Dental prescribing only |
09.05.03 |
Sodium Fluoride Toothpaste 0.619% (2800ppm), DPF |
|
09.05.03 |
Sodium Fluoride Toothpaste 1.1% (5000ppm), DPF |
|
11.08.01 |
Sodium Hyaluronate 0.15% Multi Hyabak® |
- Specialist Ophthalmologist Recommendation
|
11.08.01 |
Sodium Hyaluronate 0.2% eye drops PF Evolve HA ® |
- Specialist Ophthalmologist Recommendation
Approved onto formulary January 2019 |
11.08.01 |
Sodium Hyaluronate 0.2% PF Multi Hylo-Forte® |
- Specialist Ophthalmologist Recommendation
|
11.08.01 |
Sodium Hyaluronate 0.4% SDU Clinitas® |
- Specialist Ophthalmologist Recommendation
- Each preservative-free unit is resealable and may be used for up to 12 hours.
|
02.05.01 |
Sodium nitroprusside |
Injection (Secondary Care only) |
21 |
Sodium picosulfate |
Liquid
Palliative care use only |
02.13 |
Sodium Tetradecyl Sulphate Fibro-Vein® |
|
04.08.01 |
Sodium Valproate |
- E/C tablets
- M/R tablets
- Crushable tablets
- SF liquid
- M/R granules see Episenta®
MHRA Advice Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history.
Use in men and women of non-child bearing potential
Use in women and girls of childbearing potential (all indications). ESCA link below
Contraindicated in women of childbearing potential unless part of the Pregnancy Prevention Programme. See MHRA guidance |
04.08.01 |
Sodium Valproate Episenta® |
- Paediatrician initiation.
- For patients with epilepsy aged up to and including 16 years of age unable to swallow tablets and who require a modified release formulation in whom other formulations are more expensive or not appropriate.
MHRA Advice Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history.
Contraindicated in women of childbearing potential unless part of the Pregnancy Prevention Programme. See MHRA guidance |
09.02.01.01 |
Sodium zirconium cyclosilicate Lokelma® |
In line with NICE |
05.03.03.02 |
Sofosbuvir-velpatasvir-voxilaprevir |
Hospital only - NHSE commissioned
In line with NICE |
A5.01.02 |
Softpore - self adhesive |
Type of wound product is suitable for
Low to moderately exuding wounds, superficial wounds (closed), light amounts of
exudate.
Use alone without other products, also can be used as a protective dressing for sutured
post operative wounds. Can be used as a protective dressing for newly epithelialised wounds. Can be used for minor traumatic wounds
Duration dressing remains on wound before changing
Maximum 7 days, dependent on exudate levels
Frequency of dressing change
If daily change is required; review dressing type
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Known product or component sensitivity
Rationale for inclusion in formulary
Sutured/Post-surgical wound for protection . Most cost effective option.
Can be used as a protective dressing for newly epithelialized wounds. Can be used for minor traumatic wounds
|
07.04.02 |
Solifenacin Vesicare® |
- place in therapy is after agents that have effectiveness at lower costs
|
06.05.01 |
Somatropin |
|
08.01.05 |
Sorafenib Nexavar® |
|
A5.02.06 |
Sorbsan range |
Calcium alginate dressing
Type of wound product is suitable for
Use in moderate to highly exuding wounds with a sloughy or granulating wound bed. Also helps with haemostasis in wounds with minor bleeding or where blood is present in the exudate.
Available in flat and rope dressing
Primary dressing only. Secondary dressing will be required.
Duration dressing remains on wound before changing
Can be left in place for approximately 4 days
Frequency of dressing change
1-4 days dependent on exudate levels
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Do not use in individuals with a known sensitivity to any of the components of the dressing
Do no use on dry or lightly exuding wounds as adherence is an issue
Extreme caution if used for tumours with friable tissue
Rationale for inclusion in formulary
Sorbsan can facilitate debridement, absorb exudate and is a haemostat
Cost effective
Biodegradable
|
06.01.02.03 |
Sotagliflozin |
Sotagliflozin is not yet available in the NHS, but the company anticipates that it will be available to the NHS in England and Wales within 12 months of guidance publication. |
02.04 |
Sotalol |
Anti Arrhythmic |
|